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Abstract
Both acquired and intrinsic drug resistance are established clinical problems in many
areas of medicine. This is particularly evident with the growing resistance to platinum
chemotherapy agents in cancer treatment programmes. New, alternative treatments for
platinum-resistance patients are needed, with comparable potency, no platinum cross-
resistance, better safety profiles and which target non-repairable areas of the cell, reducing
acquired resistance.
This thesis focuses on osmium- and iridium-based organometallic anticancer agents
to fill this clinical need. Previous work has validated their potency, safety and activity
in platinum-resistant cancers, however, their mechanism of action (MOA) was yet to be
identified. Knowing the MOA of new compounds is essential for personalising and strat-
ifying cancer treatment, allowing for better patient selection and prediction of treatment
outcomes. Often identifying the biological target of a new therapeutic is not essential. In-
stead, quantifying the cellular response to that treatment, and identifying cell types which
hold beneficial biological properties to optimise compound effects, is more effective.
This thesis has applied the principles of systems biology to study the whole cell effect
of osmium and iridium compounds in epithelial ovarian cancer. Cells were studied at
the transcriptional, translational and structural level to investigate compound response,
integrating a selection of these findings using novel statistical modelling.
Results propose that these compounds induce oxidative stress in cancer cells, and sub-
sequently damage DNA to exert antiproliferative effects at submicromolar concentrations.
This is the first example of studying organometallic compounds using this combination
of techniques, and is a promising work flow for future efforts in this area.
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Chapter 1. Introduction
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As the cases of resistance continue to rise in the treatment of cancer, there is a drive
to develop new anticancer agents. Additionally, there is desperate need to develop new
therapeutics with better safety profiles and larger therapeutic indices. New treatments must
have comparable potency, higher cancer cell selectivity and alternative mechanisms of
action to those drugs currently used in the clinic. This thesis focuses heavily on developing
new metal-based anticancer agents to tackle the current limitations of platinum-based
drugs like cisplatin. These new drug compounds are osmium- and iridium-based, and
in previous work have demonstrated desirable activity, equipotency in platinum-resistant
cancers and promising selectivity profiles. However, their mechanism of action (MOA)
still remains undetermined.
Therefore this thesis aims to gain insights into the biological activity of these com-
pounds using a systems biology workflow. In the first instance, cancer cell screens are
used to filter out lead compounds, and to obtain preliminary mechanistic information.
Using RNA sequencing, protein microarrays and imaging techniques, the cellular effects
of lead compounds are investigated in epithelial ovarian cancer (EOC) cells. Collectively
this information could drive future studies to probe the direct targeting sites for these
osmium and iridium compounds, and push them through preclinical development towards
clinical studies.
1.1 Ovarian cancer
In 2009 there were 320,467 people diagnosed with cancer in the UK, a number projected
to increase to over 400,000 by 2030.1 As of April 2013, there are over 200 types of cancer,
with breast, lung, bowel and prostate cancers accounting for over half of all new cases
each year.2 There are many risk factors linked to the development of cancer; age, lifestyle
and epigenetics are main examples.
Ovarian cancer affects more than 6,500 women in the UK each year, and is the 5th
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most common cancer after breast, bowel, lung and uterine.3 Ovarian cancer is a diverse
disease with cell types falling into three main categories: epithelial, germ cell and stromal.
Epithelial ovarian cancers (EOC) are the most common, effecting the surface layers of
the ovary.4–6 The treatment of ovarian cancers depends on the stage and grade with
treatment covering surgery, radiotherapy or chemotherapy, or often all three. Ovarian
cancers diagnosed below stage 2, which have not spread to other parts of the abdomen
are generally treatable via one or more of these methods. However, diagnosis is often
complicated as many women are asymptomatic and miss-diagnosed with irritable bowel
syndrome, which delays detection and treatment considerably.7 As the most common
form of ovarian cancer, 70% of EOC are not diagnosed until late stage, after spreading to
the abdomen. In general, the earlier the detection of ovarian cancer, the higher the 5-year
survival rate, stressing the importance of regular screening in women.
1.2 Cancer chemotherapy
Chemotherapy plays an important role in both early and advance stage ovarian cancer
treatment, reducing symptoms and pain through tumour shrinkage. However, cancers
are highly heterogenous, therefore cells within the tumour may be susceptible to certain
chemotherapeutics and others may be resistant.8, 9 A study by Wang et al showed that from
fourty-seven surgically assessed stage I EOC they could detect grade III tumour, grade I
and II endometrioid, and clear-cell tumour cells, demonstrating significant heterogeneity.10
Patients are therefore often given a cocktail of drugs, with hopes of targeting all types
of cancer cells within the tumour. However, in many cases patients experience relapse
and subsequent resistance to first line therapies as a result of either insufficient surgical
removal of all tumour cells, or an inability to appropriately target all tumour cell types with
chemotherapy. Often, chemosensitive cells are successfully targetted with a chemotherapy
agent, but cells with inherent resistance are unaffected and divide to become the dominant
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cell type in the tumour. For example, cancer stem cells (CSC), a cell type often found
in tumours, can maintain a quiesent (G0) state which allows them to be chemoresistant,
as chemotherapy agents are generally most effective against fast dividing cells.11 It is also
possible for chemosensitive cells to develop resistance mechanisms during treatment, for
example by altering the drug target with mutations or expression changes, or decreasing
cellular drug accumulation.12 In cases of resistance, second line chemotherapy agents are
administered, ideally with no cross-resistant to first line treatments. Unfortunately, relapse
can continue to occur, until a patient no longer responds to any clinically available drugs.
This problem highlights the need for research and development of new chemotherapeutics,
ideally with little or no cross-resistance to current clinically used drugs.
1.2.1 Metallo-drugs
The administration of metal-based drugs into the body exposes them to reactions with a
plethora of biological substances, although the main targets are assumed to be proteins and
DNA.13, 14 Most metal complexes have easily displaced ligands which allow modification
when in contact with elements inside the cell. This can provide flexible mechanisms of
action (MOA), but also increase the complexity of work conducted during research and
development phases of drug design.
The serendipitous discovery of cisplatin, a platinum(II) based drug, together with its
subsequent derivatives, oxaliplatin and carboplatin have shown incredible success in the
clinic against testicular, ovarian and colorectal cancers (Figure 1.1).15 Generally, the first
line treatment for ovarian cancer patients is platinum based, where the length and dose
of treatment is dependent on the patient and the stage and grade of the tumour.
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Figure 1.1: Clinically used platinum(II) metallodrugs cisplatin, carboplatin and oxaliplatin.
Cisplatin and Carboplatin are commonly used to treat ovarian cancer, with oxaliplatin used to treat
colorectal.15
Although platinum (Pt) drugs have marked a major breakthrough in cancer research,
they are non-specific cytotoxic agents, which means they cannot distinguish between
fast dividing host cells and fast dividing cancer cells.16 This lack of specificity results in
severe side effects, for example disrupting patient immune systems by killing lymphocytes
required to fight off infection during the treatment duration. In addition, the cases of
inherent and acquired resistance are a common occurrence.
Pt drugs are commonly associated with DNA binding mechanisms, and an ability to
cross link DNA strands, causing irreparable damage and activating apoptotic cell death.16
If patient resistance is acquired during treatment it occurs through three common mech-
anisms: increased drug efflux, increased DNA repair mechanisms and decreased drug in-
flux.17 In ovarian patients who have relapsed after first line platinum treatment, physicians
will determine whether the patient has become platinum resistant based on the relapse inter-
val.18 A patient who suffers relapse >12 months after the first platinum treatment are still
considered platinum sensitive, when relapse occurs sooner, they are considered resistant
or partially sensitive. If a patient is deemed platinum resistant, it follows that any chemo-
therapy agent used as a second or third line treatment should have no cross resistance with
platinum i.e. it should act through alternative MOA. Drugs able to fill this category are in
high demand, and extensive research focuses on developing newer metal-based agents.14, 19
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1.2.1.1 Ruthenium
Some metal-based compounds move away from DNA-targetting, like NAMI-A (New
Anti-tumour Metastasis Inhibitor-A) a Ruthenium (Ru) compound in phase II clinical
trials as a drug able to inhibit the process of metastasis (Figure 1.2).13 This kind of drug
has potential benefits when used prior to surgery, and during phase I clinical trials showed
exceptionally low patient toxicity. NAMI-A is thought to have a low affinity for DNA
binding, and instead binds to exposed imidazole sites (histidine residues) on human and
bovine serum albumin and apo-transferrin.
Ru
S
CH3
CH3
O
NH
N
ClCl
Cl Cl
-
Figure 1.2: Ruthenium anticancer drug NAMI-A currently in phase II clinical trials to treat
metastatic cancers.13
1.2.2 Organometallic drugs
1.2.2 Osmium and iridium
The success of Pt and Ru based drugs has sparked interest in neighbouring transition
metals, like osmium (Os) and iridium (Ir).20–23 Os and Ir organometallic compounds
developed in the Sadler group at The University of Warwick are half-sandwich piano-stool
compounds chelating a variety of coordinated ligands (Figure 1.3).20, 24–27
6
Ir
Cpx
RX
Y
N
N
N
N
N
ppy phen bpy
CpxphH
CpxbiphH
+/0
N
N N
N
N
N
N
N
N
azpy dpq pyr
Os
Arene
N X
N
I
R2
R1
+
p-cym
bip
Complex Arene R1 R2 X 
Os-1 bip NMe2 H N 
Os-2 p-cym NMe2 H C 
Os-3 p-cym NMe2 H N 
Os-4 bip H F N 
Os-5 bip OH H N 
Complex CpxH XY 
Ir-6 Cpxbiph phen 
Ir-7 Cpxph phen 
Ir-8 Cpxbiph bpy 
Ir-9 Cpxbiph ppy 
Ir-10 Cpxph azpy 
Ir-11 Cpxbiph dpq 
Cl 
Cl 
Figure 1.3: Lead Osmium (Os) and Iridium (Ir) compounds synthesised in the Sadler group by Dr
Fu Ying and Dr Zhe Liu, respectively. Highlight in blue are the various arena ligands chelated
to Os compounds Os-1 - Os-5. All Os compounds are chelated to N-N azopyridine (X=N) or
iminopyridine (X=C) ligands, with varying R groups (R1 and R2) described in the left-hand table.
All Os compounds have a +1 charge. Highlighted in orange are the various arena ligands chelated
to Ir compounds Ir-6 - Ir-11. Highlighted in green are the varying N-N and C-N chelating ligands
(XY) for each Ir compound, as described in the right-hand table. All Ir compounds have a +1
charge, except for Ir-9 which is neutral.20, 24–27
These compounds show remarkable activity in the high-grade serous EOC cell line A2780,
and were designed to overcome the major hurdles currently in place with long-term use of
drugs like cisplatin: namely Pt resistance and severe side-effects. The ligands are diverse,
and allow each compound to exhibit a variety of properties. For example a neutral Ir
compound is obtained by using the phenylpyridinato (ppy) chelating ligand, compared
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to the cationic complexes obtained when using neutral chelating ligands. These alterations
in functionality have potential to alter the MOA of these compounds and provide a unique
ability to tailor drug design to target a particular pathway or biological component inside
cancer cells.
These compounds were initially designed to have the same mechanism as the Pt(II)
drugs, where the labile halide ligand undergoes a substitution reaction to form an activated
aqua compound, able to bind to the N7 group on guanine and adenine nucleobases.
Although this mechanism is possible for some of the Ir-Cl containing compounds, in some
cases the hydrolysis can be blocked, producing highly active compounds in vitro.25, 28
This is also true for the Os compounds where the Os-I bond is generally non-hyrolysable.
The hydrolysis status shown for each of the compounds in Table 1.1 is measured by
incubating each compound in deuterated methanol/water (5% MeOD/95% D2O (v/v), and
measuring the formation of new aqua species by the appearance of new peaks by proton
NMR, over a 48 h time series.
Table 1.1: Table of the 11 compounds Os-1 - Os-5 and Ir-6 - Ir-11 describing their full structure,
activity in A2780 ovarian cancer cells as the concentration to inhibit 50% of cancer cell growth,
and the hydrolysis status for their metal-halide bond.20, 24–26
Complex [Structure] Counter ion A2780 Hydrolysis
GI50 (µM) status⇤
Os-1 [Os(h6-bip)(NMe2-azpy)I]PF6 0.14 ± 0.01 N
Os-2 [Os(h6-p-cym)(NMe2-imino)I]PF6 0.80 ± 0.05 N
Os-3 [Os(h6-p-cym)(NMe2-azpy)I]PF6 0.15 ± 0.01 Y
Os-4 [Os(h6-bip)(F-azpy)I]PF6 0.63 ± 0.10 N
Os-5 [Os(h6-bip)(OH-azpy)I]PF6 0.14 ± 0.01 N
Ir-6 [Ir(h5-Cpxbiph)(phen)Cl]Cl 0.72 ± 0.01 Y
Ir-7 [Ir(h5- Cpxph)(phen)Cl]Cl 6.70 ± 0.62 Y
Ir-8 [Ir(h5-Cpxbiph)(bpy)Cl]PF6 0.57 ± 0.09 Y
Ir-9 [Ir(h5-Cpxbiph)(ppy)Cl] 0.70 ± 0.04 Y
Ir-10 [Ir(h5-Cpxph)(NMe2-azpy)Cl]PF6 0.40 ± 0.00 N
Ir-11 [Ir(h5-Cpxbiph)(dpq)Cl]Cl 0.88 ± 0.09 Y
* Y = hydrolysis occurs in under 48 h and N = hydrolysis does not occur in 48 h
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1.2.2.2 Benefits osmium compounds over platinum treatments
Circumventing platinum resistance. Figure 1.4 highlights the promising activity of the
Os and Ir compounds in Pt resistant ovarian and colorectal cell lines, suggesting that these
drug-compounds could fill an unmet clinical need.29
Activity in p53(-/-). Tumour protein 53 (p53) has a vital role in controlling cell cycle
regulation and tumour suppression.30 This protein can perform 3 main anti-cancer roles:
activate DNA repair mechanisms, arrest cell growth in G1/S phase, whilst DNA is repaired,
and finally activate apoptosis if DNA damage cannot be repaired. p53 mutations are
highly important biomarkers in high grade serous ovarian cancer and are the thought to
occur in approximately 50% of all cancers.
Figure 1.4 shows that the Os and Ir compounds not only demonstrate high activ-
ity in p53(-/-) cell lines, but that the absence of this mutation can actually increases
this activity. For example compound Os-4 is x4 more active in p53 mutated HCT116
colorectal cells compared to the wild-type.29 These promising results highlight an-
other clinical benefit, increasing the treatment window to cover p53 mutated cancers.
Mechanistic insights can also be gained from these results, when compared to cis-
platin and oxaliplatin, where the GI50 value for cisplatin increases by 4 times in the
p53 mutated cell line, the same value for oxaliplatin is > 25 times.29 The results
for the platinum drugs suggest that p53 is essential for there MOA, which is predict-
able given their activity focusses on DNA damage. As p53 is also required for Os-3
to keep its high level of activity one might suspect that DNA damage is part of the
MOA, however, Os-3 was shown not to bind to DNA models, although it is the only
Os compound to hydrolyse. The remaining compounds do not require p53 for activ-
ity.
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Figure 1.4: Graph showing GI50 values (± standard deviation) for compounds Os-2, Os-3 and
Os-4 in different cell lines. Activity values were calculated from triplicate measurements in
colorectal cell lines (purple) and ovarian cell lines (blue) and show that Os-2 and Os-3 hold
their activity in cisplatin-resistant A2780 cells (A2780cis), but only Os-2 maintains activity in
oxaliplatin-resistant HCT116 (HCT116Ox). Os-4 is more active in cisplatin-resistant A2780 and
approximatively equipotent in oxaliplatin-resistant HCT116. Interestingly, Os-4 is highly active in
p53(-/-) HCT116 cells compared to wild-type HCT116.29, 31
Cancer cell selectivity. To investigate the activity of the Os and Ir compounds in normal,
fast dividing cells versus activity in cancerous cells, the GI50 of Os-2 and Os-3 in ovarian
cancer cells (A2780) and normal lung fibroblast cells (MRC-5) was determined.29 Results
show that the two Os complexes are ⇡ 30 times more active in A2780 (Table 1.2). As a
reference, the resistance factor for cisplatin is ⇡ 10, highlighting the promising selectivity
of the Os compounds.
Combination treatment with L-BSO. L-Buthionine sulfoximine (L-BSO) depletes the
levels of glutathione (GSH) inside the cells, where GSH is an antioxidant, required to
protect the cell from reactive oxygen species (ROS). L-BSO is currently in clinical trails
as a cytostatic agent used in combination with Melphalan, an alkylating agent.32 Table
1.3 shows that when cells are co-incubated with 5 µM L-BSO, the activity of the Os and
Ir compounds increases by up to 50-fold.31
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Table 1.2: Activity data for Os-2 and Os-3 compounds in A2780 ovarian cancer cells versus
MRC-5 normal lung fibroblast cells.29 GI50 values were calculated from triplicate measurements,
shown as ±SD. The resistance factor compares the activity in each cell line, where a higher
resistance factor shows a lower sensitivity of normal cell lines to each compound. The higher
the resistance factor the safer the compound is predicted to be regarding off-target side-effects in
patients, with both Os-2 and Os-3 showing promising levels of selectivity.
Compounds A2780 GI50 MRC-5 GI50 Resistance⇤
µM µM factor
Os-2 1.20 ± 0.003 31.8 ± 0.02 25.8
Os-3 0.16 ± 0.02 4.5 ± 0.09 28.1
* Resistance factor is calculated as the ratio of activity between MRC-5/A2780
Table 1.3: Synergistic behaviour between The activity of compounds Os-2, Os-3, Ir-9 and Ir-10
in A2780 cells with and without co-incubation with reactive oxygen species (ROS) scavenger
L-buthionine sulfoximine (L-BSO). Activity values were calculated from triplicate measurements,
shown as ±SD. The activity ratio describes the effect that co-incubation has on the anticancer
activity, where a high value suggests that L-BSO increases the susceptibility of cancer cells to
each compound. The data shows that L-BSO enhances the activity of all compounds, particularly
Ir-10.29, 31
Compounds 0 µM L-BSO 5 µM L-BSO Activity⇤
GI50 µM GI50 µM ratio
Os-2 1.20 ± 0.003 0.080 ± 0.002 15.0
Os-3 0.16 ± 0.020 0.069 ± 0.002 2.3
Ir-9 0.68 ± 0.040 0.110 ± 0.040 6.2
Ir-10 0.40 ± 0.080 0.008 ± 0.002 50.0
* Activity ratio is the GI50 ratio between cells co-incubated with 0 µM/5 µM L-BSO.
Table 1.3 highlights their potential, when used in combination with L-BSO, to drop
the administered dose into a safer range for patients. Developing drugs as combination
treatments, whether synergist or additive, is an attractive prospect to reduce off target
effects and to target tumour cell heterogeneity.
The work carried out to date on the Os and Ir compounds highlights them as promising
therapeutics, particularly against EOC.
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1.3 Exploring mechanisms of action
A personalised approach to clinical treatment aims to examine each patient individually,
on a genetic level, and identify biomarkers responsible for disease development and for
treatment prognosis.33, 34 From this information, a physician would prescribe a specific
drug able to increase the effectiveness of treatments in patients. This approach is already
in use for some cancer biomarkers, however, the development of treatment systems like
this heavily relies on patient populations and access for clinical trials.
This stratified approach puts large emphasise on identifying the MOA for any emerging
anticancer compounds. If we could develop highly active chemotherapy drugs with the
ability to target such biomarkers, differentiating between fast dividing cancer cells and
fast dividing host cells, we may see a new treatment which is more effective and less
harmful to patients.
Developing a new agent, is a long and commonly unsuccessful process. The most fre-
quently used pipeline for drug development starts with identification of new carcinogenic
targets, either RNA, DNA or proteins. Developing the agent involves activity/affinity
screening against compound libraries.35, 36 From here, qualitative and quantitative read
outs of inhibition or binding to the target identify “hits”. Systems using drop-based
microfluidics can allow the testing of 100,000,000 reactions in 10 hours, reducing running
costs significantly with smaller reactant volumes.37 Identified hits are then validated with
their target and the hit-to-lead optimisation stage begins.38 The discovery of tyrosine
kinase inhibitors by this method is an excellent example of its success.
Although this drug development pipeline has shown strong merit in drug discovery,
library screening for inhibition of activity or for affinity binding is inherently complex.
Like any high throughput technique, there are incidence of both false negative and false
positive results, which makes hit selection criteria risky.39 Instead, a reverse approach
to early stage drug development is often preferable.40
12
Compounds are now synthesised based on prior knowledge and chemical and biological
principles. Simple in vitro screening can establish structure-activity-relationships, and even
allow compound optimisation at the earliest stage. Once activity has been proven, the hit is
taken forward for target identification. There are many resources and methods available to
investigate the targets and MOA of hit compounds, many of which can be complementary
techniques. Identifying the MOA of a novel hit compound is often a daunting and
expensive task, and relies heavily on scientific expertise across multiple disciplines.
1.3.1 Screening facilities
There are several institutions which offer help to early stage drug developers, screening
new compounds to allow researchers to infer MOA, or to at least move projects in the
right direction. This dramatically reduces cost in the long run.
1.3.1.1 National Cancer Institute
One of the most useful resources available is provided by the Developmental Therapeutics
Program (DTP), together with the National Cancer Institute (NCI) and the Nation Insti-
tute of Health (NIH). Here, the NCI performs drug screening in their so-called NCI-60
assays.41–43 The NCI-60 project was developed between 1985 and 1990, and became
fully implemented by April 1990, now testing approximately 3,000 compounds per year.
This NCI-60 screen tests the activity of submitted compounds in 60 of the most common
cancer cell lines, including leukemias, non-small cell lung, central nervous system, colon,
melanoma, renal, prostate, breast and ovarian. This service is free of charge for compounds
deemed promising by the NCI, with a quick turn around of results.
This provides useful data in itself, but can also be used together with information
in open access databases hosted by the DTP and NCI/NIH. Using these databases we
can compare their NCI-60 results to other compounds using the so-called “COMPARE”
algorithm.41–44 This algorithm is maintained by the NCI and calculates a Pearson’s
13
correlation coefficient (r) between activity values for one variable (NCI-60 activity results
for compound 1) and another variable (NCI-60 activity results for compound 2).
If correlated compounds have known MOA, it is possible to infer a MOA for their given
seed, by similarity. Previous work has successfully used this method to predict MOA for
anticancer compounds.31, 45–48
1.3.1.2 The Sanger Institute
The Wellcome Trust Sanger Institute is a non-profit organisation, run by Genome Research
Limited (GRL). The Cancer Genome Project (CGP) within the Sanger Institute has a
similar approach in drug development as the NCI, however, here compounds are tested in
ca. 1000 cell lines. The Sanger Institute performs a 9-dose response for each compound
on each cell lines, providing a GI50 value for each.
Like NCI data, Sanger screening provides an idea of the most suitable cancer cell
models, and together with COSMIC, a database of somatic cancer mutations, can also
provide biomarker information.49–53 The COSMIC database houses sequence data for
ca. 400 genes, describing both somatic mutations and copy number variations. These
genes are predicted or known to be important in cancer development and prognosis. The
GI50 values are then studied with respect to the cancer cell line and the respective genetic
events involved in that cell line. A study by Cowin et al used this method to show that
the high incidence of chemoresistance in patients with high-grade serous ovarian cancer
may be due in part to the depletion of a lipid transporter protein, LRP1B.54
1.3.2 Systems biology
Systems biology has become a fashionable area of cancer research. Although its concepts
are broadly interpreted, ‘assessing a system as the sum of its individual components’ is
a common definition. This concept can be useful in assessing MOA of emerging drugs,
gradually building up a complete picture of how a drug exerts its activity by seeing how
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it acts on individual aspects of a system. In a cell this could be achieved by combining
information about how the genes, proteins and cellular structures are affected by a given
compound. However, assessing an entire system as a sum of its components often creates
large complex datasets, therefore a large chunk of cancer-based systems biology is bioin-
formatics focussed, developing tools to handle and manipulate these datasets to provide
relevant clinical outcomes.
An emerging area of bioinformatics and systems biology produces tools to allow integ-
ration of heterogenous datasets. In 2012, The Cancer Genome Atlas Network used patient
data in a breast cancer study designed to integrate genomics, DNA methylation, exome
sequencing, transcriptomics, proteomics and breast cancer subtype.55 The study used data
from 825 patients showed a relation between basal-like breast tumours and high-grade
serous ovarian tumours, highlighting the potential for similar therapeutic treatments. They
also observed that plasticity and heterogeneity occurred within, and not across, the major
breast cancer subtypes. This example nicely demonstrates the merit of a systems biology
approach, combining as many different aspects of the breast cancer system to find a richer
result.
Using time series data in this context introduces further complexity into heterogenous
dataset integration, as the data are not strictly independent. Work conducted at the Warwick
Systems Biology Centre, with Professor David Wild, uses multiple dataset integration
(MDI) software to combine heterogenous datasets in a way to capture all dependences and
complementary aspects in the data.56–58 In a study by Kirk et al, transcriptomic, chIP and
protein-protein interaction (PPI) data were integrated using publicly available databases
for S. cerevisiae and produced a list of clustered genes which were “fused” across all three
datasets.56 A fused gene, is one which behaves similarly across all datasets, irrespective
of the measurement type. MDI is an unsupervised Bayesian method, which allows the
software to exploit the natural clustering of ‘omics data reducing data constraints and
the potential loss of useful information. This is a promising concept, particularly as MDI
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is amenable to gaussian, time series, categorical and discreet datasets.
The work described above was performed in a simpler eukaryotic system, however,
the use of MDI could also be extended to study more complex systems. For example,
combining time series transcriptomic and proteomic data from cells exposed to a given
compound, or to complement the Sanger screening data, capturing dependencies of drug
sensitivity with tissue type and genetic events.
The former could provide information on where gene and protein behaviour overlay,
and where there are discrepancies, both of which provide mechanistic insights. A study
by Rogers et al demonstrated the potential of using such models to combine such data
types. This study was performed with human mammary epithelial (HMEC) time series
gene and protein data, where cells had been stimulated with epidermal growth factor
(EGF).58 The number of genes and proteins modelled was relatively small (ca. 500),
however provided interesting results which demonstrated a poor correlation between
mRNA and protein expression in some biological components. These same principles
could be applied to study cancer systems, integrating gene and protein regulation from
cells exposed to anticancer agents.
1.3.3 Transcriptomics
The central dogma of molecular biology describes the flow of genetic information;
Marshall Nirenberg simply described it as “DNA makes RNA makes protein”.59 The tran-
scriptome refers to the set of transcripts (mRNA sequences) in a cell, which reflect the gene
expression profile as a result of the first step of the central dogma.60 This gene expression
can capture how a cell responds during a given process or after a given treatment. Transcrip-
tomics, principally, allows us to determine the abundance of these transcripts in the cell.
The past decade saw the development of next generation sequencing (NGS), where
RNA sequencing (RNAseq) is used to study transcriptomics, providing insights about
the transcriptome of any species.60 RNAseq provides superior sensitivity and resolution
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compared to DNA microarrays, allowing users to analyse a fuller dataset with increased
accuracy for both lowly- and highly-expressed genes.61–63
The use of RNAseq in anticancer drug development has shown notable success, partic-
ularly to investigate resistance mechanisms, however, there are still few reported studies.
For example, Houghtaling et al published a method to identify targets of known anticancer
drugs BI 2536 and bortezomib by studying resistance mechanisms in drug-resistant
clones.64 The authors suggest that such an approach would only work with singly targetted
drugs, as those with multiple targets would add too much complexity to their models. This
highlights the potential issues with using a technique like RNAseq to investigate drug
MOA, particularly if used for complex molecules likely to target many cellular profiles.
1.3.4 Proteomics
Although cancer is generally governed by genetics and epigenetics, the response to
anticancer treatments are registered at a protein level.40 Therefore the study of proteins
in response to drug exposure can provide great insights into MOA and into patient se-
lectivity. Proteomics is the concept of measuring the properties, whether it be abundance
or modification, of proteins in a given sample. In theory, the level of protein X in a system
should be positively correlated to the expression of gene X, however, this is not always the
case.58 For this reason it is often interesting to study both transcriptional and translational
systems, particularly if investigating drug MOA.
A bottom-up proteomic approach, known as shotgun proteomics, would trypsinise
native proteins and run the associated fragments through a mass spectrometer, using LC/M-
S/MS.65, 66 These methods have provided positive results in the area of cancer research,
for example, an extensive review by Flatley et al discussed studies using MALDI-MS
to study prostate cancer biomarkers.67 Ichibangase et al used a novel MS approach, with
FD-LC-MS/MS to study both protein expression and cellular events in metastatic and non-
metastatic breast cancer using fluorometry to select proteins of interest in the first step.68
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Although MS proteomic studies have high resolving power, highly abundant protein
signals often swamp smaller protein signals.69 Protein binding assays are an alternative
approach to proteomics developed from the same principles as enzyme-linked immun-
osorbent assays (ELISA), which were first introduced in 1971.70 The concept of this
approach is for a primary antibody to bind specifically to an antigen of interest, and then
for a secondary antibody, with an enzyme conjugate to bind to the primary antibody.
Substrate would then be added and subsequently processed by the conjugated enzyme
to elicit a readable, and typically amplified, response.
A modern adaptation of this approach is to use fluorescently-labelled analyte-specific
reagents, often an antibody, to quantify a response by fluorescence. Evolution of this
technique has produced the protein microarray, allowing high throughput analysis of
protein samples.71 Protein microarrays have broad applications, requiring only a small
amount of sample and a small amount of reagent. There are two types of protein arrays:
capture microarrays and reverse-phase microarrays (RPPA).72 The former are principally
similar to the DNA microarray, where analyte-specific reagents (ASR) are spotted onto an
array and a labelled experimental sample is exposed to the array.73, 74 Labelled proteins
of interest will bind to their ASR, allowing fluorescence detection. The latter, RPPA, is
more applicable if users do not wish to chemically modify their samples.71 Here, the
sample is spotted onto the array, and labelled ASRs are flushed over the sample, binding
to their proteins of interest.
This second method for studying proteomics is simpler, and less data intensive, however
studying the whole proteome by this method would be extremely expensive. Using this
method in combination with transcriptomics is a good way to gain global cellular insights
whilst keeping the cost manageable.
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1.3.5 Imaging
Clinical imaging is commonly used for diagnosis and to follow tumour progression
in cancer patients. Techniques like computerised tomography (CT) and more recently,
magnetic resonance imaging (MRI), allow direct 3D tumour evaluations to be made.
Positron emission tomography (PET) imaging is also used for detection and monitoring
of tumours by following radioactive tracer molecules, administered to patients. Glucose
is the most commonly used tracer, given cancer cells use glucose differently to normal
cells. PET is often used in combination with either CT or MRI imaging, with an ovarian
cancer study concluding that PET/MRI generally provides fewer false positives.75
For investigating in vitro drug effects, a broad range of imaging techniques can be used,
whether measuring fluorescent biomarkers or visualising entire cellular structures. For ex-
ample, high-content screening (HCS) allows the study of multiple features simultaneously,
in single cells, and has strong applications in mechanistic studies. Work by Carragher et al
used HCS to identify structural alterations in cancer cells exposed to classified anticancer
agents, by simultaneously measuring the cell membrane, cell nuclei and cytoplasm using
different fluorescent dyes.76 Applying principal component analysis (PCA) to measurable
phenotypic parameters allowed the group to separate phenotypic behaviour into subpopu-
lations. Each phenotypic subgroup corresponded to a particular class of anticancer agents,
thus highlighting this method as a good predictive tool for new anticancer agents.
Other whole cell imaging techniques include electron microscopy, particularly transmis-
sion electron microscopy (TEM) which has been reported in MOA studies for Os-based
picolinate compounds.77 Here ovarian cancer cells were exposed to the drug, and the
whole cell structures were studied. Given the heavy nature of Os atoms, if a high enough
concentration is added to cells, it should be possible to follow directly the distribution
of Os metal, due to extensive interactions with the electron beam.
Secondary ion mass spectrometry (nanoSIMS) is an imaging mass spectrometry (IMS)
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technique and has been used successfully to follow the distribution of both platinum and
gold compounds in cancer cells.78, 79 Here, drug-exposed cell sections are exposed to
a primary caesium beam which sputters the cell surface and releases secondary ions. The
detection of multiple, pre-determined masses, allows identification of the distribution of
drug, and to investigate co-localisation with other elements in the cell e.g. phosphorus
(31P), to represent DNA.
Collectively, imaging has a prominent place in cancer research, both in clinical and
preclinical applications.
1.4 Thesis structure
As the progression towards personalised and stratified medicine continues, the identi-
fication of drug compound MOA and target patient populations becomes increasingly
important. The promising organometallic compounds introduced here will struggle to
reach clinical trials unless we can gain further insights into their modes of activity.
1.4.1 Aims
The work included here, aims to use high-throughput screening techniques to filter out
lead compounds from a batch of promising osmium and iridium candidates. Large scale
experiments provide further understanding of lead compounds MOAs, combining cellular
responses at the transcriptomic, translational and structural levels. RNA sequencing is used
to study differential gene expression, reverse phase protein microarrays are used to study
translational responses, and electron microscopy and high-content screening is used to
study morphological changes in cancer cells responding to treatment with lead compounds.
This approach could pave the way for future studies to identify whether these cel-
lular responses result from a directed MOA, and if so to determine the biological tar-
get.
20
Chapter 3: Cell Screening. This chapter discusses cell screening after the organo-
metallic compounds were submitted to the National Cancer Institute (NCI), the Sanger
institute and the Edinburgh Cancer Research Centre. From each screen the activity
of each compound is discussed, as is the cell line selectivity. Using this information,
together with basic statistical methods, the activity fingerprints of the organometallic
compounds are quantitatively compared to other drug-compounds populating publicly
available databases.
Chapter 4: Transcriptomics. Using RNA sequencing, the levels of gene expression
are studied after ovarian cancer cells are exposed to Os-3 and Ir-10 at their respective
GI50 concentrations (Table 1.1). Time course measurements are taken, over a 48 h
period, and using pathway analysis the biological implications of compound-exposure
are discussed.
Chapter 5: Proteomics. Reverse phase protein microarrays (RPPA) are used to quantify
the levels of selected proteins after ovarian cancer cells are exposed to Os-3 and Ir-10
at a low and high concentration, across a 72 h time course. Flow cytometry experiments
highlight key differences in cellular response between compounds.
Chapter 6: Multiple Dataset Integration. Using a Bayesian clustering algorithm,
developed at the Warwick Systems Biology Centre, transcriptomic and proteomic datasets
are combinatorially analysed. This method of clustering allows relationships between
the heterogeneous data types to be extracted, and further conclusions about compound
MOAs to be drawn.
Chapter 7: Imaging. High-content screening, using fluorescence microscopy invest-
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igates apoptosis in ovarian cancer cell lines exposed to Os-1, Os-3, Os-4, Ir-9, Ir-10
and cisplatin at a range of concentrations. In addition, whole-cell transmission electron
microscopy (TEM) is performed to explore compound-effects on ovarian cancer cells
after exposure to Ir-6 for 24 h.
22
References
[1] Cancer Research UK (2012) CancerStats: Cancer Statistics for the UK. Online
Source. www.cancerresearchuk.org/cancer-info/cancerstats/.
[2] Cancer Research UK (2013) CanceStats: key facts. Online Source.
www.publications.cancerresearchuk.org/downloads/Product/CS KF ALLCANCERS.pdf.
[3] NHS (2012) Ovarian cancer. Online Source. www.nhs.uk/Conditions/Cancer-of-
the-ovary/Pages/Introduction.aspx.
[4] US Cancer Statistics Working Group (2013) United Cancer Statistics: 1999-2010
Incidence and Mortality Web-based Report.
[5] Kurman RJ, Shih IM (2010) The origin and pathogenesis of epithelial ovarian
cancer: a proposed unifying theory. The American Journal of Surgical Pathology
34:433–443.
[6] Kurman RJ, Shih L (2011) Molecular pathogenesis and extraovarian origin of
epithelial ovarian cancer-shifting the paradigm. Human pathology 42:918–931.
[7] Cancer Net (2013) Ovarian Cancer. Online Source. www.cancer.net/cancer-
types/ovarian-cancer/diagnosis.
[8] Heppner GH (1984) Tumor heterogeneity. Cancer Research 44:2259–2265.
[9] Marusyk A, Polyak K (2010) Tumor heterogeneity: causes and consequences.
Biochimica et Biophysica Acta 1805:105–17.
[10] Wang V, et al. (2005) Ovarian cancer is a heterogeneous disease. Cancer Genetics
and Cytogenetics 161:170–173.
23
[11] Zhan Q, Wang C, Ngai S (2013) Ovarian cancer stem cells: a new target for cancer
therapy. BioMed Research International 2013:916819.
[12] Michor F, Nowak MA, Iwasa Y (2006) Evolution of resistance to cancer therapy.
Current Pharmaceutical Design 12:261–271.
[13] Dabrowiak JC (2009) Metallo-Drugs and Their Action. Metals in Medicine pp 49–71.
[14] Garbutcheon-Singh KB, et al. (2011) Transition metal based anticancer drugs.
Current Topics in Medicinal Chemistry 11:521–542.
[15] Monneret C (2011) Platinum anticancer drugs. From serendipity to rational design.
Annales Pharmaceutiques Franc¸aises 69:286–295.
[16] Florea AM, Busselberg D (2011) Cisplatin as an anti-tumor drug: cellular mech-
anisms of activity, drug resistance and induced side effects. Cancers 3:1351–1371.
[17] Kelland L (2007) The resurgence of platinum-based cancer chemotherapy. Nature
Reviews Cancer 7:573–584.
[18] Colombo N, Gore M (2007) Treatment of recurrent ovarian cancer relapsing 6-12
months post platinum-based chemotherapy. Critical reviews in Oncology/Hemat-
ology 64:129–138.
[19] Hannon MJ (2007) Metal-based anticancer drugs: From a past anchored in platinum
chemistry to a post-genomic future of diverse chemistry and biology. Pure and
Applied Chemistry 79:2243.
[20] Fu Y, et al. (2011) Structure-activity relationships for organometallic osmium arene
phenylazopyridine complexes with potent anticancer activity. Dalton Transactions
40:10553–10562.
24
[21] Castonguay A, Doucet C, Juhas M, Maysinger D (2012) New ruthenium(II)-
letrozole complexes as anticancer therapeutics. Journal of Medicinal Chemistry
55:8799–8806.
[22] Hartinger CG, Phillips AD, Nazarov AA (2011) Polynuclear ruthenium, osmium
and gold complexes. The quest for innovative anticancer chemotherapeutics. Current
Topics in Medicinal Chemistry 11:2688–702.
[23] Liu Z, Habtemariam A, Pizarro AM, Clarkson GJ, Sadler PJ (2011) Organometallic
Iridium(III) Cyclopentadienyl Anticancer Complexes Containing C,N-Chelating
Ligands. Organometallics 30:4702–4710.
[24] Liu Z, et al. (2011) Contrasting reactivity and cancer cell cytotoxicity of isoelectronic
organometallic iridium(III) complexes. Inorganic Chemistry 50:5777–5783.
[25] Liu Z, et al. (2011) Organometallic half-sandwich iridium anticancer complexes.
Journal of Medicinal Chemistry 54:3011–3026.
[26] Fu Y, et al. (2010) Organometallic osmium arene complexes with potent cancer
cell cytotoxicity. Journal of Medicinal Chemistry 53:8192–8196.
[27] Shnyder S, et al. (2011) Anti-colorectal cancer activity of an organometallic osmium
arene azopyridine complex. Medical Chemistry Communications 2:666–668.
[28] Liu Z, et al. (2014) The Potent Oxidant Anticancer Activity of Organoiridium
Catalysts. Angewandte Chemie (International ed. in English) 53:3941–3946.
[29] Romero-Canelo´n I, Salassa L, Sadler PJ (2013) The contrasting activity of iodido
versus chlorido ruthenium and osmium arene azo- and imino-pyridine anticancer
complexes: control of cell selectivity, cross-resistance, p53 dependence, and
apoptosis pathway. Journal of Medicinal Chemistry 56:1291–300.
25
[30] Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature
408:307–310.
[31] Hearn JM, et al. (2013) Organometallic Iridium(III) Anticancer Complexes with
New Mechanisms of Action: NCI-60 Screening, Mitochondrial Targeting, and
Apoptosis. ACS Chemical Biology 8:1335–1343.
[32] Bailey HH, et al. (1994) Phase I clinical trial of intravenous L-buthionine
sulfoximine and melphalan: an attempt at modulation of glutathione. Journal of
Clinical Oncology 12:194–205.
[33] Schilsky RL (2010) Personalised Medicine in Oncology: The future is now. Nature
Reviews Drug Discovery 9:363–366.
[34] Biankin A (2011) Genotype guided personalised cancer care using next generation
sequencing. AsiaPacific Journal of Clinical Oncology 7:78–79.
[35] Makara GM, Athanasopoulos J (2005) Improving success rates for lead generation
using affinity binding technologies. Current Opinion in Biotechnology 16:666–673.
[36] Comess KM, Schurdak ME (2004) Affinity-based screening techniques for enhan-
cing lead discovery. Current Opinion in Drug Discovery Development 7:411–416.
[37] Agresti JJ, et al. (2010) Ultrahigh-throughput screening in drop-based microfluidics
for directed evolution. Proceedings of the National Academy of Sciences of the
United States of America 107:4004–4009.
[38] Keseru GM, Makara GM (2006) Hit discovery and hit-to-lead approaches. Drug
Discovery Today 11:741–748.
[39] Popa-Burke IG, et al. (2004) Streamlined system for purifying and quantifying
a diverse library of compounds and the effect of compound concentration
26
measurements on the accurate interpretation of biological assay results. Analytical
Chemistry 76:7278–7287.
[40] Carragher NO, Brunton VG, Frame MC (2012) Combining imaging and pathway
profiling: An alternative approach to cancer drug discovery. Drug Discovery Today
17:203–214.
[41] Paull K, et al. (1989) Display and analysis of patterns of differential activity of
drugs against human tumor cell lines: development of mean graph and COMPARE
algorithm. Journal of The National Cancer Institute 81:1088–1092.
[42] Shoemaker RH (2006) The NCI60 human tumour cell line anticancer drug screen.
Nature Reviews Cancer 6:813–23.
[43] Holbeck S, Collins JM, Doroshow JH (2010) Analysis of Food and Drug
Administration-Approved Anti-cancer Agents in the NCI60 Panel of Human Tumor
Cell Lines. Molecular Cancer Therapeutics 9:1451–1460.
[44] Zaharevitz DW, Holbeck SL, Bowerman C, Svetlik PA (2002) COMPARE: a web
accessible tool for investigating mechanisms of cell growth inhibition. Journal
of Molecular Graphics Modelling 20:297–303.
[45] Fagan V, et al. (2012) COMPARE analysis of the toxicity of an iminoquinone deriv-
ative of the imidazo[5,4-f]benzimidazoles with NAD(P)H:quinone oxidoreductase
1 (NQO1) activity and computational docking of quinones as NQO1 substrates.
Bioorganic and Medicinal Chemistry 20:3223–3232.
[46] Fre´de´rick R, et al. (2012) Novel trisubstituted harmine derivatives with original
in vitro anticancer activity. Journal of Medicinal Chemistry 55:6489–501.
27
[47] Zhou J, Et Al. (2005) COMPARE analysis of the NCI-60 cancer cell lines reveals
a pharmacological interplay between farnesyltransferase and tubulin deacetylase.
Proceedings of the American Association of Cancer Research 46:0.
[48] Fojo T, et al. (2005) Identification of non-cross-resistant platinum compounds with
novel cytotoxicity profiles using the NCI anticancer drug screen and clustered image
map visualizations. Critical reviews in Oncology Hematology 53:25–34.
[49] Forbes SA, et al. (2008) The Catalogue of Somatic Mutations in Cancer (COSMIC).
Current Protocols in Human Genetics Chapter 10:Unit 10.11.
[50] Forbes SA, et al. (2010) COSMIC (the Catalogue of Somatic Mutations in Cancer):
a resource to investigate acquired mutations in human cancer. Nucleic Acids
Research 38:D652–D657.
[51] Forbes SA, et al. (2011) COSMIC: mining complete cancer genomes in the
Catalogue of Somatic Mutations in Cancer. Nucleic Acids Research 39:D945–D950.
[52] Hart S, et al. (2013) VS-5584, a Novel and Highly Selective PI3K/mTOR Kinase
Inhibitor for the Treatment of Cancer. Molecular Cancer Therapeutics 12:151–61.
[53] de la Rosa J, et al. (2013) Prelamin A causes progeria through cell-extrinsic
mechanisms and prevents cancer invasion. Nature Communications 4:2268.
[54] Cowin PA, et al. (2012) LRP1B Deletion in High-Grade Serous Ovarian Cancers
Is Associated with Acquired Chemotherapy Resistance to Liposomal Doxorubicin.
Cancer Research 72:4060–4073.
[55] Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of
human breast tumours. Nature 490:61–70.
[56] Kirk P, Griffin JE, Savage RS, Ghahramani Z, Wild DL (2012) Bayesian correlated
clustering to integrate multiple datasets. Bioinformatics 28:3290–3297.
28
[57] Savage R, Ghahramani Z, Griffin JE, de la Cruz BJ, Wild DL (2010) Discovering
transcriptional modules by Bayesian data integration. Bioinformatics 26:158–167.
[58] Rogers S, et al. (2008) Investigating the correspondence between transcriptomic
and proteomic expression profiles using coupled cluster models. Bioinformatics
24:2894–2900.
[59] Leavitt S (2010) Deciphering the genetic code: Marshall Nirenberg. Online Source
- http://history.nih.gov/exhibits/nirenberg/.
[60] Wang Z, Gerstein M, Snyder M (2009) RNA-Seq: a revolutionary tool for
transcriptomics. Nature Reviews Genetics 10:57–63.
[61] Ledford H (2008) The death of microarrays? Nature 455:847.
[62] Fathallah-Shaykh HM (2005) Microarrays: applications and pitfalls. Archives of
Neurology 62:1669–1672.
[63] Venkatasubbarao S (2004) Microarrays status and prospects. Trends in
Biotechnology 22:630–637.
[64] Houghtaling BR, Wacker SA, Elemento O, Kapoor TM (2012) Using transcriptome
sequencing to identify mechanisms of drug action and resistance. Nature Chemical
Biology 8:235–237.
[65] Karpievitch YV, Polpitiya AD, Anderson Ga, Smith RD, Dabney AR (2010)
Liquid Chromatography Mass Spectrometry-Based Proteomics: Biological and
Technological Aspects. The Annals of Applied Statistics 4:1797–1823.
[66] Chen G, Pramanik BN (2009) Application of LC/MS to proteomics studies: current
status and future prospects. Drug Discovery Today 14:465–471.
29
[67] Flatley B, Malone P, Cramer R (2013) MALDI mass spectrometry in prostate
cancer biomarker discovery. Biochimica et Biophysica Acta 1844:940–949.
[68] Ichibangase T, Imai K (2012) FD-LC-MS/MS Method for Determining Protein
Expression and Elucidating Biochemical Events in Tissues and Cells. Biological
and Pharmaceutical Bulletin 35:1393–1400.
[69] Pawlak M, et al. (2002) Zeptosens’ protein microarrays: a novel high performance
microarray platform for low abundance protein analysis. Proteomics 2:383–393.
[70] Engvall E, Jonsson K, Perlmann P (1971) Enzyme-linked immunosorbent
assay. II. Quantitative assay of protein antigen, immunoglobulin G, by means of
enzyme-labelled antigen and antibody-coated tubes. Biochimica et Biophysica Acta
251:427–434.
[71] LaBaer J, Ramachandran N (2005) Protein microarrays as tools for functional
proteomics. Current Opinion in Chemical Biology 9:14–19.
[72] Wilson B, Liotta LA, Petricoin E (2010) Monitoring proteins and protein networks
using reverse phase protein arrays. Disease markers 28:225–232.
[73] Predki PF (2004) Functional protein microarrays: ripe for discovery. Current
Opinion in Chemical Biology 8:8–13.
[74] Jona G, Snyder M (2003) Recent developments in analytical and functional protein
microarrays. Current Opinion in Molecular Therapeutics 5:271–277.
[75] Iyer VR, Lee SI (2010) MRI, CT, and PET/CT for ovarian cancer detection and
adnexal lesion characterization. American Journal of Roentgenology 194:311–321.
[76] Caie PD, et al. (2010) High-content phenotypic profiling of drug response signatures
across distinct cancer cells. Molecular Cancer Therapeutics 9:1913–1926.
30
[77] van Rijt SH, Mukherjee A, Pizarro AM, Sadler PJ (2010) Cytotoxicity, hydrophobi-
city, uptake, and distribution of osmium(II) anticancer complexes in ovarian cancer
cells. Journal of Medicinal Chemistry 53:840–849.
[78] Wedlock LE, et al. (2013) NanoSIMS multi-element imaging reveals internalisation
and nucleolar targeting for a highly-charged polynuclear platinum compound.
Chemical Communications 49:6944–6946.
[79] Wedlock LE, et al. (2011) Visualising gold inside tumour cells following treatment
with an antitumour gold(i) complex. Metallomics 3:917–925.
31
Chapter 2. Materials and Methods
32
2.1 Materials
For the biological experiments, Roswell Park Memorial Institute (RPMI-1640) medium,
as well as foetal bovine serum, L-glutamine, penicillin/streptomycin mixture, trypsin,
trypsin/EDTA, phosphate buffered saline (PBS) were purchased from PAA Laboratories
GmbH. HPLC grade ethanol, b -mercaptoethanol, PI (>94%), Annexin V-FITC Apoptosis
Detection Kit and RNAse A were obtained from Sigma Aldrich. The Abcam JC-10 Mi-
tochondrial Membrane Potential Assay kit was obtained from Enzo. For RNA sequencing,
cell shredders and mini-prep kits were purchased from Qiagen. For TEM, glutaraldehyde
(2%), cacodylate buffer at pH 7.6, 2% uranyl acetate in maleate buffer, 100% propylene
oxide and Embed 812 resin were all purchased from Agar Scientific and Poly/Bed 812
was purchased from Polysciences. For ICP-MS, osmium Specpure standard was obtained
from Inorganic Ventures.
2.2 Methods
2.2.1 Compound synthesis and characterisation
All compounds were synthesised and characterised by Dr Fu Ying and Dr Zhe Liu in
previous works.1–5
2.2.2 Cell maintenance
A2780, human ovarian carcinoma were obtained from the European Collection of Cell
Cultures (ECACC). Cells were grown in Roswell Park Memorial Institute (RPMI-1640)
medium supplemented with 10% foetal calf serum, 1% (v/v) 2 mM glutamine and 1%
(v/v) penicillin (10 k units/mL)/streptomycin (10 mg/mL). All cells were maintained in
75 cm3 culture flasks at 37oC with 5% CO2 humidified atmosphere. Cells were grown
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as adherent monolayers and split when 80-90% confluent, using 0.25% trypsin.
2.2.3 GI50 determinations
All GI50 values were determined in previous work by Dr Isolda Romero and Dr Ana
Pizarro.1–5 Briefly, A2780 cells were seeded in 96 well plates with ca. 5000 cells per well.
The plates were incubated at 37oC for 48 h. A 2 mM stock solution of each compound
was prepared in 5% DMSO, 95% saline, from which final dilutions ranging from 0.1 to
100 µM were made with RPMI-1640. Drug exposure time was 24 h at 37oC, after which
supernatants were removed cells were allowed to recover for 72 h in drug-free medium
at 37oC. The sulforhodamine B (SRB) assay was used to determine cell viability.
2.2.4 Cell screening
2.2.4.1 NCI-60 screening with the National Cancer Institute
Compounds were submitted to the National Cancer Institute (USA) as solid samples.
Submissions for all compounds used in this work were made between 2010 and 2011.
The full protocols used by the NCI have been described previously.6–8 Briefly, cells were
seeded into 96 well plates at a density of 5,000 40,000 cells/well (depending on cell
line doubling time). Plates were incubated at 37oC, 5% CO2, 95% air and 100% relative
humidity for 24 h. After 24 h, two plates of each cell line were fixed in situwith TCA to rep-
resent a measurement of cell population (C) for each cell type at the time of drug addition
(T0). Stock solutions of each drug were made in DMSO and diluted. From this, 5 drug con-
centrations were made down to a 10-fold decreases from the maximum test concentration.
Drug solutions were added to appropriate cell populations and the plates left to incubate
for 48 h. Using the sulforhodamine B (SRB) assay the cell growth and survival (Ti) were
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measured on a plate reader and dose response curves plotted to calculate three parameters:
GI50 [Ti/(C T0)] ⇥ 100= 50
TGI Ti = T0
LC50 [Ti T0)/T0] = 50
Dose response curves, and activity values were returned to The University of Warwick
for downstream analysis. All figures presented in this thesis were reconstructed using R
which is a free programming language and software environment for statistical computing
and graphics.
2.2.4.2 Screening with the Sanger Institute
Compounds Os-1, Os-3, Os-4, Ir-9 and Ir-10 were submitted in January 2012 for testing
in the ‘Genomics of Drug Sensitivity in Cancer’ project at the Sanger Institute (Cambridge,
UK).9
Briefly, cells were seeded in 96 well plates at ca.15% confluency and left to incubate
for 24 h at 37oC, 5% CO2, 95% air and 100% relative humidity. For adherent cell lines,
cells were treated with nine concentrations of each compound (2-fold dilution series over
256-fold concentration range) and returned to the incubator for 72 h. Cells were then fixed
with 4% formaldehyde for 30 minutes and stained with 1 µM Syto60 for 1 h. Quantitation
of fluorescent signal intensity was performed using a plate reader at excitation/emission
wavelengths of 630/695 nm.
For suspension cell lines, cells were treated with compound immediately following plat-
ing, and returned to the incubator for 72 h. Cells were stained with 55 µg/mL Resazurin,
prepared in gutathione-free media, for 4 h. Quantitation of fluorescent signal intensity
was performed using a plate reader at excitation/emission wavelengths of 535/595 nm.
Dose response curves were constructed from the fluorescence data, and analysed as
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discussed in Chapter 3. GI50 values were returned to The University of Warwick for
downstream analysis. MANOVA analysis was performed by the Sanger bioinformatics
institute, and the results returned to The University of Warwick for interpretation. All
figures presented in this thesis were reconstructed using the R statistical programme.
2.2.4.3 Primary cell screening with The Edinburgh Cancer Research Centre
Compounds Os-1, Os-3, Os-4, Ir-9 and Ir-10 were submitted in January 2012 and were
tested for antiproliferative activity.
Primary patient cell lines were seeded in 96 well plates with ca. 5000 cells per well
in RPMI-1640 with 1% (v/v) 2 mM glutamine. The plates were incubated at 37oC for
48 h. Stock solutions of each compound were prepared and cells exposed across a dose
range for a further 48 h. Cells were extracted and the MTT (3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide) assay (Life Technologies) was used to determine
cell viability.
2.2.5 RNA sequencing
2.2.5.1 Experimental lab work
Experimental work performed at The University of Warwick. A2780 cells were
seeded in P100 petri dishes at 3 x 106 cells per 100 mm petri dish. Plates were incubated
for 24 h at 37oC, 5% CO2, 95% air and 100% relative humidity. Stock solutions of each
compound and of the vehicle control solutions were prepared in 5% DMSO, 10% saline,
and 85% RPMI-1640 medium. Cells were exposed to Os-3 at a final concentration of
150 nM and to Ir-10 at a final concentration of 400 nM, their respective GI50 values. A
final DMSO concentration for all cell samples did not exceed 0.05%. After compound
addition, cells were incubated for a further 4, 12, 24 and 48 h.
Media was aspirated from cells and cells were washed twice with PBS before trypsin-
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ising and collection. To each sample, 600 µL RTL lysis buffer (Qiagen) was added and the
samples vortexed. Lysate was pipetted directly into QIAshredder spin columns (Qiagen)
and centrifuged. Lysate was transfered to gDNA eliminator spin columns (RNeasy plus
mini kit, Qiagen) and centrifuged. Columns were discarded and 600 uL of 70% ethanol was
added to each sample flow-through. Samples were transfered into RNeasy spin columns
(RNeasy plus mini kit, Qiagen) and centrifuged. Column-bound RNA samples were
washed with RW1 and RPE buffer (RNeasy plus mini kit, Qiagen) before RNA collection
in 70 µL RNAse-free water. Samples were stored at -80 C for no more than 2 months.
Samples were diluted 1:10 fold in RNAse free water and run on a NanoDrop 1000
spectrophotometer machine and the absorbance at 230, 260 and 280 nm recorded to
calculate the 260/230 and 260/280 ratios. Samples with A260/230  2.0 and A260/280
 1.9 were passed. The concentration of RNA in each solution was also estimated using
the NanoDrop and was verified using a 2100 Agilent Bioanalyzer and an RNA 6000 Nano
Kit (Agilent), and the Qubit assay (Life Technologies). All samples had a RNA integrity
number (RIN)   9. A minimum of 1 µg RNA for each sample was transferred to Oxford
Genomics Centre (Wellcome Trust Centre for Human Gentics) in a total of 30 µL RNAse
free water in skirted 96 well plates.
Experimental work performed by the Oxford Genomics Centre. TruSeq kits (Il-
lumina) were used to prepare samples for sequencing as per the manufacturers guidelines.
From total RNA, mRNA samples were purified, fragmented and reverse transcribed to
cDNA. Sequencing libraries were produced, with incorporated barcodes to allow multi-
plexing. Samples were sequenced on an Illumina Hiseq2000 instrument across 5 lanes (6
samples per lane). 50 base pair, paired-end reads were recorded producing ca. 60 million
reads in total, per sample (Appendix 9.2).
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2.2.5.2 Data analysis
Data analysis performed at Oxford Genomic Centre. Preliminary filtering was per-
formed on the data to remove all samples with quality scores (Q)< 20. FASTQ files for the
forward and reverse reads were integrated and aligned to the hg19 (GRCh37) human gen-
ome using TopHat2.10 Files were returned to The University of Warwick in BAM format.
Data analysis performed at Warwick. Integrative genome viewer (IGV, version
2.3.13) was used to visualise BAM file mapping, and to identify somatic mutations in
mapped reads.11 Samtools (version 0.1.19-44428cd) was used to explore the raw BAM
files, extracting chromosomal reads and summary statistics.12 BAM files were sorted by
read name and then converted to SAM format.
HTSeq (version 0.5.4p5) was used to map the read locations to genomic regions using
the hg19 genome construct with the intersection-nonempty program option.13 Resulting
mapped files, were then analysed for differential gene expression using the edgeR package
(version 3.1.10) in the R statistical programme (version 3.0.2).14 A workflow of the edgeR
method is described in Chapter 4.
A list of differentially expressed genes was obtained for each time point (4, 12, 24 and
48 h) and used together with Ingenuity Pathway Analysis software to assign significantly
expressed genes to biological pathways. A detailed description of how this pathway
analysis is performed is discussed in Chapter 4.
2.2.6 Reverse phase protein microarrays (RRPA)
Compounds were submitted to The Edinburgh Cancer Research Centre (Edinburgh, UK)
as solid samples. Compounds Os-3 and Ir-10 were tested by RPPA in March 2014.
4 x 105 A2780 cells were seeded per well in 6-well plates, with samples in duplicate.
Cells were pre-incubated in drug-free media for 48 h at 37oC in a 5% CO2 humidified
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atmosphere. After this, cells were treated with each compound at 150 nM and 450 nM
(apart from Ir-9 which was only tested at 450 nM) for 4, 24, 48 and 72 h. Control samples
were treated with media containing 0.1% DMSO. Following exposure, drug-containing
medium was removed, and cells were washed twice with PBS and lysed with CLB1 buffer
(Zepotsens, Bayer) according to manufacturers instructions.
Cell lysates were normalised to a uniform protein concentration of 2 mg/mL with
spotting buffer CSBL1 (Zeptosens-Bayer) prior to preparing a final 4-fold concentra-
tion series of; 0.2; 0.15; 0.1 and 0.75 mg/mL. The diluted concentration series of each
sample was printed onto hydrophobic Zeptosens protein microarray chips (ZeptoChipTM,
Zeptosens-Bayer) under environmentally controlled conditions (constant 50% humidity
and 14o C temperature) using a non-contact printer (Nanoplotter 2.1e, GeSiM). A single
400 pL droplet of each lysate concentration was deposited onto the Zeptosens chip. A
reference grid of AlexaFluor647 conjugate BSA was spotted onto each sub-array, each
sample concentration series was spotted in between reference columns. After array
printing, the arrays were blocked with an aerosol of BSA solution using a custom designed
nebuliser device (ZeptoFOGTM, Zeptosen-Bayer) for 1 h to prevent non-specific antibody
binding. The protein array chips were subsequently washed in double-deionised water
(DDW) and dried prior to performing a dual antibody immunoassay comprising of a
24 h incubation of primary antibodies (Appendix 9.3) followed by 2.5 h incubation
with secondary Alexa-Fluor A647 conjugated antibody detection reagent (anti-rabbit or
anti-mouse A647 Fab, Invitrogen).
Following secondary antibody incubation and a final wash step in BSA solution, the im-
munostained arrays were imaged using the ZeptoREADER instrument (Zeptosens-Bayer).
For each-sub-array, five separate images were acquired using different exposure times
ranging from 0.5-10 s. Microarray images representing the longest exposure without
saturation of fluorescent signal detection were automatically selected for analysis using
the ZeptoViewTM 3.1 software.
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A weighted linear fit through the 4-fold concentration series was used to calculate the
relative fluorescence intensity (RFI) value for each sample replicate. Local normalisation
of sample signal to the reference BSA grid was used to compensate for any intra- or
inter-array/chip variation. RFI values were further normalised to a house keeping protein
and to the negative control, to provide the final RFI to represent the relative abundance
of total, phosphorylated and cleaved proteins in compound-treated samples relative to
the DMSO control for each time point.
2.2.7 Flow cytometry
2.2.7.1 Live/dead cell assay
A2780 cells were seeded at 2.5 x 106 cells per well in 6-well plates. Cells were pre-
incubated in drug-free media at 37oC for 24 h in a 5% CO2 humidified atmosphere.
Drug-compound solutions were added and the cells left to incubate for a further 24, 48
or 72 h. Following exposure, the drug-containing medium was removed, and cells were
washed, harvested and stained with Annexin V FITC and propidium iodide (Biovision,
Annexin V-FITC Apoptosis Kit) according to the manufacturers instructions. Control
samples stained with just propidium iodide or Annexin V FITC were also included for
compensation purposes. The samples were analysed using Beckton Dickinson FACScan
with fluorescence detection running Cell Quest software (20000 events were collected
from each sample). Data were processed using Flowjo software (version 7.2.5).
2.2.7.2 Cell cycle
A2780 cells were seeded at a density of 2.5 x 106 cells per well in a 6-well plate and
pre-incubated in drug-free media at 37oC for 24 h in a 5% CO2 humidified atmosphere.
Drug solutions were added and the cells left to incubate for a further 24 h. Cells were
collected and washed twice with PBS. Cells were fixed with 70% ethanol and stored at
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-20oC for 24 h. For analysis, cells were transferred into PBS, incubated with RNase (0.2
mg/mL) and propidium iodide (0.05 mg/mL) for 40 min at 37oC and then analysed by
flow cytometry using a Beckton Dickinson FACScan with fluorescence detection. The
resulting DNA histograms were quantified using the FlowJo software (version 7.2.5).
2.2.7.3 Mitochondrial membrane polarisation
A2780 cells were seeded at 2.5 x 106 cells per well in 6-well plates and pre-incubated
in drug-free media at 37oC for 24 h in a 5% CO2 humidified atmosphere. Ir-6 was added
and the cells left to incubate for a further 4 or 24 h. Cells were washed twice with PBS and
transferred to 12 x 75 mm flow cytometry test tubes in 500 µL solution of JC-10 dye and
the tubes protected from light for an incubation period of 0.5 h, at ambient temperature.
CCCP was used as positive control, with a drug exposure time of 0.5 h. Samples were
immediately run on a Beckton Dickinson FACScan with fluorescence detection and data
were processed using Flowjo software (version 7.2.5).
2.2.8 Imaging
2.2.8.1 High content screening (HCS) with Edinburgh Cancer Research Centre
Compounds were submitted to The Edinburgh Cancer Research Centre (Edinburgh, UK)
as solid samples. Compounds Os-1, Os-3, Os-4, Ir-9 and Ir-10 were imaged by HCS
in June 2012.
A2780 cells were seeded in a 96-well plate at 5000 cells/well and incubated for 48 h
before treatment with each compound for a further 48 h. Prior to image acquisition, cells
were incubated with 4 µg/mL DAPI (Sigma D8417), and 1 µM NucViewTM (Biotium)
reagent for 0.5 h. Microscopic images of DAPI and NucViewTM stained cells were
acquired with a 10x objective and appropriate optical filters using the Olympus ScanR
high-content imaging microscope. Merged images of DAPI and NucviewTM cells were
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created using the Olympus ScanR imaging software Cell-IRTM.
2.2.8.2 Transmission electron microscopy
A2780 cells were seeded at a density of 5 x 106 cells/100mm petri dish and pre-incubated
in drug-free media at 37oC for 24 h in a 5% CO2 humidified atmosphere. Ir-6 was added
to a final concentration of either 1 or 5 µM and cells left to incubate for a further 24
h. Medium was removed and the cells were washed twice with PBS, fixed with 2%
glutaraldehyde (Agar Scientific) in cadodylate buffer at pH 7.6 (Agar Scientific) and left
for 1 h agitating on a shaker. Plates were rinsed with cadodylate buffer and the cells were
transferred to falcon tubes, and centrifuged. Cells were dehydrated with graded levels
of ethanol (20-100% ethanol). Samples were then infiltrated with 100% propylene oxide
for 1 h followed by 1:1 mixture of propylene oxide and embed 812 resin for 6 h. This was
then replaced with several changes of 100% resin over an 18 h period before curing for
24 h at 72oC. Blocks were trimmed and sectioned on a Leica Ultracut E ultramicrotome
(Leica Microsystems). Sections of 70-80 nm thick were collected on 400-mech Cu grids
and stained with 2% uranyl acetate. Sections were imaged on a JOEL 1200EXII TEM
with a Gatan 1 k x 1 k CCD camera.
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Chapter 3. Cell Screening
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3.1 Introduction
This chapter analyses cell screening data obtained from two cancer institutes, for Os com-
poundsOs-1 (Os(h6-bip)(NMe2-azpy)I]PF6),Os-2 ([Os(h6-p-cym)(NMe2-imino)I]PF6),
Os-3 ([Os(h6-p-cym)(NMe2-azpy)I]PF6),Os-4 ([Os(h6-bip)(F-azpy)I]PF6),Os-5 ([Os(h6-
bip)(OH-azpy)I]PF6) and Ir compounds Ir-6 ([Ir(h5-Cpxbiph)(phen)Cl]Cl), Ir-7 ([Ir(h5-
Cpxph)(phen)Cl]Cl), Ir-8 ([Ir(h5-Cpxbiph)(bpy)Cl]PF6), Ir-9 (Ir(h5-Cpxbiph)(ppy)Cl]),
Ir-10 (Ir(h5-Cpxph)(NMe2-azpy)Cl]PF6) and Ir-11 ([Ir(h5-Cpxbiph)(dpq)Cl]Cl). Using
these data, cell line selectivity is discussed and possible mechanisms of action (MOA)
are proposed.
3.1.1 Cell screening by the National Cancer Institute
The National Cancer Institute 60 cell line screen (NCI-60) is a useful, free tool to explore
cancer selectivity and mechanisms of action (MOA) of new drug candidates. For each
of the cell lines in the screen the GI50 (concentration of compound required to inhibit the
growth of cells by 50%), TGI (concentration of compound required to inhibit 100% of cell
growth) and LC50 (concentration of drug required to kill 50% of cells) is calculated for
each compound.1–3 These measurements are made after a 48 h exposure period of each
cell line to a selected compound, by determining cell viability using standardised methods
(Methods section 2.2). The GI50 and TGI values provide insight into the cytostatic
potential of each compound, with the LC50 providing insight into their cytotoxicity.
The fingerprints of activity for each compound in the NCI-60 screen can then be used
together with an algorithm developed by Paull et al in 1989, which linearly compares
fingerprints between compounds.4 The so-called ‘COMPARE algorithm’ allows users to
predict the MOA for new compounds based on fingerprint similarity with established com-
pounds.5–8 A seed compound can be compared to thousands of anti-cancer compounds
populating various open access databases managed by the NCI, where the algorithm
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produces a quantifiable measure of similarity with a Pearson’s correlation coefficient (r),
where -1   r  1. For r = -1, two compounds are said to have a negative correlation i.e.
the pattern of activity in the NCI-60 panel is completely opposite. When r = 1, there is
positive correlation and when r = 0 there is no correlation.
There are also databases dedicated to gene expression, obtained through microarray
analysis and supplied to the NCI by external companies like Novartis. Using these datasets
it is possible to correlate activity with gene expression fingerprints in the panel of cell
lines, and thus identify any pharmacogenomic relationships between compounds and
oncogenes of interest.3
Collectively this screening process provides a wealth of information which can be
used to both explore the MOA and to make predictions about patient selection criteria.
Compounds 1 - 11 were all submitted to the National Cancer Institute (NCI) for analysis
in the NCI-60 screen.
3.1.2 Cell screening with the Sanger Institute
The Cancer Genome Project (CGP), run by the Sanger Institute, aims to advance the
development of new therapeutics in a similar manner to the NCI by investigating cell
line selectivity, but focusing more on pharmacogenomics.9 The CGP is on a larger scale,
analysing data in ca. 1000 cell lines for a larger set of cancer subtypes, working on the
same principle as the NCI-60; comparing activity fingerprints between a seed compound
and between ca. 400 compounds in the Sanger database.
The pharmacogenomic comparisons take a different approach to that of the NCI, repla-
cing gene expression with genetic mutation i.e. copy number variations (CNV) and point
mutations, for 464 oncogenes of interest. A gene is said to be altered if it has a coding
sequence variation, small insertion/deletion, gene-fusion or CNV of 0 or   7. These data
were obtained from exome sequencing coupled with in-depth bioinformatics analysis,
where all genes identified as oncogenic are stored in COSMIC, a publicly accessible
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database.10–15
Cell viability is measured using fluorescence techniques, extracting and dyeing viable
cells before measuring fluorescence with a plate reader (Methods 2.2). Unlike NCI-60
screening, cell lines in the Sanger screen are exposed to a selected compound for 72 h,
and the calculation of cell viability (GI50) is more complex, to allow a more accurate
prediction of GI50 values outside of the testable range (Figure 3.1).
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Figure 3.1: Dose response curve. Green data points represent the effect of the drug at varying
concentrations. A sigmoid curve is fitted to these measurements and predicts drug-responses
outside of the tested range. The slope parameter (b ) measures the steepness of the drug-response,
where a higher gradient represents a drug with a smaller therapeutic window, representing the
concentration of a drug required to elicit a desired response against the concentration of drug
required to elicit an adverse response. A larger therapeutic window (small b ) is more clinically
beneficial in reducing side-effects.
Fluorescence readings are fitted to a bespoke Bayesian sigmoid model, capturing the
uncertainties in the data and allowing reasonable interpretation of predicted response
values outside of the tested range (Figure 3.1 and Method 2.2). Resulting GI50 values
cover ± 1000x the testing range, with 95% probability mass coverage. In addition to the
GI50 values, a slope parameter (b ), which is simply the dose-response gradient, is also
provided. This gradient can give insights into the therapeutic index for an agent.
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The main aim of Sanger screening is to extract significant correlations between com-
pound activity and oncogenic behaviour. To do this, an analysis of variance (ANOVA) test
is used, in place of the NCI-60’s Pearson’s correlation method. The dependent variable is
presented as an n X 2 matrix for each compound, containing GI50 and b values, therefore
a multivariate ANOVA (MANOVA) is used for the analysis. For each gene, a linear model
explains these activity observables with ‘mutation status’ as the predictive variable. Only
genes found mutated in   2 cell lines were included in the analysis, and a Benjamin-
Hochberg multiple testing correction was used to identify significant results (FDR< 0.20).
This quantitative assessment of pharmacogenomics uses an effect size parameter, cal-
culated between wild type and mutant populations. If the effect size   1, the difference
in mean value between the mutated and wild-type populations is greater than the variance
in at least one population, and the effect is therefore large. If the effect size   2, the
difference in mean value between the mutated and wild-type populations is greater than
the variance of both populations, and the effect is therefore very large.
CompoundsOs-1 [Os(h6-bip)(NMe2-azpy)I]PF6,Os-3 [Os(h6-p-cym)(NMe2-azpy)I]PF6,
Os-4 [Os(h6-bip)(F-azpy)I]PF6, Ir-9 [Ir(h5-Cpxbiph)(ppy)Cl] and Ir-10 [Ir(h5-Cpxph)(NMe2-
azpy)Cl]PF6 were all submitted to the Sanger Institute for screening, this compound
selection was made based on a combination of NCI-60 screening data, and prior in vitro
and in vivo assays.16–18
3.1.3 Primary cell screening with the Edinburgh Cancer Research
Centre
Primary cells are those which are derived directly from living tumour samples, and when
cultured in vitro are generally more representative of in vivo environments, mostly as they
have undergone fewer population doublings. Compounds Os-1, Os-3, Os-4, Ir-9 and
Ir-10 were screened in three ovarian adenocarcinoma primary cell lines at the Edinburgh
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Cancer Research Centre, where these cell lines were developed at the Edinburgh Medical
Oncology Unit.19
PE01 - ovarian cancer cells prior to treatment
PE04 - ovarian cancer cells after taxane/cisplatin treatment
PE01-CDDP - ovarian cancer cells prior to treatment, which have been ex vivo cultured
in low doses of cisplatin (CDDP) to create a CDDP resistant line
Compounds Os-1, Os-3, Os-4, Ir-9 and Ir-10 were all tested and the GI50 values
determined after 48 h exposure.
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3.2 Results
3.2.1 60 cell line screening with the National Cancer Institute
Table 3.1 shows the activity results for Os compounds Os-1 - Os-5 and Ir compounds
Ir-6 - Ir-11 (for structures see Table 1.1 and Figure 1.3 in section 1.2), as well as cisplatin
(CDDP) and oxaliplatin (OXA) in the NCI-60, as the average GI50 and LC50 value across
all cell lines in the screen.
Table 3.1: Table of mean GI50 and LC50 values from the NCI-60 screen for compounds 1 - 11,
cisplatin (CDDP) and oxaliplatin (OXA) Mean values are calculated as the average value across all
60 cancer cell lines, with the ratio of cytostaticity (GI50) against cytotoxicity (LC50) exploring
whether a compound inhibits cancer cell growth or kills cancer cells.
Compound Mean GI50 Mean LC50 Ratio LC50/GI50
(µM) (µM)
Os-1 0.07 2.50 35.71
Os-2 3.72 48.60 13.06
Os-3 0.31 7.76 25.03
Os-4 4.68 37.20 7.95
Os-5 0.17 3.52 20.71
Ir-6 2.34 31.60 13.50
Ir-7 10.7 93.30 8.72
Ir-8 4.17 67.60 16.21
Ir-9 0.71 8.13 11.45
Ir-10 0.59 6.61 11.20
Ir-11 0.83 19.50 23.49
CDDP⇤ 1.49 44.00 29.53
OXA⇤ 2.85 95.30 33.44
⇤ Data for CDDP and OXA data were taken from the most recent round of NCI testing in March
2012, found in the DTP/NCI database
In most cases, the organometallic compounds are more active than the platinum
metallodrugs, and all compounds apart from Os-1 ([Os(h6-bip)(NMe2-azpy)I]+) have
a lower LC50/GI50 ratio. This ratio is a good predictor of the cytostatic versus cytotoxic
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properties of compounds, where a lower value may indicate dual activity at low con-
centrations. As the mean GI50 values are much lower than the LC50 it can be said that
these compounds are first and foremost cytostatic agents, with cytotoxicity occurring at
higher concentrations. However, the LC50 values for Os-1, Os-3 ([Os(h6-p-cym)(NMe2-
azpy)I]+), Os-5 ([Os(h6-bip)(OH-azpy)I]+), Ir-9 ([Ir(h5-Cpxbiph)(ppy)Cl]) and Ir-10
([Ir(h5-Cpxph)(NMe2-azpy)Cl]+) were still below<10 µM suggesting that both cytotoxic
and cytostatic activity are attainable with low exposure. Such multi-targetting activity has
many benefits over singly targeted agents, particularly with regards to resistance, where
cells would struggle to develop adequate resistance mechanisms if several areas of the
cell are targeted simultaneously.
Figure 3.2 shows the GI50 values for each compound. The boxes of the box-and-whisker
plots are constructed from the first and third quartiles and the median log10GI50. The
whiskers represent the lowest value (and highest value) still within 1.5 X interquartile
range (IQR) of the lower (and upper) quartile. The IQR is a measure of the dispersion,
and is calculated as the difference between the upper and low quartiles. log10GI50 values
outside of this range are labelled as outliers with empty circles.
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Figure 3.2: Tukey box-and-whisker plots showing the distribution of GI50 values for Os
compounds Os-1 - Os-5 and Ir compounds Ir-6 - Ir-11, cisplatin (CD) and oxaliplatin (OX)
in the NCI-60 screen. Boxes show the median and the first and third quarters. The whiskers
represent the highest/lowest values within 1.5 times the interquartile range (IQR), calculated as
the differences between the upper/lower quartiles. Open circles represent outliers in the data,
which fall outside 1.5x IQR. The large number of outliers for Os-2 result from a majority of the
data points lying within a small range, and a smaller selection of cell lines showing significantly
higher/lower sensitivity.
In Figure 3.2 the median activity values for compounds Os-1, Os-3, Os-5, Ir-9, Ir-10,
Ir-11 are all lower than that of CDDP and OXA, in the NCI-60 screen. Compound Os-2
([Os(h6-p-cym)(NMe2-imino)I]+) has a broad distribution of outliers, suggesting strong
selectivity in small selection of cell lines i.e. most activity values fall within a small range.
OXA, in comparison has a generally broad range of selectivity in the screen, with no
outliers.
Drug compounds with large ranges in cancer cell screens suggest a non-targeting nature,
i.e. they show no specificity in their potency. Although this has it’s benefits, it means
that these compounds can be equally active against normal cells, resulting in significant
side-effects. Oxaliplatin has the broadest selectivity in Figure 3.2, with the Os and Ir
compounds, particularly the Ir compounds, show more targeted behaviour.
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Figure 3.2 also shows that Ir compounds Ir-6 ([Ir(h5-Cpxbiph)(phen)Cl]+), Ir-7 ([Ir(h5-
Cpxph)(phen)Cl]+) and Ir-8 ([Ir(h5-Cpxbiph)(bpy)Cl]+) are all much less active than
Ir-9 ([Ir(h5-Cpxbiph)(ppy)Cl]), Ir-10 ([Ir(h5-Cpxph)(NMe2-azpy)Cl]+) and Ir-11 ([Ir(h5-
Cpxbiph)(dpq)Cl]+). This suggests that phenanthroline and bipyridine chelated ligands
produce lower activity compounds, compared to 2-phenylpyridinato, azopyridine and
dipyridoquinoxaline.
This also highlights the importance of exploring the activity of compounds in more
than one cell line, as Table 1.1 shows that activity in A2780 is similar for all compounds.
The heat map in Figure 3.3 explores the cell line selectivity in the NCI-60 screen for each
of the eleven compounds, together with CDDP and OXA.
54
X
1
X
3
X
5
X
7
X
4
X
8
X
2
X
6
O
X
A
C
D
D
P
X
11 X
9
X
10
NCI/ADR-RES
A498
TK-10
HCT -15
CAKI-1
ACHN
UO-31
COLO 205
MDA-MB-468
K-562
HCT-116
MDA-MD-435
SW-620
RPMI-8226
HT29
MCF7
SR
CCRF-CEM
MOLT-4
SF-295
786-0
NCI-H23
NCI-H460
A549/ATCC
OVCAR-5
NCI-H322M
SK-OV-3
HOP-62
DU-145
SNB-75
UACC-257
KM12
PC-3
SNB-19
BT-549
MDA-MB-231/ATCC
EKVX
HS578T
NCI-H226
RXF 393
HOP-92
SF-268
M14
OVCAR-8
SN12C
SK-MEL-5
HCC-2998
IGROV1
SK-MEL-2
SK-MEL-28
T-47D
NCI-H522
SF-539
LOX IMVI
HL-60(TB)
MALME-3M
UACC-62
OVCAR-4
U251
OVCAR-3
!
MDA-MB-468 
COLO205 
NCI-ADR/RES 
1      3     5      7     4     8      2     6                   11     9    10         
O
X
A 
C
D
D
P 
0.1 mM                              GI50         10 nM                               
HCT-15 Renal 
Figure 3.3: Heat map of NCI-60 data for Os compounds Os-1 - Os-5 and Ir compounds
Ir-6 - Ir-11, cisplatin (CDDP) and oxaliplatin (OXA). Dendrograms show clustering of data
by compound (top) and cell lines (side). CDDP and OXA data were taken from the most recent
round of NCI testing in March 2012, found in the DTP/NCI database. Figure 3.4 highlights
the trends shown in this heat map, with separation of compounds into a subsets of similarity
{Os-1, Os-3, Os-2, Ir-6 - Ir-8 and Ir-11}. In addition, renal cell lines show significantly poor
sensitivity to all compounds, and MDA-MB-468 (breast) and COLO205 (colon) cell lines showed
significantly high sensitivity.
Figure 3.3 presents trends in selectivity across each of the compounds, including those
compounds with similar patterns of selectivity and cell lines which similar sensitivities.
The dendrograms along the rows shows clustering of individual cell lines by similarity
in sensitivity to each compound, with the dendrogram along the columns clustering the
compounds by similarity across all 60 cell lines. Figure 3.4 should be used as reference
for Figure 3.3, highlighting these trends further.
55
X
1
X
3
X
5
X
7
X
4
X
8
X
2
X
6
O
X
A
C
D
D
P
X
11 X
9
X
10
NCI/ADR-RES
A498
TK-10
HCT -15
CAKI-1
ACHN
UO-31
COLO 205
MDA-MB-468
K-562
HCT-116
MDA-MD-435
SW-620
RPMI-8226
HT29
MCF7
SR
CCRF-CEM
MOLT-4
SF-295
786-0
NCI-H23
NCI-H460
A549/ATCC
OVCAR-5
NCI-H322M
SK-OV-3
HOP-62
DU-145
SNB-75
UACC-257
KM12
PC-3
SNB-19
BT-549
MDA-MB-231/ATCC
EKVX
HS578T
NCI-H226
RXF 393
HOP-92
SF-268
M14
OVCAR-8
SN12C
SK-MEL-5
HCC-2998
IGROV1
SK-MEL-2
SK-MEL-28
T-47D
NCI-H522
SF-539
LOX IMVI
HL-60(TB)
MALME-3M
UACC-62
OVCAR-4
U251
OVCAR-3
X
1
X
3
X
5
X
7
X
4
X
8
X
2
X
6
O
X
A
C
D
D
P
X
11 X
9
X
10
NCI/ADR-RES
A498
TK-10
HCT -15
CAKI-1
ACHN
UO-31
COLO 205
MDA-MB-468
K-562
HCT-116
MDA-MD-435
SW-620
RPMI-8226
HT29
MCF7
SR
CCRF-CEM
MOLT-4
SF-295
786-0
NCI-H23
NCI-H460
A549/ATCC
OVCAR-5
NCI-H322M
SK-OV-3
HOP-62
DU-145
SNB-75
UACC-257
KM12
PC-3
SNB-19
BT-549
MDA-MB-231/ATCC
EKVX
HS578T
NCI-H226
RXF 393
HOP-92
SF-268
M14
OVCAR-8
SN12C
SK-MEL-5
HCC-2998
IGROV1
SK-MEL-2
SK-MEL-28
T-47D
NCI-H522
SF-539
LOX IMVI
HL-60(TB)
MALME-3M
UACC-62
OVCAR-4
U251
OVCAR-3
X
1
X
3
X
5
X
7
X
4
X
8
X
2
X
6
O
X
A
C
D
D
P
X
11 X
9
X
10
NCI/ADR-RES
A498
TK-10
HCT -15
CAKI-1
ACHN
UO-31
COLO 205
MDA-MB-468
K-562
HCT-116
MDA-MD-435
SW-620
RPMI-8226
HT29
MCF7
SR
CCRF-CEM
MOLT-4
SF-295
786-0
NCI-H23
NCI-H460
A549/ATCC
OVCAR-5
NCI-H322M
SK-OV-3
HOP-62
DU-145
SNB-75
UACC-257
KM12
PC-3
SNB-19
BT-549
MDA-MB-231/ATCC
EKVX
HS578T
NCI-H226
RXF 393
HOP-92
SF-268
M14
OVCAR-8
SN12C
SK-MEL-5
HCC-2998
IGROV1
SK-MEL-2
SK-MEL-28
T-47D
NCI-H522
SF-539
LOX IMVI
HL-60(TB)
MALME-3M
UACC-62
OVCAR-4
U251
OVCAR-3
X
1
X
3
X
5
X
7
X
4
X
8
X
2
X
6
O
X
A
C
D
D
P
X
11 X
9
X
10
NCI/ADR-RES
A498
TK-10
HCT -15
CAKI-1
ACHN
UO-31
COLO 205
MDA-MB-468
K-562
HCT-116
MDA-MD-435
SW-620
RPMI-8226
HT29
MCF7
SR
CCRF-CEM
MOLT-4
SF-295
786-0
NCI-H23
NCI-H460
A549/ATCC
OVCAR-5
NCI-H322M
SK-OV-3
HOP-62
DU-145
SNB-75
UACC-257
KM12
PC-3
SNB-19
BT-549
MDA-MB-231/ATCC
EKVX
HS578T
NCI-H226
RXF 393
HOP-92
SF-268
M14
OVCAR-8
SN12C
SK-MEL-5
HCC-2998
IGROV1
SK-MEL-2
SK-MEL-28
T-47D
NCI-H522
SF-539
LOX IMVI
HL-60(TB)
MALME-3M
UACC-62
OVCAR-4
U251
OVCAR-3
1  3  5  7  4  8  2  6         11 9 10        
O
X
A 
C
D
D
P 1  3  5  7  4  8  2  6         11 9 10        
O
X
A 
C
D
D
P 
1  3      7      8  2  6        11                5      4                         9 10        
O
X
A 
C
D
D
P 
Sensitive cell lines Resistant cell lines 
A B 
C D 
Figure 3.4: Heat maps highlighting trends in NCI-60 data shown in Figure 3.3 for Os
compounds Os-1 - Os-5 and Ir compounds Ir-6 - Ir-11, cisplatin (CDDP) and oxaliplatin
(OXA). (A) Compounds with similar patterns of selectivity, (B) Compounds with novel selectivity
patterns, (C) Cell lines with higher sensitivity (MDA-MB-468 and COLO205) and (D) Cell lines
with low sensitivity (renal cell lines).
Performing 2D principal component analysis (PCA) on the GI50 data for Os-1 - Ir-11
separates the compounds and cell lines per the selectivity trends identified in Figure 3.3
(Figure 3.5). This PCA plot is called a bi-plots, showing the similarity of cell lines (black
text) represented by euclidean distance i.e. the closer the cell lines in space, the more
similar the sensitivity of each cell line to all compound. The similarity in compound
selectivity is shown in red, where the angle between the vectors is proportional to the
similarity i.e. the smaller the angle the more similar the compounds are.
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Figure 3.5: Bi-plot of GI50 values for Os compounds 1 - 5 and Ir compounds 6 - 11. Data
were plotted using principle component analysis (PCA), which separates variables by euclidean
distance, based on similarity. Cell lines were plotted in black, with those closer together having
similar sensitivities to compounds. The resistant cell lines in the NCI-60 screen are circled in
blue, with the renal cell lines in one cluster and ovarian cell line NCI-ADR-RES in the other.
The remaining more sensitive cell lines are clustered together. The compounds were plotted in
red, with their similarity in NCI-60 selectivity proportional to the vector angles between pairs of
compounds.
The heat map (Figure 3.3) and the PCA plot (Figure 3.5) shows a high level of similarity
in compound sensitivity across most of the cell lines, however there are several outliers.
For example NCI-ADR-RES is isolated in the plot, suggesting the activity values in this
cell line are significantly different to the other cell lines. The subset {HCT-15, CAKI,
SCHN, UO-31} is also isolated in a cluster, where these cell lines showed poor sensitivity
in Figure 3.3. The two subsets of compounds {Ir-10, Os-5, Os-4} and {Os-2, Ir-6, Ir-7,
Ir-8} are plotted a wide distance apart, with Os-1 appearing to plot alone from the others.
Os-1 was significantly more active than the other compounds.
The similarity matrix in Figure 3.6 displays a Pearson’s correlation coefficients quan-
tifying compound-to-compound similarity in GI50 values from the NCI-60 screen.
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Figure 3.6: Similarity matrix showing the Pearson’s correlation coefficients (r) between
the compounds. Correlation coefficients were calculated from the NCI-60 data, ranging from 0.4
to 0.9. The higher r values between Os-1, Os-2, Os-3, Ir-6, Ir-7, Ir-8 and Ir-11 represent the
subset of compounds identified in Figures 3.3 and 3.4. The lower r values for Os-4, Os-5, Ir-9
and Ir-10 highlight their more novel patterns of selectivity.
Figure 3.6 highlights again the subsets of compounds, in particular Os compounds
Os-4 and Os-5 show very different selectivities to the rest of the compounds, with Ir-9
and Ir-10 showing lower levels of similarity.
3.2.1.1 COMPARE analysis
COMPARE analysis was performed for each compound, using the GI50 datasets. Activ-
ity fingerprints were compared to drugs populating both the standard agents database,
which contains ca.175 agents selected as highly promising by the NCI, and the synthetic
agents database containing > 40,000 synthetic compounds and natural products of known
structure. Only those results with r > 0.5, between Os compounds Os-1 - Os-5 and Ir
compounds Ir-6 - Ir-11 and drugs with known MOA were included (Figure 3.7).
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Figure 3.7: COMPARE results for Os compounds Os-1 - Os-5 and Ir compounds Ir-6 -
Ir-11 showing NCI-60 patterns of similarity against other compounds in the NCI/DTP compound
database. Coloured bars shows a summary of the top 100 positive correlations to each compound,
including only those with known mechanisms of action (MOA) and r > 0.5. Correlations were
split into seven classes: oxidative stress inducers, mitosis inhibitors, protein synthesis inhibitors,
topoisomerase inhibitors. DNA alkylating agents, DNA antimetabolites, DNA interacting agents.
Compounds Os-1, Os-2, Os-3, Ir-6, Ir-7, Ir-8 and Ir-11 all correlated to the same classes of
compound, primarily DNA interacting agents and protein synthesis inhibitors. Os-5 correlates to
different classes of compounds, namely DNA alkylating agents andOs-4, Ir-9 and Ir-10 correlated
to few compounds, highlighting their novelty.
Results show positive correlations to DNA interactors, DNA antimetabolites, topoi-
somerase inhibitors, protein synthesis inhibitors, mitosis inhibitors and redox mediators,
suggesting a multi-targetted MOA. The subset {Os-1, Os-2, Os-3, Ir-6, Ir-7, Ir-8, Ir-
11} showed high similarity in the correlations returned, with drugs in a broad range
of MOA subclasses. Os-5 showed an increased correlation to DNA alkylating agents,
as did Ir-10, with overall fewer returned correlations for Os-4, Os-5, Ir-9 and Ir-10.
This suggests that these compounds are not only different within this set of organo-
metallics, but are also novel in MOA with respect to drugs populating the NCI data-
bases.
COMPARE can also be used to assess pharmacogenomic relationships to determine
whether compound activity is dependent on cell line genetics. Figure 3.8 shows the
correlation coefficients when the activity of Os compoundsOs-1 -Os-5 and Ir compounds
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Ir-6 - Ir-11 were compared to gene expression in the NCI-60 cell lines.
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Figure 3.8: Heat maps representing Pearson’s correlation coefficients (r) for comparisons
of similarity between the GI50 values for compounds Os-1 - Ir-11 and the expression of
genes, in the NCI-60 cell lines (a) Heat map showing genes which correlated to n> 2 compounds
and (b) Individual analysis showing the lack of correlation in the top 10 genes returned for Os-4
and a higher level of correlation between GI50 and expression of the top 10 genes returned for Ir-9.
Microarray data were taken from the DTP/NCI database.
Figure 3.8 shows the top 10 correlations returned after compounds Os-1 - Ir-11 were
run through the COMPARE algorithm together with all microarray datasets in the NCI
database. These microarrays have measured the expression of important cancer genes
in NCI-60 cell lines, and are often donated from pharmaceutical companies.
Figure 3.8(a) shows common correlations between compounds, reflecting the selectivity
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shown in previous figures. Figure 3.8(b) shows the top 10 correlations to the most novel
compounds Os-4 and Ir-9, with no commonality between compounds and much higher r
values for Ir-9. This suggests that the activity fingerprint of Os-4 has little dependence on
the genetics of the cancer cells. The selectivity pattern of this compounds could therefore
be related to uptake mechanisms instead of intracellular targetting.
The overlapping genes which correlated primarily to Os-1 - Os-3, Ir-6 - Ir-8 and
Ir-11 encode a broad spectrum of proteins. Selecting out a few examples, like HNRPLL
(heterogenous nuclear ribonucleoprotein L-like), NUP188 (nucleoporin), MDH2 (malate
dehydrogenase 2) can provide insights into the MOA of the seven similar compounds.
Heterogenous ribonucleoproteins bind to and control RNA processing, mediating the
formation of mature mRNAs from pre mRNAs.20 Nucleoporin is part of a nuclear pore
complex (NPC) in the nuclear membrane, which controls the transport of molecules
between the nucleus and cytoplasm.21 Malate dehydrogenase is a mitochondrial-based
protein which catalyses the oxidation of malate and utilises NAD+ in the citric acid cycle.22
Figure 3.9 shows that all three genes are found in high levels in cell lines which
show high sensitivity to osmium compound 3, and conversely are found in low levels
in renal cell lines like UO-31 and TK-10, which were particularly resistant to most of
the compounds. Here gene expression is shown as log (mRNA level in a cell line/mRNA
level in pool of NCI-60 cell lines).
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Figure 3.9: Heat map showing the expression levels of genesMDH2,HNRPLL andNUP188
in a selection of cell lines in the NCI-60 screen. Gene expression values for each cell line were
calculated by subtracting the mean expression across the NCI-60 screen from the individual cell
line expression values. Positive values indicate high expression in a given cell line with respect to
the mean, negative values indicate low expression compared to the mean expression in the screen.
The cell lines will high expression levels were cell lines with high sensitivity to the organometallic
compounds, cell lines with low expression levels were those which showed poor sensitivity to
the organometallic compounds. This suggests a possible pharmacogenomic relationship for the
mechanisms of action.
This suggests that the compounds are most active when cells are efficiently producing
mature mRNA, transporting molecules and undergoing respiration, suggesting that cell
division could play an important role in the MOA of 3.
Collectively this section has utilised NCI-60 activity data for Os-1 - Os-5, Ir-6 - Ir-11,
cisplatin and oxaliplatin to explore similarities and differences between the compounds
with regards to cell line selectivity. There appeared to be no discrimination between the
different metals, Os and Ir compounds commonly clustered together and gave similar se-
lectivity profiles. Correlating the fingerprints of activity with other anticancer compounds
suggested that the compounds possess multiple MOA, with Os-4, Os-5, Ir-9 and Ir-10
emerging as particularly novel compounds. In addition, the possible molecular targets
were explored and showed that when genes associated with cell growth were amplified
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in a given cell line, this cell line showed higher sensitivity to the compounds.
From these eleven compounds, five were taken forward for screening by the Sanger
Institute. The compound selection was based on both the level of activity in the NCI-60
screen and on the novelty of the selectivity patterns.
3.2.2 Cell screening with the Sanger Institute
CompoundsOs-1,Os-3,Os-4, Ir-9 and Ir-10 were selected for Sanger Institute screening
based on their selectivity patterns in the NCI-60 panel, where Os-1 and Os-3 had highly
similar activities and were highly active,Os-4, Ir-9 and Ir-10 showed more novel patterns
of selectivity, with Ir-10 showing the highest potency.
Screening was performed in 974 cancer cell lines. Table 3.2 shows the mean GI50
values for each of the compounds and Figure 3.10 shows the median and the distribution
of the log10GI50 values.
Table 3.2: Table of the mean GI50 from the Sanger Institute screen for Os-1, Os-3, Os-4, Ir-9,
Ir-10 and cisplatin (CDDP). Mean values were calculated as an average across 974 cancer cell
lines
Compound Mean GI50 (µM)
Os-1 2.10
Os-3 40.36
Os-4 420.44
Ir-9 251.44
Ir-10 38.54
The levels of activity for the compounds fits the same trend as that shown in the NCI-60
screen, where compounds Os-1, Os-3 and Ir-10 are the most active, and Os-4 and Ir-9
are the least. Os-1 and Os-3 show a large number of outliers, as the majority of activity
occurs within a small range, shown with the small boxes in the Tukey plots. Ir-10 also
presents a large number of outliers, primarily with low sensitivity.
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Figure 3.10: Tukey box-and-whisker plots showing the distribution of GI50 values of each
compound in the Sanger screen, together with cisplatin (CDDP). Boxes show the median
and the first and third quarters. The whiskers represent the highest/lowest values within 1.5x the
interquartile range (IQR), calculated as the differences between the upper/lower quartiles. Open
circles represent outliers in the data, which fall outside 1.5x IQR. The large number of outliers for
Os-1 and Os-3 result from a majority of the data points lying within a small range, and a smaller
selection of cell lines showing significantly higher/lower sensitivity. The weighted outliers for
Ir-10 suggest a small selection of cell lines show significantly higher sensitivity.
The heat map in Figure 3.11 clusters compounds by GI50 value and shows the simil-
arities in selectivity between Os-1 and Os-3. The increased number of blue values for
Os-4 and Ir-9 highlights their poor activity.
Figure 3.11 shows minimal segregation of activity into cancer subtypes, however, there
are a few boxed areas highlighting low sensitivity. Particularly in the gastrointestinal (G.I)
cell lines, where the majority show poor sensitivity towards compound Ir-10. There are
also a selection of leukemia/lymphoma cell lines, and central nervous system (CNS) lines
which show poor sensitivity towards to Os-1 and Os-3.
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Figure 3.11: Heat map of GI50 values for compounds Os compounds Os-1 and Os-3 and Ir
compounds Ir-9 and Ir-10 in 974 cell lines of the Sanger screen. Visible clustering of low
sensitivity are highlighted with grey boxes showing resistance of gastrointestinal (GI) cancers to Ir-
10 and leukaemia and central nervous system (CNS) cancers to Os-1 and Os-3. The dendrogram
clusters the compounds by similarity and shows that Os-1 and Os-3 share high similarity in the
screen and that Os-4 and Ir-9 share similarity to each other, but significant differences to Os-1,
Os-3 and Ir-10.
Further analysis focussed only on Os-3 and Ir-10. Os-3 was selected as the Sadler
group had previously published in vivo and in-depth in vitro data for this potent compound.
In addition, Os-3 was part of a large subset of compound which behaved similarly in the
NCI-60 screen. Ir-10 was chosen for it’s potency and it’s novelty in NCI-60 selectivity.
correlating more similarly to DNA-targeting agents than the other Os and Ir compounds.
Given Os and Ir centers chelated to para-substituted azopyridine ligands, this would also
provide a good comparison of ligand dependencies on mechanisms of action.
The mean and median activities of Os-3 and Ir-10 are similar in Table 3.2 and Figure
3.10, however the outlying data points for Ir-10 are skewed towards more resistant cell
lines. Figure 3.12 breaks down the activity into stricter cancer subtypes for Os-3 and
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Ir-10 to investigate where these differences arise.
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Figure 3.12: GI50 values in cancer subtype for compounds Os-3 (a) and Ir-10 (b) in the
Sanger Institute screen. The mean values for each population are shown with coloured lines,
boxed sections highlight the key differences in activity between the two compounds. These differ-
ences are highlighted in the blood cancers, pancreatic, neuroblastoma, lung and gastrointestinal.
For example, neuroblastoma cell lines are significantly more susceptible to Ir-10 than to Os-3 and
blood cancers like leukemia and lymphomas are more susceptible to Os-3.
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Figure 3.12 highlights the significant difference in GI50 values for compound Os-3 and
Ir-10 in leukaemia, myeloma and lymphoma cell lines, with poor sensitivity for Ir-10.
The female cancers retain similar sensitivity between Os-3 and Ir-10, however, shown
in the second grey box is a significant drop in activity in neuroblastoma cell lines exposed
to Os-3. The third and fourth grey boxes highlight poor activity of both Os-3 and Ir-10
towards lung and GI cancers, particularly so for Ir-10. This behaviour was shown in the
heat map of Figure 3.11.
3.2.2.1 Pharmacogenomic studies
Gaining insights into the most sensitive and least sensitive cancer cell lines in screens like
the NCI-60 and the CGP can help select patient populations, and in some cases provide
insight into drug MOA. To build on this, it is useful to investigate the genetics upon
which each cancer line is defined and to link these carcinogenic properties with compound
activity.
A MANOVA analysis was performed to correlate compound activity with the genetic
status of 379 cancer genes in the screen. Table 3.3 shows the genetic mutations that
had an effect size   0.5 (and FDR  0.20) on the GI50 of the five compounds. These
include point mutations in genes PGR, HGF, ERBB3, FOXP1, CASP8 and KIT, and
amplifications of regions R184, and R198. Regions of gene amplification or deletion may
contain multiple genes. For example R184 covers twenty-one genes and R198 covers four
(Appendix Table 9.1).
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Table 3.3: Table showing the most significantly correlated genes to the activity of Os compounds
Os-1 and Os-3 and Ir compounds Ir-9 and Ir-10. The effect size measures the significance of this
correlation between genomic expression and cell susceptibility, the higher the effect size the higher
the correlation. The most significant correlation was for Os-1 with PGR mutation (m), where
cell lines carrying this mutation were more sensitive (s) to this compound. Conversely cell lines
carrying mutations in HGF were more resistant (r) to Os-3.
Compound Gene No. cell lines Effect size FDR
Os-1 R184 a 9 0.95 0.07 r
PGR m 3 2.00 0.01 s
R198 a 17 0.87 0.02 r
Os-3 R184 a 9 0.93 0.02 r
HGF m 5 1.70 0.01 r
Os-4 ERBB3 m 3 1.10 0.01 s
FOXP1 m 9 0.63 0.01 s
Ir-9 CASP8 m 17 0.57 0.02 s
Ir-10 KIT m 4 0.83 0.08 s
a = amplification; m = mutation; r = amplification/mutation infers resistance; s = amplification/muta-
tion infers sensitivity
Figure 3.13 graphically highlights the effect of R184, HGF and KIT alterations on the
GI50 values for compounds Os-3 and Ir-10.
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Figure 3.13: Plot showing the effect of genetic mutation on compound activity for Os-3 and
Ir-10. All grey dots represent wild-type cancer cells lines not carrying mutations/amplifications of
R184, HGF and KIT. Blue dots represent cell lines carrying amplified R184 (a), green dots are
HGF mutated (mt) cell lines and pink dots are KIT mutated cell lines. Blocked central lines are the
mean values, with the upper and lower bars showing the standard deviation. The plot shows that
R184 amplifications (effect size 0.93) and HGF mutations (effect size 1.70) both cause cell lines to
show resistance to Os-3, where as KIT mutated cell lines (effect size 0.83) are more sensitive to
Ir-10.
Taking a closer look at cell lines with mutations in KIT, HGF and amplifications in R184
could provide reasons for the cell line selectivity for Os-3 and Ir-10 shown in Figure 3.12.
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Figure 3.14: Plot showing the breakdown of pharmacogenomic responses into cancer cell
subtypes for R184 (a), HGF (b) and KIT (c). (a) show the cell line sensitivities to Os-3, with
the wild-type cell lines in grey and the R184 amplified breast and lung cancer cell lines in blue,
showing that in both cancer subtypes this amplififed region increases resistance to Os-3. (b) shows
the sensitivity of HGF mutated lung and large intestine cancers (green) and wild-type cancers
(grey) to Os-3, again showing that mutated cell lines showed lower susceptibility to Os-3. (c)
shows the sensitivity of KIT mutated lung cancers (pink) and wild-type cancers (grey) to Ir-10,
this time showing that mutated cell lines are ore sensitive to the drug compound.
Amplifications in R184 only occur in either breast or non-small cell lung cancer
(NSCLC) in the screen. Figure 3.14(a) shows that alterations in R184 causes Os-3 to lose
activity. HGF is only mutated in NSCLC and large intestine cancers in the screen, again,
when genes related to this region are altered, the cell is less sensitive to the action of Os-3.
In contrast, KIT mutations are only found in NSCLC, and when present, cell lines become
more sensitive to Ir-10.
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Looking at the function of proteins encoded by HGF and KIT can provide insight into
the MOA of these compounds. HGF codes for the hepatocyte growth factor, which reg-
ulates cell growth and motility through tyrosine kinase activity. HGF is a multifunctional
cytokine, and is commonly associated with increased tumor motility and migration.23
Alterations in HGF expression, particularly of increased expression have been linked to in-
trinsic and acquired drug resistance, and may be the cause for reduced sensitivity toOs-3.24
KIT encodes the human homolog of the proto-oncogene C-KIT and is a type III
transmembrane receptor for the stem cell growth factor.25 Once bound to growth factor,
this protein activates signal transduction through the cell, affecting cell survival and
differentiation. Disrupting this gene might render cancer cells less viable, resulting in
higher susceptibility to Ir-10.
Given the broad activity of these proteins it is more useful to use an approach
similar to that of the COMPARE analysis, and to explore the MOA by assessing
which other anticancer drugs share the pharmacogenomic properties shown for com-
pounds Os-3 and Ir-10. Table 3.4 lists the other drug compounds in the Sanger data-
base whose activity correlated with genetic mutations in R184, HGF and KIT. In all
cases, HGF mutations and R184 amplifications were associated with low drug sens-
itivity. KIT mutations were not shown to be associated with any other drug com-
pound.
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Table 3.4: Table showing all drug compounds in the COSMIC database that are also associated
with mutations/amplifications in R184, HGF and KIT. R184 amplifications caused cells to show
resistance to both Os-1 and Os-3, and also to bleomycin and SN-38, where the latter is a known
topoisomerase inhibitor. Conversely, Ir-10 was the only compound in the COSMIC database
which showed an increased potency towards KIT mutated cell lines, highlighting it’s novelty.
Gene Function Drug associations Drug target
R184 Os-1 and Os-3 -
SN-38 TOPO1
Bleomycin
HGF Os-3 -
CEP701 FLT3, JAK2, NTRK1, RET
AZD7762 CHK1/2
Obatoclax mesylate BCL-2, BCL-x, MCL-1
CI-1040 MEK1/2
KIT Ir-10 -
The MOA of bleomycin is thought to result in DNA and RNA damage via production
of reactive oxygen species.26 In contrast, SN-38 is the active metabolite of irinotecan,
a topoisomerase I inhibitor.27 All three of these MOAs were predicted for compounds
Os-1 and Os-3 by the COMPARE algorithm.
CEP-701 (lestaurtinib) is a tyrosine kinase inhibitor, targetting FLT3, JAK2, NTRK1
and RET and is currently in phase II clinical trials.28, 29 AZD7762 is often used to
potentiate the activity of standard chemotherapy agents, as it targets CHK1/2 proteins
which ordinarily detect DNA damage during the S/G2 phase of the cell cycle.30 Obato-
clax, also in phase II trials, activates apoptosis by inhibiting the family of BCL pro-
teins.31 Finally, CI-1040, is a highly specific MEK (MAPKK) inhibitor, however, due
to poor solubility and tolerability by patients, analogues of this drug are in develop-
ment.32
The Sanger screen allowed an assessment of more tumor subtypes, and highlighted
GI cancers and NSCLC as potentially insensitive cell lines, particularly for Os-3 and
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Ir-10. Much like the results from the NCI, the Sanger screen results in similar MOAs
between the organometallic compounds and a broad range of other drug compounds, thus
reinforcing a proposed multitargeted mechanism.
3.2.3 Primary cell screening with the Edinburgh Cancer Research
Centre
Os compounds Os-1, Os-3 and Os-4 and Ir compounds Ir-9 and Ir-10 were tested in
ovarian patient-derived lines PE01 (patient prior to treatment), PE04 (patient after tax-
ane/platinum treatment) and PE01-CDDP (PE01 cells exposed to low levels of CDDP,
to create Pt resistance). Table 3.5 summarises the activity of each compound.
Table 3.5: Compound activity in primary ovarian cell lines: PE01 patient prior to treatment, PE04
patient after taxane/platinum treatment and PE01-CDDP cells from PE01 exposed to low levels
of CDDP in vitro to create Pt resistance. Table shows that Os-1, Os-3 and Ir-10 all maintain
activity in platinum/taxol-treated and platinum-resistant ovarian cancer, highlight a clear clinical
benefit. However, Os-4 and Ir-9 lost activity in platinum-treated and platinum-resistant cancers,
respectively.
Cell line Compound GI50
(µM)
PE01 Os-1 0.26
Os-3 0.85
Os-4 2.24
Ir-9 22.4
Ir-10 1.21
Os-1 0.58
Os-3 2.15
PE04 Os-4 20.8
Ir-9 64.3
Ir-10 1.65
Os-1 0.17
Os-3 0.68
PE01-CDDP Os-4 2.01
Ir-9 110.3
Ir-10 1.56
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Os-1, Os-3 and Ir-10 maintain reasonable activity in all four cell lines. Conversely,
Os-4 loses activity in patient cells treated with taxane/cisplatin, although retains activity
in PE01-CDDP cells, suggesting that taxane cross-resistance becomes a problem for Os-4
and not CDDP resistance. Given taxane is a mitotic inhibitor, the data could suggest that
Os-4 has significant involvement in disrupting mitosis. Unfortunately, compound Ir-9
showed low activity in all of the primary cell lines suggesting that neutral complexes may
not exert as potent an activity over cationic complexes, in patient-derived lines.
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3.3 Discussion
3.3.1 Cytotoxicity versus cytostaticity
Os compounds Os-1 - Os-5 and Ir compounds Ir-6 - Ir-11 were all tested in the NCI-60
screen, and their activity finger prints compared to established anticancer agents. Table
3.1 and Figures 3.2 and 3.3 display the GI50 values for each organometallic compound,
together with those for the platinum metallodrugs CDDP and OXA. Compounds Os-1
- Ir-11 show comparable activity values to CDDP and OXA, with Os-1, Os-3, Os-5 and
Ir-9 - Ir-11 showing an improved activity compared to the platinums.
Assessing the cytostatic versus cytotoxic nature of the compounds highlights further
differences between the organometallic compounds and the platinum metallodrugs. The
ratio of cytotoxicity:cytostaticity is generally higher for the platinums, with LC50 values
outside of the acceptable in vitro range (100 µM). In comparison, Os compounds Os-1,
Os-3 andOs-5 and Ir compounds Ir-9 and Ir-10 all achieve cytotoxic activity at<10 µM.
Such dual cytostatic/cytotoxic activity has been demonstrated for organometallic
ruthenium anticancer compounds.33 This dual activity is often first obtained through
cell cycle arrest and subsequent activation of pro-apoptotic signals.34, 35 For example,
the treatment of prostate cancer cells with dihydroartemisinin (DHA), results in cell
cycle arrest, induced by disrupting the interaction of specificity protein 1 (Sp1) and the
CDK4 promoter. This dissociation of the Sp1-CDK4 complex goes on to promote caspase
activation and subsequent cell death.36 By exhibiting both cytostatic and cytotoxic activity
in this sequential manner, it is possible for a single agent to both control tumour size and
allow tumour shrinkage, perhaps reducing the need for combination therapy.
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3.3.2 Structure activity relationships
It is possible to propose optimum chemical structures within this selection of organo-
metallic compounds by using the activity values presented in Table 3.1 and the selectivity
patterns in both the NCI-60 and the Sanger cell screens. For example the structures of
Os compounds Os-1 ([Os(h6-bip)(NMe2-azpy)I]+) and Os-3 ([Os(h6-p-cym)(NMe2-
azpy)I]+) are identical except for the additional phenyl substituent on the arene ligand
for Os-1. Given their similarity in patterns of selectivity in both screens, this suggests that
the additional phenyl group does not play a key role in the MOA, it more likely increases
uptake for Os-1, resulting in a more potent compound. Indeed, this was also shown for
Ir where Ir-6 ([Ir(h5-Cpxbiph)(phen)Cl]+) > Ir-7 ([Ir(h5- Cpxph)(phen)Cl]+), and has
been previously linked to cellular uptake.18, 37
Table 3.1 and Figure 3.2 show that when the NMe2 group on the azopyridine ligand
is exchanged for an OH, the activity is retained, shown between Os-1 and Os-5 ([Os(h6-
bip)(OH-azpy)I]+). However, if the NMe2 group is exchanged for a F, now at the para
position (Figure 1.3) activity is lost, as shown between Os-1 and Os-4 ([Os(h6-bip)(F-
azpy)I]+)). Figure 3.3 and 3.6 also shows a significance difference in the pattern of selectiv-
ity between Os-1, Os-4 and Os-5, as a result of exchanging the NMe2. This change in se-
lectivity is most significant in renal cell lines, which show low sensitivity to all compounds,
including CDDP and OXA, apart from Os-4 and Os-5. This loss in activity and change in
cancer cell selectivity is either due to the exchange of the electron donating amine for the
strongly electron withdrawing halide, or to the change in position on the azopyridine ligand.
Changing either the charge or the electron density around a compound can have a
significant effect on cellular targeting. For example, a positively charged compound
could feasibly target the mitochondria, as a negatively charged organelle. Negatively
charged DNA could also be a more favourable target to positively charged compounds.
A recent study reported the difference in activity between neutral compound Ir-9 ([Ir(h5-
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Cpxbiph)(ppy)Cl]) and a charged analogue, [Ir(h5-Cpxbiph)(ppy)py]+, which substitutes
the Cl ligand for a pyridine.38 The charged complex proved to have higher potency
compared to Ir-9, linked to the slow hydrolysis of the Ir-py bond, compared to the rapid
hydrolysis of the Ir-Cl bond for Ir-9, which affected downstream mechanisms of action.
Collectively, these data show that the activity and selectivity of these compounds can
be tailored.
3.3.3 Cancer cell selectivity
The clustering of cell lines and compounds in the NCI-60 cell line screen (Figure 3.3)
provides specific information regarding the cancer cell selectivity. The least sensitive
cancer subtype was renal, including cell lines CAK-I, ACHN and UO-31. This panel
showed low sensitivity to all compounds, apart from Os-4 and Os-5.
Renal cell chemoresistance is a common occurrence; these lines often have a high
abundance of multi-drug resistant (MDR1) protein expression, related to the levels of
P-glycoprotein (Pgp).39, 40 This increased expression means that drug efflux is a major
problem in the treatment of these cancers.41 As Os-4 and Os-5 have increased activity
in these cell lines it could be proposed that the F and OH substituents on the azopyridine
ligand are better able to circumvent Pgp efflux. However, NCI-ADR-RES, which is an
adriamycin-resistant ovarian cell line, also has a large abundance of Pgp and MDR1 ex-
pression and Figure 3.3 shows that this cell line is insensitive to all compounds, including
Os-4 and Os-5. Therefore the increased activity of these two compounds in renal cell
lines may be mechanistically based, and not due to uptake mechanisms.
Common to all of the organometallic compounds in the NCI-60 were the high sens-
itivities of breast cell line MDA-MB-468 and colorectal cell line COLO205 (Figure 3.3).
COLO205 colorectal cells have reduced levels of glutathione-S-transferase P1 (GSTP1),
an enzyme which detoxifies drugs by conjugating them to glutathione (GSH) often limiting
the efficacy of anticancer agents.42 Without this enzyme, there may be less conjugation
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and inactivation by GSH, which could make cells more sensitive to anticancer compounds.
Interestingly, HCT-15 which is also a colorectal cell line, showed poor sensitivity to
all of the Os and Ir compounds, thus highlighting a good level of selectivity for these
compounds, even within cancer subtypes.
The breast cell line, MDA-MB-468 showed a consistently high sensitivity in the NCI-60
(between 17 nM and 1.8 µM). This cell line has a glucose 6-phosphate dehydrogenase
(G6PD) A phenotype, meaning it lacks the proper functioning of this enzyme in the
pentose phosphate pathway.43 G6PD is the rate-limiting enzyme in this pathway; its
deficiency blocks the conversion of glucose-6-phosphate to 6-phosphoglucono-d -lactone
and in the process prevents the conversion of NADPH from NADP+, a required step
in GSH synthesis.44 This suggests that a GSH deficiency may play an important role
in potentiating the activity, something previously demonstrated when A2780 cells were
co-incubated with low levels of the GSH inhibitor, L-buthionine sulfoxamine (Table
1.3). Multiple studies have shown that this deficiency prevents the cells from mediating
oxidative stress, and often results in apoptosis and necrosis of cells in patients.45
3.3.4 Correlations to drug fingerprints
Each of the compounds was run through the COMPARE algorithm, and the top 100 “hits”
were studied for correlations to known drug compounds in the NCI databases, using
the GI50 fingerprints. In addition, using the Sanger database, compounds with similar
pharmacogenomic profiles were studied.
The COMPARE analysis showed that these compounds do not correlate to one singular
class of anti-cancer agents, instead correlating to a number of classes. A group was clas-
sified if n > 2 compounds correlated within it. Compounds appear to correlate primarily
to DNA and protein-targetting drugs in the database, although it is not possible to deduce
that this is therefore their primary MOA. This could be because the databases used for this
analysis do not have an equal number of compounds from each MOA class i.e. there may
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be more DNA interacting agents in the database than there are redox mediators, which
would skew the results. Instead, only qualitative conclusions can be drawn.
Compounds Os-4, Ir-9 and Ir-10 each correlated to only 3 known drugs, suggesting
they are novel with respect to the NCI database.46 Os-1 - Os-3 and Ir-6 - Ir-8 and Ir-11
not only correlated to the same class of anti-cancer agents, but to the same drugs within
each class. Although Os-5 showed novel selectivity in Figure 3.3 with respect to the other
organometallic compounds, it is not novel with respect to the NCI database, correlating to
twenty known anti-cancer agents. However, the correlation classes for Os-5 were distinct
from the others, with a notable increase in alkylating agents.
3.3.4.1 Protein synthesis inhibitors
The loss in control of protein synthesis can often promote tumour growth, with common up-
regulation of translation initiation factors like eIF4A to allow increased cell division.47, 48
There is often thought to be good selectivity with this sort of MOA, as elongation factors
can often control specific protein translation.49 For example eIF4F controls translation
of pro-survival components like MCL-1. In addition, cancer cells often have inherent
deficiencies in the protein synthesis machinery; for example ovarian, thyroid, pancreatic
and colorectal cancer cell lines all have mutations in 12S and 16S rRNA, both of which are
required for protein synthesis.50, 51 It is evident that blocking protein synthesis would have
global downstream effects and has gained significant interest in the area of cancer research,
where blood cancers seem to be the most susceptible to inhibitors of protein synthesis.47
Correlations to a large number of protein synthesis inhibitors included phyllanthoside,
aurantimycin B, undulatone and bouvardin, which inhibit translation by a variety of dif-
ferent mechanisms.52, 53 The defective ribosomes found in ovarian cancer cell lines, could
correlate to the high sensitivity of A2780 cells to these compounds, as shown in Table
1.1.54 Mechanisms for translational inhibition could involve direct protein targeting, or oc-
cur through DNA interactions. Protein synthesis inhibition is closely linked to interactions
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with DNA, particularly as DNA targeting can only occur when unwound from nucleosomes,
which occurs during replication and protein synthesis. Indeed, the binding of platinum-
based drugs to the DNA has been shown to hinder both transcription and translation.55
3.3.4.2 DNA targetting
The most well known DNA-targetting chemotherapeutics are the platinum metallodrugs,
cisplatin, carboplatin and oxaliplatin. The development of resistance to these standard
agents has brought to light new anticancer agents, with higher specificity for DNA tar-
geting. For example, targetting telomeric DNA is a new approach, specifically designed to
cause genomic instability inside cancer cells.56 Ruthenium compounds have also shown
selectivity in DNA attack, specifically targetting the DNA of chromatin.57 However, this
direct-targetting of DNA has its limitations, irrespective of how selective they are, most
agents cause significant adverse side effects and increasing the metastatic properties of
tumours in clinical studies.58
This is where Os compounds Os-1 - Os-5 show promise, as they do not hydrolyse, and
do not directly bind to DNA, yet according to the COMPARE results they are still able
to damage DNA.59 In contrast, chlorido Ir(III) cyclopentadienyl compounds can interact
with DNA, binding both directly via Ir coordination to DNA bases (N7 in guanine) and via
intercalation of extended (phenylated) cyclopentadienyl ligands.18 Compound Ir-6 was
shown to bind to nucleobases in pSP73KB plasmid DNA, blocking RNA/DNA synthesis.18
However, given that both Os and Ir compounds correlated to the same DNA interacting
agents, it could be proposed that DNA-binding by the Ir compounds is not the primary
MOA. Correlated DNA-interacting agents include drugs like daunorubucin, olivomycin
and chromomycin, all DNA binding antibiotics.60, 61 Interestingly, anthracylines like
daunorubicin have been shown to induce oxidative stress, and to damage DNA through
generation of reactive oxygen species (ROS) generation.62 As a result, cell lines with
redox deficiencies, like MDA-MB-468 show particular sensitivity to this drug, as do
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compounds Os-1 - Ir-11, but not the platinums.63
Os-1, Os-3 and Ir-10 compounds also showed similar pharmacogenomic profiles to
DNA damaging agents and to topoisomerase inhibitors. The activity of compounds Os-1
and Os-3 were both affected when genes within R184 regions were amplified in breast
and NSCLC cell lines. Drug compounds SN-38 and bleomycin were also affected by this
amplification with effect sizes of 1.1 and 0.91, respectively (Table 3.4).
Bleomycin is used as an anticancer antibiotic in the treatment of a variety of cancers,
namely testicular, cervical, lymphoma and cancers of the head and neck.64, 65 Bleomycin
causes both single- and double-DNA strand breaks in cancer cells, although the exact
mechanism continues to be studied.66, 67 Reports have shown that it can directly bind
to DNA and cause breaks and that it can chelate with metals and molecular oxygen to
create reactive oxygen species (ROS) and damage DNA.68
Topoisomerase enzymes are required for the unwinding of supercoiled DNA and the
cutting and religation of DNA during replication and protein synthesis.69 As the active
metabolite of irinotecan, SN-38 is a topoisomerase I (TOP1) inhibitor.27 TOP1 relaxes
supercoiled DNA during replication and transcription, and generates and ligates cleaved
single strands. Inhibitors of TOP1 prevent the ligation of cleaved strands, maintaining
DNA breaks and activating cell death mechanisms in cancer cells.
COMPARE analysis also reported correlations ofOs-1 andOs-3 to topoisomerase inhib-
itors, although not specifically to SN-38. Instead they included drugs like doxorubicin and
etoposide, topoisomerase II (TOP2) poisons.53 TOP2 poisons specifically target the TOPO-
DNA complex, preventing re-ligation of double strand DNA and resulting in lethal breaks.
Through HGF, Os-3 also had a similar pharmacogenomic profile to AZD7762 (effect
size 2.1), which targets the CHK1/2 proteins in the DNA damage response pathway.30
This correlation was made through the HGF gene, which infers resistance in NSCLC and
large intestine cancers for both compounds. Inhibiting check point proteins like CHK1
and 2, mean that cancer cells cannot repair DNA damage and maintain genomic stability.
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Inhibitors like AZD7762 are generally used in combination with DNA-damaging agents,
like gemcitabine, to potentiate their activity.70
Interestingly, in both the NCI and the Sanger database, Ir-10 was highlighted as novel
with respect to other drug compounds. In the Sanger screen, it was the only drug to have
a sensitivity association with mutations in the KIT gene, primarily found in NSCLC. KIT,
encodes C-KIT, an important cytokine receptor commonly associated with blood and bone
cancers. Once the receptor is activated it controls signalling for cell survival, proliferate
and differentiation. KIT mutations have been associated with an increased sensitivity to
imatinib and has been proposed as an important biomarker in imatinib treatment.71 The
sensitivity of cell lines to Ir-10 also increased in response to KIT mutations. Functional
C-KIT often infers chemoresistance by augmenting the expression of DNA repair genes.
Its mutated form may therefore render cells more sensitive to DNA damage.72 It is
possible therefore to propose that Ir-10 has some involvement in DNA damage.
3.3.4.3 Mitosis inhibitors
The most well known anticancer agent which inhibits mitosis is taxol, disrupting micro-
tubule polymerisation.73, 74 Unfortunately anti-mitotic agents are often associated with
poor patient response, and are often used in combination with DNA-targetting agents,
hitting multiple areas of the cell cycle in dividing cancer cells.75 Interestingly, recent
research has taken a different approach to inhibiting mitosis, by targeting kinase enzymes
like CDK1 to prevent cells from entering into mitosis, resulting in cell death. However,
these compounds still have poor clinical efficacy.76
From the COMPARE algorithm, compounds correlated to anti-mitotic agents include
taxol, vinblastine sulfate and vincristine sulfate.77, 78 Recent experimental work in the
Sadler group has measured disruption of microtubule polymerisation by several of the
Os compounds used in this work (Fu, Y., Sanchez, C., unpublished work). As is evident
in Table 3.5, Os-4 retains activity in primary ovarian cancer cell lines with and without
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CDDP resistance, however, in cell lines pretreated with both CDDP and taxol, the activity
of Os-4 dropped drastically. This could suggest that cells have developed resistance
mechanisms to taxol, and that Os-4 may have involvement in the inhibition of mitosis.
3.3.4.4 Apoptosis activators
One of the cancer hallmarks is the ability for cells to evade apoptotic signals, this is
sometimes achieved due to high levels of BCL-2 protein which prevent pro-apoptotic
proteins from diffusing through pores in the mitochondria.79 In efforts to disrupt the over
expression of pro-survival elements like BCL-2, BCL-X and MCL-1 and to sensitise cells
to apoptosis, small molecules like ABT-263, were developed to mimic proteins able to
bind to BCL-2, allowing the release of pro-apoptotic proteins.79, 80
Obatoclax, is an example of a BCL-targeting agent, able to bind with high affinity to
BCL-2, BCL-X and MCL-1.81 Obatoclax shows a dependence of activity related to HGF
mutations (effect size 1.5), and like Os-3, is less active in cell lines with this mutation.
This could suggest that Os-3 has some direct pro-apoptotic effects.
3.3.4.5 Redox mediation
Cancer cells are naturally oxidatively stressed, this is often coupled to the function of
mitochondria which are the biggest source of reactive oxygen species (ROS) inside cells.82
Anticancer agents may therefore indirectly produce ROS by targeting the mitochondria.82
Given that cancer cells are already oxidatively-stressed, and have deficiencies in their
detoxification systems, drugs able to increase ROS may show a strong selectivity towards
cancer cells over normal cells.
COMPARE analysis returned correlations to redox mediators like asiaticoside, which
induces an oxidative stress response in cancer cells as a result of collagen formation
and angiogenesis.83 In addition, previous reports have shown that the activity of Os-1,
Os-3, Os-5, Ir-8, Ir-9 and Ir-10 increased dramatically when cells were co-incubated
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with agents targeting the detoxification/antioxidant response in A2780 cells.7, 59, 84 For
example, when cells were co-incubated with L-BSO, an inhibitor of GSH production, the
activity off Ir-8 - Ir-10 increased by 6.3-, 6.4- and 5.0-fold, respectively.7
The production of ROS has a global effect on the cells, with mitochondrial ROS having
a cyclic effect on the dysfunction of the mitochondria.82 DNA and proteins are notable
targets of ROS, it is therefore possible that the DNA damage proposed by COMPARE
and the Sanger screen is a result of ROS production, as measured experimentally for these
organometallic compounds.85, 86
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3.4 Summary and Conclusions
Cancer screens like those used in this chapter can provide a wealth of information, not
just on activity/selectivity towards cancer cells, but also to explore MOA and molecular
targets. Collectively both the NCI-60 and the Sanger Institute screens suggest multiple
MOAs for Os compounds Os-1 - Os-5 and Ir compounds Ir-6 - Ir-11. It is possible that
these targets are either hit simultaneously, or more likely that there are primary, secondary
and tertiary phases to the compounds MOA. Cell lines with redox deficiencies seem to
be more sensitive to these compounds, therefore it is highly possible for redox mediation,
resulting in reactive oxygen species (ROS) production to be the cause of the proposed
DNA and protein disruption.
In general, cancer cells are more oxidatively-stressed compared to normal cells, and
redox mediation by metal-based compounds is a well-documented mechanism.87 Any
targeting of DNA by this indirect method may provide a much more selective treatment,
given non-cancerous cells have functional mitochondrial and adequate detoxification
systems, which could recover the cell from drug-induced ROS production.
This chapter has shown the wealth of information that can be extracted from screening
results, particularly when correlating those findings with other sources. However, in vitro
cultured cells often undergo adaptive mutations, which can effect compound activity.
Therefore these screens provide more of a preliminary set of results, highlighting areas
of focus for researchers. In addition, the pharmacogenomics conclusions drawn from the
Sanger Institute screening hold little significance due to the low n values for cell lines
with cancer gene mutations. Therefore these findings need to be supported with further
in vitro investigations.
The results obtained in this chapter, have allowed the identification of two lead com-
pounds Os-3 and Ir-10, and has suggested multiple areas in which their MOAs may lie.
Given the broadness of these MOA predictions, Chapter 4 assess how cells response to
85
both lead compounds on a whole transcriptome level.
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Chapter 4. Transcriptomics
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4.1 Introduction
This chapter investigates the transcriptome profiles in A2780 human ovarian cancer
cells exposed to compound Os-3 ([Os(h6-p-cym)(NMe2-azpy)I]PF6) and Ir-10 ([Ir(h5-
Cpxph)(NMe2-azpy)Cl]PF6) at their GI50 concentration (Table 1.1) over 48 h time series
using RNA sequencing (RNAseq). These two compounds were selected based on the
results presented in Chapter 3, where both were highlight active, both had azopyridine
chelated ligands, yet both had different screening patterns. The A2780 ovarian cancer
cell line was chosen as a highly invasive form of serous ovarian cancer, and one which
is commonly used for in vitro cell work.
The transcriptome refers to the set of transcripts (mRNA sequences) in a cell, which
reflect the gene expression profiles. This gene expression will capture how A2780 cells
responds during exposure to Os-3 and Ir-10 treatment. Transcriptomics, principally,
allows us to determine the abundance of these transcripts in the cell.
The past decade saw the development of next generation sequencing (NGS), where RNA
sequencing (RNAseq) is used to study transcriptomics.1 RNAseq provides superior sensit-
ivity and resolution compared to DNA microarrays.2–4 Studying cancer cells using sequen-
cing has it’s difficulties, primarily contending with copy number variations (CNV) which
can cause over expressed mRNA transcripts to swamp the reads of those less abundant. To
tackle this problem, sequencing must be performed with high coverage, ideally between
25 - 30 million reads per sample. The experiments presented here measured 30 million,
paired-end reads per sample in efforts to avoid missing important, lowly-expressed genes.
In depth pathway analysis aims to pull out specific response profiles in A2780 cells
exposed to both compounds, and gain insights into compound MOAs.
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4.1.1 Experimental overview
Shown in Figure 4.2 is the experimental work flow, where library preparation and sequen-
cing were performed at The Wellcome Trust Centre for Human Genetics in the Oxford
Genomics Centre.
4.1.1.1 RNA extraction
In two separate experiments, A2780 cells were seeded and incubated for 24 h, after this
time they were either exposed to a vehicle control solution or to a solution of Os-3 at 0.15
µM (Experiment I) and Ir-10 at 0.40 µM (Experiment II). Cells were collected at 4, 12,
24 and 48 h after addition of either solution. In addition, six 0 h time points were collected
during Experiment I. After exposure, collected cell pellets were lysed in RNase-denaturing
buffer using detergents to solubilise proteins and salts like guanidine isothiocyanate to dis-
rupt RNase enzymes. Whole cell RNA was collected and purified using Qiagen RNAeasy
extraction kits, which allows for a series of spin column procedures to collect and wash
the RNA. Lysed solutions were passed through a DNA-eliminating column, where DNA
and RNA have different, pH dependent, binding to the column matrix. Column-bound
RNA was then washed with ethanol and multiple buffer solutions designed to remove
residual proteins and salts. RNA was collected in RNase-free water and stored at -80 C
before QC checking.
4.1.1.2 Quality control checks
NanoDrop. The NanoDrop 1000 allows direct measurement of RNA sample solutions,
using surface tension to hold the sample in place. A light was passed through the solution,
between 220-750 nm, and a spectrum measured. The absorbance was recorded at 230,
260 and 280 nm to test for RNA purity, and to estimate RNA concentration using the Beer
Lambert equation. A230 measures for protein peptide bonds and organic contaminants,
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A280 measures amino acids and phenolic contaminants and A260 measures the RNA.
Generally, researchers check the A260/A230 and A260/A280 ratios to determine purity,
aiming for the first ratio to be > 1.8 and the second to be > 2.0. All samples from both
Experiments I and II passed this QC check.
Bioanalyzer. The Agilent 21000 Bioanalyzer was a secondary means of measuring the
RNA integrity by assessing the rRNA. It is more accurate than the NanoDrop, analysing
RNA samples dispensed onto chips using capillary electrophoresis, based on the same
principles as gel electrophoresis. Each chip holds sixteen wells for sample, gel and refer-
ence ladder, with micro-channels interconnecting the wells. During manufacturing, the
micro-channels are filled with a sieving polymer and a fluorescent dye, which intercalates
with RNA. 16-pin electrodes were inserted into each well and a charge applied. The
charged biomolecules were separated by size, as smaller fragments migrate faster through
the gels than larger fragments. The laser-induced fluorescent dye molecules intercalate
with the RNA samples and with the RNA ladder, passing the detector at speeds relative to
the size of the fragment. Data were produced as both gel-like bands and as peaks in an
electropherogram. Figure 4.1 shows the gels for the six 0 h control samples extracted
from A2780 cells (1 - 6).
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Figure 4.1: Gel showing the RNA integrity for 0 h control samples 1 - 6. The bands for
each sample correspond to subunits of rRNA present in each sample, and is a measure of RNA
degradation as a result of the extraction process. A high quality sample will have two main bands,
one for 18S and one for the 28S subunit, and sometimes for the 5.8S subunit. The intensity of
these peaks, and any other bands around these, are used to calculate the RNA integrity number
(RIN). For the 6 samples in this Figure, all samples had RIN of 10/10.
The total eukaryotic RNA has two ribosomal bands/peaks, corresponding to the 18S
and 28S subunits. A pure sample produces a flat baseline between the peaks in the
corresponding electropherogram. Agilent have developed an algorithm which assess all
features of the electrophoreogram and produces an RNA integrity number (RIN) between
1 and 10, where 1 is a highly degraded RNA sample and 10 is an intact sample. Generally
a sample should have an RIN > 7 to be suitable for sequencing. All RNA samples from
Experiment I and II had RIN   9.50.
Qubit assay. The Qubit 2.0 Fluorometer was used to quantify the concentration
of RNA in each sample. Again, a fuorescent dye was used, emitting selected signals
when bound to the RNA. This signal was referenced against a calibration curve, and the
concentration of RNA in each sample determined. Samples were transferred to the Oxford
Genomics Centre for sequence analysis.
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The schematic in Figure 4.2 summarises the experimental work flow performed at
Warwick, and introduces the work performed by the Oxford Genomics Centre.
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Lyse Eliminate 
DNA 
Bind to 
column 
Wash Elute 
RNA Extraction/purification 
Collect cell pellet 
RNA QC checks 
Nanodrop Agilent bioanalyzer Qubit RNA 
quantification 
cDNA library prep 
rRNA  
removal 
Adapter/barcode 
ligation 
Sequencing 
Data analysis 
Vehicle control cells Drug exposed cells 
1st and 2nd  
strand synthesis 
Fragmentation and 
end repair 
A tailing 
UDGase 
treatment 
Amplification 
Attach to 
flow cell 
Amplify Linearisation Primer 
annealing 
Sequence by 
synthesis 
Performed at Oxford 
Figure 4.2: RNAseq experimental workflow showing RNA extraction, purification, library
preparation and sequencing. Boxed area highlights the work performed by Oxford Genomics
Centre, with everything outside of this box performed at the University of Warwick.
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4.1.1.3 Library preparation5
It is cDNA, not RNA, which is used during the sequencing procedure as DNA is more
stable than RNA, and samples are amplified by polymerase chain reaction (PCR) which
requires DNA. RNA can be used but RNA-dependent RNA polymerase are known to
incorporate errors. The complementary DNA strands were reverse transcribed from the
mRNA provided in each sample. cDNA strands were fragmented to allow more accurate
sequencing, and the end tails paired to allow adapter ligation. These adapters (in red in
Figure 4.3) were required for paired-end sequencing to maintain forward and backward
strand polarity (Figure 4.3).
UDGase treatment 
   AnAnnnnnAAnnnnAnnnAnnNNNNNN  
   n!nnnnn!!nnnn!nnn!nnnnnnnnA 
TCTAGCCTTCTCG 
GCTCTTCCGATCT
CGAGAAGGCTAG
GATCGGAAGAGC 
Ad 2 
Ad 1 
Ad 1 
Ad 2 
Fragment A 
Adapter ligation 
   AnAnnnnnAAnnnnAnnnAnnNNNNNN  
   nUnnnnnUUnnnnUnnnUnnnnnnnnA 
TCTAGCCTTCTCG 
GCTCTTCCGATCT
CGAGAAGGCTAG
GATCGGAAGAGC 
Ad 2 
Ad 1 
Ad 1 
Ad 2 
Fragment A 
Figure 4.3: cDNA fragment A, together with its complementary strand are ligated with
Y-shaped adapter sequences 1 (Ad 1) and 2 (Ad 2) at the 3’ and 5’ ends. Ad 1 and Ad 2
allow sequencing to be performed along the forward and reverse strands, which is the fundamental
benefit of using paired-end sequencing, maintaining strand polarity. Figure 4.4 details the use of
these adapters. Image adapted from Parkhomchuk (2009) Nuc. Acid Res. 37(18):e1235
Uridine bases were removed to prevent second strand amplification during PCR. Primers
were attached to each adapter during PCR, as well as an index sequence to allow barcod-
ing and multiplexing during sequencing. Multiplexing allowed multiple samples to be
sequenced in a single lane on the sequencer, saving time and money.
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4.1.1.4 Sequencing6
Once strands were bound and amplified into clusters on the sequencer flow cell the process
of sequencing could begin. In these experiments each sample was subject to 30 million
paired-end reads (60 million in total) across five sequencing lanes, using multiplexing.
Figure 4.4 outlines the process of nucleotide reading for each strand.
Flow cell 
Rd1 SP 
A 
C 
G 
A 
T 
G 
T A 
C 
G 
A 
T 
G 
T 
G 
T 
C 
2. 
3. 
4. 
Wash 
Fluorescent  
read 
Remove dye 
and blocker 
1. Add  
RT-bases 
5. Add  
RT-bases 
Figure 4.4: Process of nucleotide reading during strand sequencing. Shown in grey on the
far left is a cDNA sequence (grey); attached either side are the forward and reverse primers (beige
and blue), adapters 1 and 2 (pink and red) and sample-specific barcode (green). Figure 9.2.2.3 will
detail sequencing of the reverse strand, utilising the barcode, reverse primer and adapter 2. The
first step exposes the strand to a pool of labelled nucleotides, which complementarily bind using
the read 1 sequence primer (Rd1SP), and are read using lasers to excite fluorescent tags attached to
each nucleotide. Once the signal is read, and the nucleotide identified, the tags and blocker groups
are removed, and the process repeated until 50 base pairs have been read. Image adapted from an
Illumina multiplexing worksheet6
In step 1, fluorescently labelled nucleotides with blocker groups, bind complementarily
to the strand clusters, starting from the read 1 sequence primer (Rd1 SP). The blocker
groups prevent more than one nucleotide from binding before the fluorescence can be
read. Each nucleotide was read as a different colour, excited by two lasers (step 2 and 3).
After reading, the blocker group was chemically removed and the process repeated
with a second nucleotide pool (step 4 and 5). For the work conducted in this chapter,
50 nucleotides were to be read at each end of each strand. The process of paired-end
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sequencing is shown in Figure 4.5.
Rd1 SP 
Ind SP 
Rd2 SP 
DNA insert 
Index 
Flow cell 
1. 2. 3. 
Figure 4.5: Process of paired-end sequencing. Step 1 shows the forward strand being sequenced,
as shown in Figure 4.4, with step 2 showing the sequencing of the barcode index (green) required
for multiplexed samples. This barcode is read using the index primer (IndSP), and assigns a
particularly set of sequencing reads to a specific sample. Between steps 2 and 3, a complementary
reverse strand is constructed so that in step 3 the reverse strand is sequenced, now using the reverse
strand read 2 primer (Rd2 SP). Once 50 nucleotides have been read from both the forward and
reverse strands, the information is combined using sequencing analysis software. Image adapted
from an Illumina multiplexing worksheet6
In step 1, nucleotides were read down the forward strand starting from the Rd1 SP. In
step 2, the barcode index (Ind SP) was read. To read nucleotides for the reverse strand,
a complementary strand was synthesised for the entire strand, including adapters, primers
and barcodes. From this complementary strand, the reverse nucleotide sequence was
determined starting from the read 2 sequence primer (Rd2 SP).
The associated quality score, assigned per nucleotide read is a measure of the accuracy
of that read. Although four different colours were used for the detection of each of the
four nucleotides, only two lasers were used to excite the fluorescent probes. For example
A and C were both read by red lasers and both G and T read by green lasers.
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The quality score for each base call was calculated using a phred-like algorithm, which
is a four-phase procedure assessing the observed versus the predicted peak locations.7, 8
The value produced for each base call represents the probability p that that base call is
incorrect, usually presented as -10log10p. Therefore, a quality score of 30 for a nucleotide
read, means that the probability that the base call is incorrect is 1 in 1000 (accuracy of
99.9%), therefore the higher the quality score the more accurate the read. Generally a
quality score > 20 (i.e. 1 in 100) is accepted as an accurate read, therefore this is the cut
off value during data analysis.
4.1.2 Data analysis overview
The data analysis is generally the most time consuming and complex stage of any next
generation sequencing project. As discussed in Chapter 1, there are numerous tools
which can be used to analyse RNAseq data, each offering users different capabilities
and statistical methods. The Tuxedo suite, including TopHat, Bowtie and Cufflinks
is the most commonly used tool set for this analysis.9–11 However, packages like
DESeq and edgeR generally offer a more accurate data analysis for differential ex-
pression, making fewer statistical assumptions and allowing a better incorporation of
time series data.12–17 Figure 4.6 summarises the chosen work flow for the data ana-
lysis.
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Bowtie & Tophat 
HTSeq 
Calculate differential expression 
between treatment replicates 
edgeR 
Align sequence reads to the 
hg19 genome 
Count the number of sequence 
reads per gene 
Network and pathway analysis 
 
IPA 
Figure 4.6: Data analysis work flow chosen to analyse Experiments I and II. Tophat and
Bowtie were used for filtering out poor quality sequence reads and for aligning reads to the human
genome. HTSeq was used to count the number of reads associated to each gene in the human
genome. And edgeR was used to explore differential gene expression between drug-exposed and
control samples.
4.1.2.1 Bowtie and Tophat
Bowtie and Tophat mappings were performed at the Oxford Genomics Centre. Bowtie is a
program and was used to align the short DNA sequences, read from the RNA sequencing
experiment, to the hg19 human genome.10 Bowtie is integrated into TopHat, a splice
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junction mapping tool which uses the Bowtie program to align reads before identifying
splice junctions.11 Tophat analysis produces a so-called BAM file for each sequenced
sample. These files describe the chromosomal positions to which each sequence read has
mapped, and the number of times this mapping has occurred. These data are paired-end,
which also identifies whether partner read mapping is conserved.
4.1.2.2 HTSeq
HTSeq is a Python program used to prepare datasets for downstream analysis in edgeR.18
The purpose of this program is to construct a list of genes and an associated count for
the number of reads mapped to that gene. HTSeq used a hg19 genome annotation file
and the chromosomal read positions generated from Tophat to construct a list of genes
expressed for each sample in Experiment I and II.
4.1.2.3 edgeR
Although the Tuxedo suite, specifically Cuffdiff, is the most comprehensive software to use
for differential expression (DE) analysis, it does not support multifactorial experimental
designs and is therefore not optimal for time series DE analysis. A recent review by
Rapaport et al highlighted several other limitations with Cuffdiff when compared to other
sources of DE analysis like edgeR or limmaVoom.19
The edgeR package was selected for DEG analysis, a summary of the steps involved
is shown in Figure 4.7.12, 20–23
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Define experimental contrasts i.e. 
drug vs control at each time point 
Combine HTSeq files and estimate 
library size 
Filter for gene count > 10 and genes 
present in all replicates 
TMM normalise data 
Calculate DE and likelihood ratios for 
each contrast, with FDR < 5% 
Figure 4.7: edgeR data analysis work flow. HTseq was used to count the number of reads per
gene, with edgeR filtering out those genes with low counts or which did not provide ¿10 counts
in all three triplicate samples. edgeR then normalised the data using trimmed mean of M-values
(TMM) which scales each dataset so that genes with large read counts do not swamp those with
low. Finally edgeR allows exploration of differential gene expression between treatment and
control groups.
edgeR focusses on DE analysis and not on relative expression levels, minimising tech-
nical influences and focusing on relative changes between conditions. The normalisation
process in edgeR was model-based, estimating scaling factors to account for RNA compos-
ition between each pair of samples. These scaling factors were estimated using a trimmed
mean of M-values (TMM), and were used to adjust the sample library size.22 This scaled
‘effective library size’, was implemented for library size normalisation of each sample.
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When performing DE analysis, edgeR fits a negative binomial distribution to the count
data and estimates dispersions using the Cox-Reid profile-adjusted likelihood method,
which allows for multifactorial experiments by using general linear models (GLMs)
together with a given design matrix.24 This process accounts for all sources of variation
in the experiment.
The GLM likelihood ratio test is used to compute a p value for significance testing
between genes in each sample, based on a given null hypothesis.23 The Benjamin-
Hochberg method was used to account for multiple testing correction and false discovery
rate (FDR) estimation.25
edgeR provided a list of differentially expressed genes (DEG) and associated logFC
ratios (i.e. the fold change in expression between compound-exposed and control-exposed)
and FDR values, for which pathway analysis was performed and biological significance
investigated.
4.1.2.4 Ingenuity pathway analysis (IPA).
Functional analysis was performed with IPA (Ingenuity Pathway Analysis, Ingenuity R 
Systems) using the Information Knowledge Base (IKB).26 All data contained within the
IKB database are sourced from published literature and currently contains information on
16,900 human genes, 968,000 biological/chemical concepts from 2.44 million literature
findings. IPA is used to produce functional networks and pathways of interest based on a
dataset of DE values. Figure 4.8 summarises each stage used by the IPA network algorithm.
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Form network edges 
Focus genes sorted by 
interconnectivity 
Network construction from focus 
genes 
Linked genes are used to merge small 
networks 
Grow small networks using 
neighbourhood genes 
Compute hypergeometric p values 
and rank networks 
Figure 4.8: Ingenuity Pathway Analysis (IPA) data analysis work flow. IPA was used to
allocate highly- and lowly-differentially expressed genes into biological pathways to allow
interpretation of results. Networks of expression are gradually built up by IPA, by first forming
nodes for key genes and then gradually growing networks outwards from these genes. Each
pathway formed is associated with a hypergeometric probability for over-representation and
identifies the significance of a particular pathways involvement in drug-response with respect to all
other pathways in the dataset.
IPA provides ranked information on biological processes, cellular networks, functional
networks, upstream regulators and disease profiles. Biological inferences for compound-
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effects can be made from collating this information.27
113
4.2 Results
This chapter investigates the differential gene expression for ovarian cancer cell line,
A2780, when exposed to compound Os-3 ([Os(h6-p-cym)(NMe2-azpy)I]+) for 4, 12, 24
and 48 h at its GI50 concentration of 0.15 µM (Experiment I) and to compound Ir-10
([Ir(h5-Cpxph)(NMe2-azpy)Cl]+) for 4, 12, 24 and 48 h at its GI50 concentration of 0.40
µM (Experiment II). The experiments were performed independently, however, their
results are presented side-by-side. Os-3 and Ir-10 were chosen based on screening results
presented in Chapter 3, where Os-3 was active and performed similarly to many of the
other compounds, and Ir-10 was both active and novel.
4.2.1 Sample quality checks
Nanodrop and bioanalyzer data for sample quality checks all passed with A260/230  
1.8, A260/280   2.0 and RIN > 9.50 (Appendix 9.2 and 9.4).
4.2.2 Sequencing sample statistics
Tables 4.1 and 4.2 summarise the RNAseq statistics for all samples in Experiment I (Os-3).
Samples were multiplexed across 5 lanes (6 samples per lane), with lane clusters and
yields shown in Table 4.1 and the total reads per sample, mapping and quality scores
shown in Table 4.2. Samples were paired-end sequenced, which means that 50 base pairs
were sequenced from each end of each transcript fragment, bringing the total number of
reads per sample to ca. 60 million. The sample statistics for Experiment II are shown
in Appendix 9.2.
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Table 4.1: Summary statistics for each lane. Showing yields, mapping and quality scores. The %
of mapped reads are those which have mapped successfully to the human genome, the few percent
that did not map may be mutated reads or may be of poor quality. Only those nucleotide calls with
a quality score (Q) ¿ 20 were included for analysis.
Lane⇤ Yield (Mb Q20⇤⇤) % Mapped Mean quality
reads score
1 20,999 98.1 34.4
2 18,291 97.9 35.6
3 19,081 98.5 35.3
4 16,367 98.3 36.5
5 16,860 98.3 36.4
⇤6 samples per lane. ⇤⇤A quality score of 20
4.2.3 Mapping to the human genome
The % mapped reads shown in Tables 4.1 and 4.2 for Experiment I refers to the number of
nucleotide reads in each sequence which were mapped to the hg19 genome successfully.
The ca. 2% which were not mapped could be due to several things. This could stem from
Tophats inability to tolerate too many sequencing errors, or where a pairing has failed and
thus not been mapped. It could also be that cancer progression has re-arranged the genome
to the extent that some read pairs will not map. As the % of unmapped reads is so low, it
does not affect the analysis. The same tables are shown for Experiment II, in Appendix 9.2.
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Table 4.2: Summary statistics for each sample, showing total reads, mapping and quality scores.
The total reads refers to the total number of reads measured, however, the total number of paired-
end reads is exactly half of this. The % mapped shows the total number of reads which were
able to map to the human genome, with the mean quality score signifying whether these mapped
reads were of high quality. Any reads with quality scores ¡ 20 were filtered out before reads were
mapped.
Sample Sample Total reads %Mapped Mean quality
number name reads score
1 0 h control 58,453,334 98.53 36.5
2 0 h control 52,958,428 98.32 36.4
3 0 h control 52,411,032 98.11 36.5
4 0 h control 57,489,392 98.72 36.5
5 0 h control 53,112,138 97.75 36.5
6 0 h control 54,962,488 98.12 36.4
7 4 h control 82,071,522 98.19 34.4
8 4 h control 84,555,686 98.11 34.4
9 4 h control 73,333,434 97.93 34.4
10 4 h 3 69,130,568 97.87 34.4
11 4 h 3 59,742,704 97.99 34.5
12 4 h 3 72,018,526 98.38 34.4
13 12 h control 50,690,134 97.87 36.4
14 12 h control 55,041,730 99.25 36.4
15 12 h control 60,723,390 97.88 36.4
16 12 h 3 58,813,794 98.12 36.4
17 12 h 3 57,945,078 98.82 36.4
18 12 h 3 56,092,354 97.97 36.4
19 24 h control 60,331,926 98.14 35.6
20 24 h control 67,939,036 98.93 35.0
21 24 h control 59,240,982 98.09 35.6
22 24 h 3 64,300,818 95.65 35.5
23 24 h 3 61,522,272 98.48 35.6
24 24 h 3 61,343,334 98.18 35.5
25 48 h control 69,027,526 98.61 35.4
26 48 h control 65,550,492 97.69 35.3
27 48 h control 55,141,160 98.55 35.3
28 48 h 3 66,793,080 98.39 35.4
29 48 h 3 66,227,334 99.20 35.3
30 48 h 3 69,306,494 98.19 35.3
Figure 4.9 shows a heat map of the mean number of reads (from Table 4.2) mapped
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to chromosomes 1-22, X and M, for each sample type: 0 h control (inner circle), 4 h
control, 4 h Os-3-exposed, 12 h control, 12 h Os-3-exposed, 24 h control, 24 h Os-
3-exposed, 48 h control and 48 h Os-3-exposed (outer circle). The mean read counts
for each sample type are represented as log10FPKM, and thus normalised to chromo-
some length and sample library size (total reads). The log10FPKM values for mapping
to the mitochondrial chromosome (ChrM) were significantly higher than that of the
other chromosomes. This is a result of length bias, since ChrM is much shorter than
the other chromosomes (ca. 16,600 base pairs). In addition to length bias, the copy
number variations in the mitochondria of cancer cell lines may also weight read map-
ping.28
48 h compound 
48 h control 
24 h compound 
24 h control 
12 h compound 
12 h control 
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Figure 4.9: Mapping of reads to individual chromosomes from Experiment I. Heat map
showing chromosomal mapping of sequence reads to the human genome after normalisation to
chromosome length and sample library size (FPKM). Chromosomes are described in the centre
of the heat map, from 1 - 22, X and M. The key on the left describes the sample order, starting
from the inner most circle (0 h control) to the outer most circle (48 h compound-exposed), where
each ring is a mean value from each triplicate sample. Darker boxes indicate a large number
of reads per length of each chromosome. For all samples, control- and compound-exposed,
the mitochondrial chromosome (M) has the largest log10FPKM values, suggesting a significant
expression of mitochondrial genes both before and after compound-exposure.
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In Figure 4.9, the ChrM log10FPKM values appear to be equal across the sample range,
however, Figure 4.10 shows a significant differential mapping between control- (blue)
and compound-exposed (green) samples after exposure to Os-3 and Ir-10.
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Figure 4.10: Graph showing total number of reads mapped to the ChrM. Graphs show
normalised reads for control- and compound-exposed samples across each time series for Os-3
(left) and Ir-10 (right). The reads are normalised to sample library size, with the grey line as the
mean across the triplicate values. * indicates p < 0.10 and ** indicates p < 0.05 after a Welch two
sample t-test. In response to Os-3 there is a significant increase in mitochondrial gene expression
after 12 and 24 h. In contrast, the response to Ir-10 is only significant after 12 h exposure.
The differential mapping after exposure to Os-3 is particularly evident at 12 and 24
h, where there are significantly more reads mapped in the compound-exposed versus
the control samples (p = 0.030 and 0.016, respectively, after a Welch two sample t-test),
suggesting that Os-3 induces a mitochondrial genomic response. Interestingly, Ir-10 does
not induce as significant a mitochondrial response, except at 12 h (p = 0.097).
4.2.4 Mitochondrial mutations
The ChrM encodes 13 polypeptides which constitute the hydrophobic cores of components
in the electron transport chain (ETC) and oxidative phosphorylation pathway (OXPHOS).
The remaining genes on ChrM code for RNA machinery required for mitochondrial
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translation.29 Figure 4.11 is a simplified schematic of the ETC, showing the positions
of protein complexes I-V (CI-CV) which orchestrate the transfer of electrons and protons,
and the production of ATP.
Electron transport chain 
2H+ 4H+ 2H+ 3H+ 
ATP ADP 
2H2O 4H+ + O2 
NADH NAD+ 
FADH2 FAD 
e- e- 
e- e
- 
CI 
CII 
CIII CIV CV 
Q 
Cyt C 
Figure 4.11: Schematic of the components in the electron transport chain (ETC). The grey
coloured region is the inner mitochondrial membrane, with the blue and purple structures as enzyme
complex I (NADH dehydrogenase), II (succinate dehydrogenase), III (coenzyme Q reductase),
IV (cytochrome C reductase) and V (ATPase) of the ETC. During oxidative phosphorylation, the
last step in aerobic respiration, electrons are transferred from complex I to complex IV utilising
NADH, FADH2, co-enzyme Q (Q) and cytochrome C (Cyt C) electron carriers. As these electrons
are transferred, protons are pumped across the inner membrane to the outer membrane space by
complexes I, III and IV. This creates a proton-motive gradient which is used by complex IV to
catalyse the production of ATP from ADP and organic phosphate. A byproduct of this process is
water, through reaction of protons with molecular oxygen.
Given the transcriptomic response associated with the mitochondria, and that mutations
in mtDNA are well documented in cancer cells, the ChrM sequence reads from Experiment
I were compared with those in the hg19 human genome, highlighting multiple nucleotide
read discrepancies.30, 31
These mutations were found in all 30 samples of Experiment I, with   99% homology
in ca. 1200 2000 counts. Most base substitutions resulted in silent mutations, however,
the MT-ND5 gene, coding for the ND5 membrane-bound subunit of CI, had 3 missense
mutations at positions m.13106, m.13677 and m.13887. These mutations translate to
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peptide substitutions at p.I257V (isoleucine > valine), p.N447S (asparagine> serine) and
p.L517P (leucine > proline).
Multiple mutations were identified throughout the mtDNA, although most were silent
mutations. However, 3 missense mutations resulting in amino acid substitutions p.I257V,
p.N447S and p.L517P were identified in the coding sequence of theMT-ND5 gene.
The p.I257V (dbSNP variant rs2853501) and p.N447S have been reported in previous
work, the former is thought to have no functional effect, however, the p.447 asparagine
substitution has been demonstrated in patients with CI deficiencies.32–34 The p.L517P
mutation has been reported in cases of optic neuropathy, however, this report provides
an incorrect assignment for the associatedMT-ND5 nucleotide substitution.35
The MT-ND genes on the ChrM encode helical polypeptides which constitute the
membrane bound subunits of NADH dehydrogenase complex I (CI), responsible for
maintaining a proton gradient between the matrix and inter-membrane space.36 MT-ND5
codes for the 5th subunit in this complex.
Figure 4.12 shows the point mutations in the MT-ND5 amino acid sequence (red),
where residues highlighted in blue are transmembrane helices in the subunit. In addition
to multiple transmembrane domains, the ND5 subunit of CI has a transverse helix, which
stretches across ND4 and ND2 before ending with a final transmembrane helix.37
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Complex I: ND5 subunit 
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p.I257V   p.N447S   p.L517P 
•  Somatic mutations not reported in ovarian cancer before 
•  p.125 and p.447 are known sequence variants 
•  p.447 has been demonstrated in patients with CI deficiencies  
•  p.L517P has not been reported 
LIT!
Figure 4.12: Amino acid sequence of protein MT-ND5. The MT-ND5 subunit sits in the inner
mitochondrial membrane and is responsible for pumping protons across the membrane. Residues
highlighted in blue are part of transmembrane helices, with those in black found outside of the
membrane. The mutations identified in A2780 cells were highlighted in red: p.I257V (isoleucine to
valine substitution at the 257th residue), p.N447S (asparagine to serine substitution) and p.L517P
(leucine to proline substitution). The p.N447S and p.L517P substitutions would have the most
significant structural implications.
Only the p.I257V substitution is found in a transmembrane domain, the p.N447S
substitution known to cause CI deficiencies is outside of the membrane, and the new
p.L517P substitution is found in the transverse helix. The ND5 subunit is responsible
for proton pumping from the matrix to the intermembrane space of the mitochondria,
therefore mutations in the CI machinery could impact on the metabolic efficiency.
4.2.5 Compound-induced differential expression
Using HTSeq and edgeR, differential gene expression analysis was performed for samples
exposed to Os-3 and Ir-10, relative to the negative controls in each experiment. Prior
to differential expression (DE) analysis, the samples in each experiment were compared
for similarity.
Using multidimensional scaling (MDS) plots, compound- and control-exposed samples
across both time series were plotted. These plots are a means of visualising the level
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of similarity in sample sets, by placing each of them in N-dimensional space, where
between-object distances are preserved. Coordinates were assigned to each of the samples
in two dimensions, where those plotted closer together share higher similarity (Figures
4.13 and 4.14).
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Figure 4.13: Multidimensional scaling (MDS) plot for Experiment I.MDS allows the simil-
arity between variables to be assessed by plotting each dataset in space, by euclidean distance. In
these plots, samples which are plotted close together share higher similarity. Both plots display the
same data, grouping samples 1-24 by similarity where samples 1-3 are 4 h controls, 4-6 are 4 h
Os-3-exposed, 7-9 12 h control, 10-12 12 h Os-3-exposed, 13-15 are 24 h controls, 16-18 are
24 h Os-3-exposed, 19-21 are 48 h controls and 22-24 are 48 h Os-3-exposed. The plot on the
left highlights grouping of samples into control (blue) and Os-3-exposed (orange) demonstrating
a drug-induced differential response at the gene level. The right-hand plot shows grouping of
samples across the time series, with 4 h control and Os-3-exposed samples in blue, 12 h in green,
24 h in orange and 48 h in red. This second plot highlights how different the 48 h datasets are,
compared to earlier time points.
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Figure 4.14: Multidimensional scaling (MDS) plot for Experiment I.MDS allows the simil-
arity between variables to be assessed by plotting each dataset in space, by euclidean distance. In
these plots, samples which are plotted close together share higher similarity. Both plots display the
same data, grouping samples 7-30 by similarity where samples 7-9 are 4 h controls, 10-12 are 4 h
Ir-10-exposed, 12-15 12 h control, 16-18 12 h Ir-10-exposed, 19-21 are 24 h controls, 22-24 are
24 h Ir-10-exposed, 25-27 are 48 h controls and 28-30 are 48 h Ir-10-exposed. The plot on the
left highlights grouping of samples into control (blue) and Ir-10-exposed (orange) demonstrating
a drug-induced differential response at the gene level. The right-hand plot shows grouping of
samples across the time series, with 4 h control and Ir-10-exposed samples in blue, 12 h in green,
24 h in orange and 48 h in red. This second plot highlights how different the 48 h datasets are,
compared to earlier time points.
Both Figures 4.13 and 4.14 show natural separation of the samples into clusters, and
show good agreement between the triplicate measurements. The biggest source of vari-
ation is by time point, the second by exposure-status i.e. whether they are exposed to
a control or to a compound. Therefore the first dimension, allows the separation of the
samples across the time series, with 4 h in blue, 12 h in green, 24 h in orange, and 48
h in red. In the second dimension, samples separate into two clusters, one for control
samples (blue) and the second for compound-exposed samples (orange). These plots
provide clear evidence that the samples exposed for 48 h to both Os-3 and Ir-10 are
significantly different from those exposed for shorter time periods, both in the control
and in the compound-exposed samples.
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Using edgeR, the number of differentially expressed genes (DEGs) at each time point
was determine. The number of DEG at 4, 24 and 48 h post-exposure to Os-3 and Ir-10
are shown in Figure 4.15.
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Figure 4.15: Venn diagrams showing the number of differentially-expressed genes at 4, 24
and 48 h after exposure to Os-3 (left) and Ir-10 (right). Only those genes with -1.0 < LogFC
> 1.0 and FDR < 0.05 were included. The Venn diagrams show that cells exposed to Os-3 have
the largest gene response after 48 h, compared to those exposed to Ir-10 where the largest response
is after only 24 h. Overall there were 668 genes differentially-expressed at these time points in
response to Os-3 and 746 in response to Ir-10.
The maximum number of DEGs after exposure to Os-3 was at the 48 h time point
(668), in contrast to 12 h for Ir-10 (746), highlighting a difference in response for each
compound. Overall, there was a higher level of differential expression in cells exposed to
Ir-10. Figure 4.16 looks at the number of genes which were DE by both Os-3 and Ir-10
compared to the number which were specific to each compound.
Figure 4.16 shows some overlap between the compound responses, however, the re-
sponses are predominantly specific. Figure 4.17 shows the number of DEG which are up-
and down-regulated at each time point in cells exposed to Os-3 (left) and Ir-10 (right).
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Figure 4.16: Venn diagrams showing the overlap in differential-expression between Os-3
and Ir-10 at 4, 24 and 48 h. Only those genes with -1.0 < LogFC > 1.0 and FDR < 0.05
were included. After 4 and 24 h there were more genes differentially expressed in response to
Ir-10 (blue) compared to Os-3 (green), with ⇡ 100 genes differentially expressed to both, and the
remainder showing compound-specific expression. At 48 h, there were more genes differentially
expressed to Os-3, with almost 200 genes differentially expressed to both compounds, and the
remainder compound-specific.
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Figure 4.17: Graphs showing the number of up- (red) and down-regulated (green) genes
at each time point. The results for Os-3 are shown in the left graph, and for Ir-10 on the right.
Only those genes with -1.0 < LogFC > 1.0 and FDR < 0.05 were included. The graph on the left
shows that at 4 and 48 h there are more genes down-regulated (green) then up (red), in contrast to
12 h, where there are more genes up-regulated in response to Os-3. In response to Ir-10 there are
significantly more down-regulated genes after 12 h exposure, compared to 4, 24 and 48 h where
the number of genes up- and down-regulated was almost equal.
Again, these plots show a different response in cells exposed to Os-3 and Ir-10. The
Venn diagrams showed that maximum DE was at 48 h after exposure to Os-3; Figure
4.17 shows that at this time point there are slightly more up- (393) than down-regulated
(275) genes. Maximum DE to Ir-10 was achieved after 12 h, where the graph shows
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significantly more down-regulation (229) than up- (517).
4.2.6 Pathway analysis for Os-3 and Ir-10
Using Ingenuity Pathway Analysis (IPA) software, the DEG with 1.0 < LogFC > 1.0
and FDR < 0.05 were assigned to biological pathways. Tables 4.3 and 4.4 show the top
five upstream regulators of these pathways, across the time series, for each compound.
The tables show the p value as calculated by a hypergeometric test of over representation,
and the z-score which describes the extent of activation/inhibition of each pathway.
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Table 4.3: The upstream regulators from IPA analysis for the top five most mapped processes for
DEGs with -1.0 < LogFC > 1.0 and FDR < 0.05 after exposure to Os-3. IPA has identified the
pathways with the most differential expression and has then performed a hypergeometric test for
over-representation to provide a p-value to identify the most significant results. The z-score is a
measure of how much a pathway is up- or down-regulated (activated or inhibited), where -2 < z >
2 is said to be a significant result. There are similar pathways affected by Os-3 across the time
course, including tumour necrosis factor (TNF), transforming growth factor (TGF), interleukin-b1
(IL-b1) and interferon g (IFNg), which are all activated.
Time Upstream p-value Activation Predicted
point (h) regulator z-score activity
UO126 4.41 x 10 14 -3.709 Inhibited
TGFb1 5.90 x 10 14 2.169 Activated
4 TNF 1.65 x 10 13 3.794 Activated
LY294002 6.76 x 10 12 -2.313 Inhibited
LPS 1.59 x 10 11 3.867 Activated
SB203580 2.12 x 10 10 -3.542 Inhibited
IL1b 4.52 x 10 10 3.742 Activated
12 NFKb 1.20 x 10 09 3.170 Activated
TGFb1 2.05 x 10 09 1.342 -
LY294002 2.36 x 10 09 -2.293 Inhibited
TGFb1 3.56 x 10 11 1.876 Activated
TNF 7.97 x 10 10 4.622 Activated
24 Tretinoin 2.41 x 10 09 1.323 -
IL1b 6.86 x 10 09 4.218 Activated
IFNg 1.46 x 10 08 3.404 Activated
TNF 1.48 x 10 15 3.752 Activated
IL1b 1.12 x 10 14 3.501 Activated
48 LPS 3.79 x 10 14 4.061 Activated
TGFb1 1.01 x 10 10 1.714 -
IFNg 2.38 x 10 10 2.347 Activated
From Table 4.3, UO126 is a selective MEK kinase inhibitor, found to inhibit AP-1
(activator protein) complex transcription. The AP-1 complex, regulates gene expression
due to many different stimuli, including stress response.38 After 4 h exposure, pathway
analysis suggested that the associated downstream effects of the UO126 drug were in-
hibited (z score -3.709). This suggests that the AP-1 complex was not transcriptionally
inhibited by Os-3; in fact AP-1 transcription was activated. This is discussed later with
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elements like FOS genes, which code for components of the AP-1 transcription factor
complex, together with Jun, which was also up-regulated.
The other upstream regulators at 4 h were transforming growth factor (TGFb1, z score
2.169), tumour necrosis factor (TNF, z score 3.794), LY294002 (z score -2.313) and lipo-
polysaccharide (LPS, z score 3.867), which also control up-regulation of genes involved
in stress response. For example, LPS activation can initiate an immune response in cancer
cells and LY294002 is a PI3K inhibitor, suggesting that Os-3 does not inhibit PI3K.39
The same stress response pathways continued to be activated throughout the rest of
the time series, and progress to include the activation of interleukin 1 (IL1b , z score
3.742) and interferon gamma (IFNg , z score 3.404) pathways at 12 and 24 h, respectively.
IL1b is a pro-inflammatory cytokine, essential for both innate and adaptive immune
response.40, 41 IFNg is a cytokine commonly associated with adaptive chemotherapy
response in cancer, and can be both anti- and pro-tumorigenic.42
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Table 4.4: The upstream regulators for the top five most mapped processes for DEGs with -1.0 <
LogFC > 1.0 and FDR < 0.05 after exposure to Ir-10. Similar to Table 4.3, IPA has identified
pathways of interest, with associated significance p- and z-values. The biological pathways
responding to Ir-10 show more variability across the time series then they did for Os-3. Tumour
necrosis factor (TNF) and transforming growth factor (TGF) were still consistently activated,
however there was also involvement from platelet-derived growth factor (PDGF BB).
Time Upstream p-value Activation Predicted
point (h) regulator z-score activity
TNF 3.25 x 10 15 3.676 Activated
LY294002 2.67 x 10 14 -2.413 Inhibited
4 PDGF BB 2.15 x 10 13 4.766 Activated
TGFb1 2.62 x 10 13 3.063 Activated
ERK 1.31 x 10 12 4.221 Activated
TNF 1.48 x 10 14 3.238 Activated
UO126 2.19 x 10 11 -2.470 Inhibited
12 LY294002 2.34 x 10 11 -2.466 Inhibited
beta-estradiol 3.29 x 10 11 -0.400 -
TREM1 6.67 x 10 11 1.771 Activated
TGFb1 1.30 x 10 24 2.206 Activated
TNF 3.94 x 10 22 6.101 Activated
24 LPS 7.13 x 10 22 7.223 Activated
PDGF BB 1.33 x 10 21 5.287 Activated
beta-estradiol 3.42 x 10 21 2.230 Activated
TNF 4.93 x 10 12 3.646 Activated
IL1b 7.74 x 10 09 3.343 Activated
48 LPS 1.87 x 10 09 2.211 Activated
ESR1 3.17 x 10 09 0.282 -
TGFb1 3.48 x 10 09 1.717 Activated
Interestingly, similar pathways were activated in response to Ir-10, including TNF,
TGFb1, ILb1 and LPS. However, platelet-derived growth factor (PDGF) and extracellular
signal-related kinase (ERK) were not a pathway activated by Os-3, yet showed signific-
ant activation by Ir-10. Likewise, beta-estradiol and estrogen receptor 1 (ESR1) were
pathways only activated/inhibited by Ir-10, although the z-scores were not significant.
ERK and PDGF were the most significant pathways involved in the response at 4h (z
score 4.221 and 4.766), with PDGF also highly activated at 24 h (z score 5.287). ERKs
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are widely expressed in the cell, and control a plethora of biological processes, including
cell division. PDGF is another widely expressed component, and has involvement in
regulating cell division, and angiogenesis.43, 44
Assessing upstream regulators makes it difficult to pinpoint the MOA of either com-
pound, although these results show that cells are activating stress response pathways even
after short exposure. Probing further down the pathways can provide more insights.
4.2.6.1 Oxidative stress
Some of the most prominently activated pathways in cells exposed to both Os-3 and Ir-10
were in response to oxidative stress. For example, genes associated with a vitamin C anti-
oxidant response (p = 1.58 x 10 3 at 24 h) and an NRF2 (nuclear factor erythroid-derived
2-like 2) oxidative stress response (p = 3.74 x 10 17 at 4 h) were activated in response
to Os-3. With the Ir -10 response also showing NRF2 activation after 4 h exposure (p
= 8.72 x 10 3 at 4 h).45
The NRF2 transcription factor (encoded by the NFE2L2 gene) is involved in an im-
portant antioxidant response pathway, binding to the hARE (human antioxidant response
element) cis-element to transactive detoxifying/antioxidant genes. AP-1 complexes C-
FOS/C-JUN and FRA-1/c-JUN, encoded by FOS, FOSL1 and JUN genes, compete with
NRF2 for binding to hARE to active antioxidant genes.46
Figure 4.18 shows some of the components of the NRF2/AP-1 oxidative response
pathway, with transactivation of eight response genes. Upon detection of ROS, NRF2
dissociates from actin and KEAP1, translocates to the nucleus, and interacts with cofactor
proteins (e.g MAF) to allow binding to hARE.
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Figure 4.18: Diagram showing the main components in the NRF-2 and AP-1 transcription
factor pathways during oxidative stress response. Upon detection of oxidative stress, NRF2
dissociates its KEAP1/actin complex and translocates from the cytosol to the nucleus. Using
co-factors like MAF, NRF2 binds to the human antioxidant regulatory element (hARE) and
transactivates the expression of various antioxidant genes. In a dition to this, two AP-1 transcription
factor complexes (C-FOS/C-JUN and FRA-1/C-JUN) also bind to the hARE cis-regulatory element
and activate different antioxidant genes. All three transcription factors bind competitively to hARE
depending on the type of antioxidant response activated.
Figure 4.23 shows that after exposure toOs-3 NRF2 (NFE2L2) and ne of its co-factors,
MAF (MAF), are up-regulated at 4 h and remain so throughout the time series, showing a
maximum level of DE at 48 h (LogFC 1.57, FDR 1.17 x 10 17 and LogFC 1.18, FDR 2.57
x 10 19, respectively). Interestingly, even though NFE2L2 is up-regulated throughout
the time series in response to Ir-10, the MAF co-factor is significantly down-regulated
throughout the time series.
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Figure 4.19: Heat map of DEG in the oxidative stress response pathway across the time
series after exposure to Os-3 (left) and Ir-10 (right). Only DEG with FDR< 0.10 are included,
blank values lie outside of this significance threshold. In response to Os-3, cells activate the NRF2
(NFE2L2) and FRA-1(FOSL1)/C-JUN (JUN) complexes, with up-regulation of these genes after
just 4 hours, and maximum expression after 48 h. In contrast, in response to Ir-10, cells activate the
FOS (FOS)/C-JUN (JUN) and FRA-1/C-JUN complex, with a particularly high up-regulation of
FOS after just 4 h exposure. Although NFE2L2 is up-regulated in response to Ir-10, it’s co-factor
MAF is significantly down-regulated, suggesting less involvement of NRF2 compared to the AP-1
transcription factor complexes.
Of the two AP-1 complexes, only FRA-1 (FOSL1) is the most up-regulated throughout
the time series, showing significant DE after just 4 h to both Os-3 and Ir-10. The second
AP-1 complex, with C-FOS (FOS) is up-regulated for Ir-10, but down-regulated for Os-3.
This suggests that this AP-1 complex does not play a role in Os-3-induced oxidative stress
response, but may have involvement in Ir-10 response. This could explain the increased
DE of transactivation genes by Ir-10.
Only a selection of antioxidant genes downstream of the transcriptional activators are
up-regulated. Antioxidant genes CAT (catalase) and EPHX (epoxide hydrolase), are both
down-regulated in response to Os-3 and Ir-10. This may suggest that the C-FOS/C-JUN
AP-1 complex controls activation of these genes and not NRF2 nor FRA-1/C-JUN.
GSR (glutathione reductase) and NQO (NADP(H) quinone oxidoreductase) are both up-
regulated by Os-3 and Ir-10, although more so by Ir-10. This expression only becomes
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significant after 12 h exposure, highlighting the delay between transcription/translation
of NRF2 and AP-1 and the activation of antioxidant genes. Although these genes are
activated after 12 h, they remain expressed at low levels, even after 48 h.
4.2.6.2 Mitochondrial dysfunction
Pathway analysis for Os-3 exposed samples, also suggested that mitochondrial dysfunc-
tion plays a role in compound response (p = 7.78 x 10 15 at 4 h). Figure 4.20 shows the
DEG (FDR 0.10) of nuclear encoded mitochondrial genes.
133
X
X
.1
X
.2
X
.3
NDUFA2
NDUFA12
NDUFA6
NDUFA9P1
NDUFAB1
NDUFB11
NDUFA5P11
NDUFA7
NDUFB4
NDUFB6
NDUFB3
NDUFC1
NDUFS1
NDUFS2
NDUFS6
NDUFV3
NDUFAF5
SDHA
SDHB
SDHC
SDHDP2
CYCS
MT-CYB
UQCRBP1
UQCR10
UQCR11
UQCRFS1
UQCRHP2
COX6B1
COX6C
COX7A2
COX7B
MT-CO2
ATP5B
ATP5D
ATP5E
ATP5F1
ATP5G1
ATP5G2
ATP5H
ATP5I
SNCA
MAOA
DHODH
PDHA1
APP
OGDH
GSR
GPX8
UCP2
Complex I 
NADH dehydrogenase 
Complex II 
Succinate dehydrogenase 
Complex III 
Ubiquinol cyt. C reductase 
Complex IV 
Cyt. C oxidase 
Complex V 
ATP synthase 
SNCA 
MAOA 
DHOH 
PDAH1 
APP 
OGDH 
GSR 
GPX8 
UCP2 
   4 h          12 h         24 h         48 h  
BrBG
PiYG
PRGn
PuOr
RdBu
RdGy
RdYlBu
RdYlGn
Spectral
Accent
Dark2
Paired
Pastel1
Pastel2
Set1
Set2
Set3
Blues
BuGn
BuPu
GnBu
Greens
Greys
Oranges
OrRd
PuBu
PuBuGn
PuRd
Purples
RdPu
Reds
YlGn
YlGnBu
YlOrBr
YlOrRd
LogFC -1.5 1.5  
Figure 4.20: Heat map showing the differential gene expression of elements involved in
mitochondrial function after exposure to Os-3. Only DEG with FDR < 0.10 are included,
blank values lie outside of this significance threshold. In response to Os-3 there is a significantly
higher level of differential expression after 48 h, compared to earlier time points, so nuclear-genes
encoding mitochondrial proteins. There is a mixture of up- and down-regulation, however, there is
significant down-regulation of genes coding for Complex I components, suggesting an impact in
the electron transport chain (ETC). Up-regulation of genes like UCP2 and MAOA occur when
reactive oxygen species (ROS) are detected at the mitochondrial inner membrane, suggesting
mitochodrially-driven oxidative stress.
Figure 4.20 shows an increase in DE through the time series, with a large number
of DEGs at 48 h only. This is compared to the mitochondrial-encoded genes, which
were maximally, differentially expressed at 24 h (Figure 4.10). Interestingly, many of
the nuclear-encoded mitochondrial genes were down-regulated. For example, eleven of
eighteen genes encoding subunits of complex I (CI) were significantly down-regulated,
with the NADH dehydrogenase alpha subcomplex 2 (NDUFA2) and NDUFA6 being the
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most significantly down-regulated of all the other components. This is in contradiction
to the mitochondrial genes for CI, which were consistently up-regulated in the compound-
exposed samples, throughout the time series. NDUFA2 and NDUFA6 are accessory
subunits to CI and as such do not directly take part in CI activity, but are involved with
complex I assembly.47 Down-regulation of these genes could imply mitochondrial damage,
which would no longer require CI assembly.
Up-regulation of SNCA (a-synucein), MAOA (monoamine oxidase) and UCP2 (mito-
chondrial uncoupling protein 2) supports mitochondrial specific ROS production. SNCA
is primarily located in the cytoplasm, but has been shown to localize in the mitochondria
and have involvement in mitochondrial dysfunction and cell death.48 MAOA is found in
the outer mitochondrial membrane, and produces hydrogen peroxide from deamination of
dietary amines.49 It is generally implicated in Parkinson’s disease; however, recent studies
have shown an overlap in cancer.50 Significant up-regulation of MAOA, particularly at
48 h, highlights a route to the production of hydrogen peroxide by the mitochondria.
UCP2 is found on the inner mitochondrial membrane, and is responsible for the de-
toxification of mitochondrial superoxide produced in the matrix by increasing the influx
of protons into the matrix and reducing electron leakage.51, 52 Up-regulation of UCP2
has been shown during drug-induced oxidative stress, and when functional, can drastically
reduce the levels of mitochondrial superoxide. The continual up-regulation of this gene
could suggest that too much superoxide is being produced for this protein to control.
Figure 4.20 also shows down-regulation of nuclear-encoded mitochondrial genes, par-
ticularly OGDH (2-oxoglutarate dehydrogenase) and GPX8 (glutathione peroxidase 8).
OGDH is responsible for the conversion of 2-oxoglutarate to succinyl-CoA and is known
to increase the superoxide and hydrogen peroxide levels inside mitochondria.53 This step
in the Krebs cycle produces NADH, protons and carbon dioxide, from NAD+ and ketoglut-
arate. Its down-regulation in response to compound Os-3 could suggest disruption of the
Krebs cycle and OXPHOS, and therefore targeting of multiple pathways in mitochondrial
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metabolism. GPX8 is another antioxidant protein, which catalyzes the reaction of gluta-
thione with hydrogen peroxide as a detoxification step. Both CAT (catalase) and GPX8 are
down-regulated after 12 h, suggesting that hydrogen peroxide detoxification is disrupted.
4.2.6.3 Immune response and cell migration
The activation of an immune response in cancer cells exposed to chemotherapy compounds
indicates a stress response in vitro. In vivo there are many downstream events linked to
the activation of an immune response, including up-regulating epithelial-mesenchymal
transition and cell migration components. The purpose of these cellular responses is to
recruit immune cells to the sight of stress and involves initial remodelling of the cell, and
release of cytokines and interleukins which facilitate leukocyte recruitment.
Of the main upstream regulators, most were immune and inflammation related cytokines
like interferon, TNFa and TGF-b after exposure to both Os-3 and Ir-10. For example,
after 4 h exposure to Os-3, cells up-regulated interferon signalling, with IFIT3 (LogFC
1.25, FDR 7.65 x 10 28) and SOCS1 (LogFC -1.49, FDR 0.0017), where IFIT3 codes
for an interferon-induced protein, and SOCS1 encodes a suppressor of cytokine immune
signalling. After 12 h, both Os-3 and Ir-10 induced expression of components controlling
the agranulocyte adhesion and diapedes pathway, which controls the migration of leuk-
ocytes from the vascular system during inflammation. iCAM1 (intracellular adhesion
molecule 1) is important in this signalling pathway, encoding a cell surface glycoprotein
which facilitate leukocyte recruitment, and was up-regulated in response to Os-3 (LogFC
1.06, FDR 1.5 x 10 4) and 10 (LogFC 1.97, FDR 2.82 x 10 19) after 12 h.
Other inflammatory pathways activated by Os-3 and Ir-10 include fibrosis and coagu-
lation, controlled by genes like TGFa , PDGFb and SERPINE1. SERPINE1 was highly
up-regulated by both Os-3 (LogFC 2.36, FDR 8 x 10 26 at 48 h) and Ir-10 (LogFC 2.84,
FDR 3.19 x 10 34 at 24 h).
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4.2.6.4 Cell death
There are three main methods of cell death: type I (apoptosis), type II (autophagy) and
type III (necrosis). Os-3 appears to have an affect on the mitochondria, which is a key
regulator of apoptosis in the cell. Investigating the method of cell death can provide im-
portant insights into the MOA of a compound. Figure 4.21 summarises the two apoptotic
mechanisms of cell death; extrinsic and intrinsic.
Extrinsic pathway 
Intrinsic pathway 
Figure 4.21: Diagram showing themain components in the extrinsic and intrinsic apoptosis
pathways. Intrinsic pathway activation is normally associated with chemotherapy and UV damage,
first triggering BAX and BID, before activating cytochrome C release from the mitochondrial and
subsequent capsize activation. The extrinsic pathway is activated by death ligands, which trigger
caspase-8 activity through FADD. Inhibitor of apoptosis (IAP) proteins can control the process of
apoptosis at the capsize level, for example XIAP inhibiting the caspase-3 and -9 activity. Image
taken from Legewie S, et al (2006) PLoS Comput. 2(9): e120
Figure 4.22 is a heat map for the DEGs related to apoptotic cell death in cells exposed
to Os-3. Classical caspase markers include caspase (CASP)-3, -7 and -9 as downstream
markers, or caspase-8 as an upstream marker of extrinsic apoptosis.
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Figure 4.22: Heat map of DEG in the apoptosis pathway across the time series after expos-
ure to Os-3. Only DEG with FDR< 0.10 are included, blank values lie outside of this significance
threshold. Shown with high levels of differential expression are non-apoptotic capsizes like CASP1
and CASP12, mostly associated with inflammatory responses. There is some up-regulation of
intrinsic apoptotic genes BID an BAX after 12 h exposure to Os-3, suggesting some apoptotic
invitation. However, down-regulation of apoptotic capsases like CASP3 and CASP9 suggest
apoptosis may only be initiated and not put into effect. Cell survival gene BIRC3 which codes
for survivin, an inhibitor of apoptosis (IAP) protein shows significant up-regulation after just 4 h
exposure, suggesting further that caspase activity is not activated within 48 h exposure.
Figure 4.22 shows significant down-regulation of CASP-9 after 4 h, CASP-6, -2 and -9
after 12 h, and CASP-3 and -7 after 48 h. Ge es for inhibitors of apoptosis (IAP) proteins,
which inhibit the activation of caspase proteins, like BIRC2 and BIRC3, are up-regulated
after 4 h (LogFC 2.06, FDR 1.53 x 10 12). BIRC5, which codes for survivin, another
IAP, was down-regulated until 24 h (LogFC -0.43, FDR 1.03 x 10 5), suggesting specific
modulation of apoptotic signals through caspase inhibition.
Figure 4.22 also shows up-regulation of BID (LogFC 0.90 (48 h), FDR 1.77 x 10 14)
and BAX (LogFC 0.50 (24 h), FDR 3.46 x 10 6) which both code for apoptotic initiators,
BID from extrinsic activation and BAX from intrinsic apoptotic activation. This suggests
that apoptotic signals are being initiated in response to Os-3, but that signals do not
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translate through to the effector caspases. The only caspase genes which were up-regulated,
were CASP-1 and CASP-12 which are inflammatory caspases, activated by IL-1b , which
was one of the most significant upstream regulators after 12 h (Table 4.3).
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Figure 4.23: Heat map of DEG in the apoptosis pathways across the time series after
exposure to Ir-10. Only DEG with FDR < 0.10 are included, blank values lie outside of this
significance threshold. There are noticeably fewer genes with significant differential expression
after cells were exposed to Ir-10 compared to Os-3. However, there are similarities in the up-
regulation of apoptotic inhibitor BIRC3, and inflammatory caspases like CASP5 and CASP1. The
expression of apoptotic initiator genes like BAX and BID were hardly affected by Ir-10, suggesting
there may be less initiation of apoptosis compared to that shown after Os-3-exposure.
A similar expression pattern is shown in response to Ir-10, with down-regulation of
BCL2 and apopotic caspases, and up-regulation of IAPs like BIRC3. As with Os-3,
BAX and BID apoptotic initiators showed some low level up-regulation after 12 h and
inflammatory caspases, CASP-5 and -1 were significantly up-regulated after 12, and 24
h, respectively.
Overall, this suggests a similar apoptotic profile between Os-3 and Ir-10, with expres-
sion of apoptotic initiators and inflammatory caspases and down-regulation of apoptotic
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effector caspases possibly due to IAP intervention. This shows strong control of the
apoptotic pathway by stressed cells, and may suggest prolonged exposure or multiple
dosing is required for cell death.
Autophagy was proposed as another potential mechanism of cell death, given its link
to an immune response, as an effector. Both Os-3 and Ir-10 showed activated immune
responses, particularly evident with up-regulation of inflammatory caspases. Figure 4.24
shows the expression profiles of autophagic genes.
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Figure 4.24: Heat map of DEG in the autophagy pathways across the time series after
exposure to Ir-10. Only DEG with FDR < 0.10 are included, blank values lie outside of this
significance threshold. Autophagy is an important mechanism of cell death, often linked to
inflammation. The heat map shows minimal up-regulation of autophagy markers, the most
common of which are BECN1 (beclin) and MAP1LC3B/A (LC3), in response to both Os-3 and
Ir-10 across the time series. This suggests that this mechanism of cell death does not play an
important role in drug-response.
The classical markers for autophagy are BECN1which codes for beclin, andMAP1LC3A/B
which codes for LC3-I/II. Beclin and BCL-2 proteins are involved in the initiation phase
of autophagy, with LC-3 and the ATG proteins involved further downstream. Figure
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4.24 shows down-regulation of most of these components throughout the time series,
suggesting autophagy does not feature significantly in cellular response.
Necrosis is another form of programmed cell death and similar to autophagy, can
activate an immune response. Necrosis results in the emptying of cell contents into the
extracellular space, as a result of the loss of cell membrane integrity. Unlike apoptotic
cell death, immune cells are not recruited to the degraded cellular debris, instead necrotic
tissue can build up and often has to be removed surgically. Interestingly, necrosis also
has strong links to reactive oxygen species (ROS) production, a response pathway which
showed involvement to both Os-3 and Ir-10.
RIP proteins are involved in the activation stage of necrosis,54 for example, RIPK1
which codes for the RIP1 protein. In response to Os-3, RIPK1 was down-regulated
throughout the time series, most significantly at 48 h (LogFC -0.55, FDR 5.79 x 1011).
A similar profile was shown in response to Ir-10, with maximum down-regulation at 12
h (LogFC -0.55, FDR 4.78 x 1014), suggesting programmed necrosis is not activated in
exposed-cells.
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4.3 Discussion
4.3.1 Mitochondrial deficiencies in A2780 epithelial ovarian can-
cer cells
The mitochondrion is fast becoming an important target in cancer research.55, 56 This
organelle introduces an element of selectivity for therapeutic targeting, as the metabolic
profile of cancer cells is often primarily glycolytic to increase the efficiency of cancer cell
division and distinct from that of normal cells, which produce ATP primarily by oxidative
phosphorylation (OXPHOS).57–61 This phenomenon is known as the Warburg effect. Gly-
colysis is generally less efficient for ATP production, however, it is faster than OXPHOS,
permits macromolecule biosynthesis and can function during hypoxic conditions.62, 63
This is thought to reduce the production of reactive oxygen species (ROS), which are
often byproducts of the OXPHOS pathway, and can be deadly to cellular function.
Copy number variations in the mitochondria of cancer cells can account for an abnormal
number of reads mapping to the mitochondrial chromosome (ChrM) during RNA or DNA
sequencing. In response to both Os-3 and Ir-10, the cells showed increased reads mapped
to ChrM, with a more significant result for Os-3.
The genes found on the ChrM code for important polypeptides present in components
of the electron transport chain (ETC), controlling the process of oxidative phosphoryla-
tion (OXPHOS). The overall increase in reads mapped to the mtDNA after exposure to
these compounds suggested that the mitochondrion is mobilising components required
for a functional ETC, and thus shifting the metabolism from favourable glycolysis to
unfavourable OXPHOS. Os-3 and Ir-10 may therefore be targeting glycolysis in some
form, forcing the cells to use alternative OXPHOS energy production.
This effect has been shown in several reported studies, where glycolysis has been
targeted by an inhibitor like 2-deoxyglucose, and the cell has responded with a shunt of
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metabolism into OXPHOS, increasing sensitivity to chemotherapy agents.62, 64 OXPHOS
is not an optimal process in cancer cell division; therefore if Os-3 and Ir-10 shift the
metabolism in this way, the cell may be energetically strained.
Point mutations in the mtDNA of A2780 affect complex I components. Mutations
in the mtDNA are a common occurrence in cancer cells, and are thought to be partly
responsible for a favouring of glycolysis.65, 66 There are two main types of mtDNA
mutations, the first are major mutations, which directly affect OXPHOS machinery and
ROS production. The second are minor mtDNA mutations, which allow cancer cells
to adapt to new environments. The presence of mutations in mtDNA was therefore
investigated, which could result in defective OXPHOS machinery in A2780 cells.
The MT-ND genes on the ChrM encode helical polypeptides which constitute the
membrane bound subunits of NADH dehydrogenase complex I (CI), responsible for
maintaining a proton gradient between the matrix and inter-membrane space.36 The
efficiency of maintaining this coupling gradient is directly proportional to the efficiency of
ATP production by the last complex in the ETC, ATPase complex V (CV).65 CI actually
accounts for 40% of the proton gradient generated in NADH oxidation.67
Point mutations in CI machinery have been found in breast, colon, prostate, thyroid and
EOC, however, most reported mutations in EOC focus on the D-loop of ChrM.37, 66, 68–72
This is the first report of p.I257V, p.N447S and p.L517P MT-ND5 mutations in EOC.69
Errors in the function of CI have been shown to potentiate electron transport errors and
create an inherently, oxidatively-stressed environment inside cancer cells.31
4.3.2 Oxidative stress
Performing pathway analysis of differentially expression genes (DEGs) revealed the ac-
tivation of oxidative stress response pathways by both Os-3 and Ir-10, and mitochondrial
dysfunction in response to Os-3.
The mitochondrion is the biggest source of superoxide production in the cell, partic-
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ularly from CI. Superoxide species are normally broken down by superoxide dismutase
(SOD) to hydrogen peroxide, which is then broken down by catalase (CAT) to water and
oxygen.73 Neither CAT nor SOD genes were up-regulated after exposure to compounds
Os-3 or Ir-10. In fact, CAT was expressed in higher levels in the control samples, high-
lighting the oxidatively-stressed nature of A2780 cells, and that no response to hydrogen
peroxide was mobilised after compound exposure. Disruption of CAT and SOD function
has been shown to have a knock-on effect on the function of other antioxidant enzymes,
potentiating the damage caused by ROS.74
Generally, both the antioxidant and detoxifying systems work in synergy to remove
damaging ROS inside cells.75 The down-regulation of key response genes suggests that
Os-3 and Ir-10 both induce ROS production and reduce the ability of A2780 cells to
respond to excessive ROS.
The production of ROS from mitochondria has a cyclic effect on the function of
mitochondria, potentiating the production of higher and higher levels of ROS.76 These
ROS can damage mtDNA and proteins within the mitochondria, in addition to disrupting
the polarisation of the mitochondrial membrane.28 Previous work on Os-3 has shown
polarisation of the mitochondrial membrane after just 4 h exposure towards A549 lung
cancer cells.77 Mutations in OXPHOS machinery causes ROS production, and that this
ROS production is potentiated by compound 1 through metabolic targeting.
Mitocans, which target the bioenergetics of cancer cells and increase ROS, are becoming
a focus of anticancer drug development.78 ROS production can damage mitochondrial com-
ponents, however, ATP depletion and imbalance in calcium homeostasis are also caused
by mitochondrial targeting.76 Calcium overload, in particular is common in tumors, so dis-
rupting these levels further can have multiple downstream effects, including cell death.79
Of course, ROS may not be generated through the mitochondria, and instead Os-3 and
Ir-10 may induce them by some other mechanism. ROS production during cell stress is
well documented, and occurs indirectly in response to many drugs, including cisplatin.80
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In previous studies,Os-3 has been shown to induce ROS production in lung cancer cells.77
The results here build on this, identifying an NRF2 cellular response. Given NRF2 is
also up-regulated in response to Ir-10, it is likely that this compound also induces ROS.
Future studies should determine whether these ROS originate from the mitochondria or
from another source and Os-3 and Ir-10 would need to be validated as oxidative stress
inducers, by comparing their activity to other agents in this class.
4.3.3 Immune response
An immune response seems to play a prominent role in the response of A2780 cells toOs-3
and Ir-10, with both type I (interferon, TNFa) and type II (TGFb ) cytokine involvement.
Chemotherapy agents have been shown to activate an immune response, and for this
response to be beneficial. They do this through various methods, including promoting
remodelling of targeted cancer cells, which make them visible to the immune system.81
Epithelial remodelling was highlighted as one of the pathways activated in response
to both compounds, and if it occurs in vivo would help the recruitment of leukocytes to
the cell. Chemotherapy agents have also shown to induce an immunogenic type of cell
death, for example pyroptosis.81 This mechanism of cell death is characterised by high
levels of CASP-1 and ILb1, which were both up-regulated in response to Os-3 and Ir-10.
On the other hand, an inflammatory response via TNF can also be indicative of meta-
stasis by kick-starting the invasion of tumour cells and increasing angiogenesis.82 This
is often also accompanied by growth factor release, like PDGF, which was a prominent
upstream regulator activated in response to Ir-10, but not Os-3. The induction of tumour
invasion by chemotherapy treatment is an established occurrence, activating a host response
which is tumour-promoting.83 Successful experiments have prevented tumourigenesis
by co-incubating chemotherapeutic agents with growth factor suppressors.84
There are several methods in which Os-3 and Ir-10 may be activating an immune
response, the production of ROS is often linked to the production of inflammatory cy-
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tokines. A study by Taulet et al showed that ROS can modulate networks which control
protrusion in mammalian epithelial cells, which would facilitate leukocyte recruitment.85
Interestingly, ovarian cancers are highly immunogenic, which means that inherently they
are highly capable of activating immune response.
Future work, following on from results obtained here will need to assess the outcome
of an immune response, performing metastatic in vitro assays and studying the immune
response in in vivo models.
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4.4 Summary and Conclusions
Studying the mechanism of action (MOA) of new anticancer agents using sequencing
is a relatively unexplored strategy, and subject to various limitations. Due to the complex
nature of drug-targetting, the exact mechanisms can be masked behind dominant processes.
In this work, a lot of the mechanisms have been masked by an overall immune response
in cells, which did not reveal the exact nature of the immune response, but did highlight
some differences between the compounds. For example, Ir-10 showed a growth factor
response which Os-3 did not; this could suggest that cells exposed to Ir-10 could be
activating a stronger invasive response. By assessing the cell line A2780, and identifying
the mitochondrial deficiencies, it was possible to start unravelling how the immune
response may have been activated, linking in oxidative stress.
Both Os-3 and Ir-10 appear to elicite an inflammatory response, related to caspase-1
and a response to oxidative stress, related to NFR2 and possibly to the mitochondria.
Zhong et al highlighted a link between these two processes, starting with ROS gener-
ation by the mitochondria, followed by inflammasome activation through TRPM2 and
NLRP3.86 The inflammasome could subsequently activate caspase-1 which stimulates
interleukin/cytokine maturation, and allows the cell to attempt the recruitment of leuk-
ocytes (early response) but may eventually activate cell death via pyroptosis/apoptosis
(late response). The immune response may also be indicative of tumour invasion, and
should be assessed in future studies outside of this thesis.
The mitochondrial mutations identified in the ND5 protein also need future in-depth
investigation to determine whether there is a functional link between OXPHOS-generated
ROS and deficiencies in this ETC machinery. Given cell lines can spontaneously develop
mutations, A2780 cell lines from multiple sources would need to be sequenced to confirm
whether this is an inherent mutation for this cell line, or an adaptive response during in
vitro culturing at The University of Warwick.
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In efforts to investigate downstream effects of oxidative stress, Chapter 5 explores
differential protein levels in A2780 cells exposed to Os-3 and Ir-10, using flow cytometry
to validate these findings. In addition, Chapter 7 further explores the mechanisms of cell
death using imaging techniques.
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Chapter 5. Proteomics
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5.1 Introduction
This chapter focusses on the study of protein behaviour when ovarian cancer cells
are exposed to compounds Os-3 ([Os(h6-p-cym)(NMe2-azpy)I]PF6) and Ir-10 ([Ir(h5-
Cpxph)(NMe2-azpy)Cl]PF6), using reverse phase protein microarrays (RRPA) in collab-
oration with the Edinburgh Cancer Research Centre. In this chapter, the results for Os-3
and Ir-10 are discussed in relation to the sequencing results presented in Chapter 4.
RPPA is a technique which measures the levels of protein in a sample using epitope-
specific fluorescently-tagged antibodies. The RPPA analysis was done using a Zepto-
MARK platform, produced by Bayer.1, 2 This is considered the gold standard in proteomic
analysis, allowing measurements of protein concentrations in the zepto-molar range. The
cost of reagents are also much lower compared to mass spec-based proteomics and the
automated slide spotting is environmentally controlled, and is highly reproducible.
The Edinburgh Cancer Research Centre has applied this technique in a number of areas,
with a number of collaborations.3 For example, together with the Edinburgh Experimental
Cancer Medicine Centre, RPPA has been used in breast cancer work to study protein
kinase cascades in response to cancer treatment.1, 3, 4 A similar approach is applied in
this chapter, studying the effect of Os-3 and Ir-10 on protein pathways in ovarian cancer.
5.1.1 Experimental overview
A2780 cells were exposed to Os-3 and Ir-10 at two concentrations each, 0.15 and 0.45
µM, and protein samples collected at 4, 24, 48 and 72 h. This allowed the extension of the
48 h time course performed with RNA sequencing. This chapter also includes validation
of findings by RNAseq and RPPA, using flow cytometry, and in Chapter 7, using imaging
techniques. Shown in Figure 5.1 is the experimental work flow, all of which was carried out
at the Edinburgh Cancer Research Centre. All samples, for each of the time points, were
measured on the same chip, and therefore each compared to the same vehicle controls.
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Figure 5.1: Figure summarising the experimental workflow for reverse phase protein mi-
croarrays (RPPA). Once seeded cells were exposed to either control- or drug-containing solutions
across a 72 h time series. Cells were then collected, and the soluble protein extracted. Protein
lysates were then immobilised onto microarray slides, and using antibody staining, the levels of
individual proteins were determined. All experimental work was performed at the Edinburgh
Cancer Research Centre, with the data analysis performed by the author at University of Warwick.
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5.1.1.1 Cell lysate collection
Cells were exposed to each compound and to a DMSO control for 4, 24, 48 and 72 h.
After this time, cells were lysed and soluble protein extracted. Protein concentrations
were determined using the Bradford reaction and diluted down to a maximum of 2 mg/mL.
Samples were then diluted to construct a dose curve for each sample on the chip with
final protein concentrations of 0.2, 0.15, 0.1 and 0.05 mg/mL.
5.1.1.2 ZeptoCHIP dispensing
In a single run, the Zeptosens machine can analyse ten ZeptoCARRIERS, each holding six
ZeptoCHIPS. Each ZeptoCHIP holds six arrays, with each array holding sixty-four spots
for protein lysates, and eighty reference points used for background measurements. The
diluted protein extracts were spotted using a GeSIM Nanoplotter and left to dry, before
blocking and washing. A schematic of the slide design is shown in Figure 5.2.
Each array has its own microfluidics setup, allowing each array to be exposed to a
single antibody, and therefore six antibodies to be tested simultaneously per ZeptoCHIP.
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Figure 5.2: Schematic of the layout of a ZeptoCHIP. The top diagram shows 6 microarrays
per ZeptoCHIP, with the experimental layout of each array (middle) described. The 2 columns
for each compound (Os-3 and Ir-10) represent duplicate measurements, with the respective time
series points down the rows: 4, 24, 48 h and 72 h. The 0.1% DMSO control sample (C) is run on
the same array as each sample. Each protein lysate extracted from each sample is serial diluted
across 4 concentrations: 0.2, 0.15, 0.1 and 0.05 mg/mL. This allows a concentration gradient to be
plotted for fluorescence measurements of each protein. Either side of these dilutions are reference
controls, shown in red. These are used to correct for slide variation.
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5.1.1.3 Immunoassay
Antibodies were selected based on pathways of interest highlighted after RNA sequencing,
namely assessing apoptosis, cell cycle arrest and cytokine activation. All antibodies were
validated by the Edinburgh Cancer Research Centre, and a complete list together with
manufacturer is shown in Appendix 9.3. Primary antibodies were incubated with the
spotted lysates, before secondary incubation with Alexa-Fluor647 conjugated antibody
detection reagents.
5.1.1.4 ZeptoREADER
The fluorescence readings recorded by the ZeptoREADER were collected through wave-
guide technology. Here, gratings on each side of the ZeptoCHIPs direct light across the
surface of the chip, preventing excitation of free fluorophore in the rest of the matrix
(Figure 5.3).
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Figure 5.3: Schematic showing the difference in excitation between standard confocal
excitation compared to that for RPPA. Each schematic shows bound antibodies to a surface,
with unbound fluorescently-labelled antibodies floating above the surface. The top figure shows
standard confocal excitation, with a 2µm distance exciting both the bound and unbound antibodies.
The figure below shows the excitation achieved using an evanescent technique with RPPA, where
the excitation distance from the surface is much smaller at 0.1 µm, thus exciting only bound
antibodies. Fluorescence measurements using evanescent instead of confocal excitation reduce
background noise and allow the high-sensitivity achieved using RPPA.
This so-called evanescent excitation increases the sensitivity of readings compared to
conventional confocal excitation achieved with standard techniques, by reducing back-
ground noise. The increased sensitivity of Zeptosens technology negates the need for
enzymatic signal amplification, even for low abundant protein detection.
Fluorescence readings were normalised for each sample, to a house keeping protein
(Prohibitin). A ratio of fluorescence between the exposed sample and the negative control
sample was then calculated to give relative fluorescence intensity (RFI) values.
164
5.2 Results
5.2.1 RPPA analysis of A2780 cells exposed to Os-3 and Ir-10
5.2.1.1 Cell cycle arrest and DNA damage
Chapter 4 explored the potential for reactive oxygen species (ROS) production in cells
exposed to both Os-3 and Ir-10 at their GI50 doses, with activation of oxidative stress
response pathways. Whether this induction of oxidative stress was due to disruption of
respiration in A2780 cells, by exploiting the mutation in their machinery, or by another
means, the downstream effects of ROS production can be studied at the protein level.
DNA is a well-known target for ROS, particularly at guanine bases.5 The cell is
equipped with mechanisms to repair such damage, however, ovarian cancers often lack
the proper tools for DNA damage repair (DDR). Using Zeptosens reverse phase protein
microarrays (RPPA), the abundance and activation state of proteins involved in DDR were
studied.2
Figure 5.4 shows two DDR/cell cycle arrest pathways, the CDC25A rapid response
pathway and the p53/p21 delayed response pathway.6, 7
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Figure 5.4: Diagram showing some of the components in the DNA damage response (DDR)
pathways. Boxed components indicate areas where cell cycle arrest may occur. Circled-P symbols
designate phosphorylation/dephosphorylation processes and * counterparts as the phosphorylated
form of the protein. When DNA damage is detected, ATM is phosphorylated to ATM* which
in turn phosphorylates CHK2 and BRCA1. There are two main branches of activation after this
point, the right branch acting as a faster response and the left as a delayed response. Both branches
primarily control the progression of cells from G1 into S phase, thus preventing damaged DNA
being replicated during S phase.
The boxed areas highlight areas where successful progression from one component to
the next would result in cell cycle progression, if the process within these boxes does not
occur then cell division is halted at either G1, S or G2/M. Components with an asterisk
(*) represent the phosphorylated form of the protein. For example, the Rb protein can
be phosphorylated at two sites and is therefore labeled Rb, Rb* and Rb**. The circled-P
symbol represents a phosphorylation step. For example phosphorylated CDC25A* must be
dephosphorylated itself, before dephosphorylating CDK1, which then allows progression
through the G2/M transition.
ATM, among other proteins, is mobilised in response to DNA double strand breaks.
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ATM is auto-phosphorylated to ATM*, which in turn phosphorylates CHK2 to CHK2*.
At this point, the response pathway branches, the first, a rapid response to DNA damage,
permits phosphorylation of the CDC25A phosphatase to CDC25A* by CHK2*. CDC25A
or CDC25C must be dephosphorylated, before dephosphorylating CDK1-CyclinA/B to
allow G2/M cell cycle transition. Dephosphorylated CDC25A can also dephosphorylate
CDK2-CyclinA to permit S progression or CDK2-CyclinE to allow cells to pass the G1/S
transition.
The slow response pathway, involves the p53 activation, and expression of downstream
targets like the p21 protein. p21 inhibits CDK2-CyclinE and CDK4/6-CyclinD, preventing
the phosphorylation of Rb to Rb* and Rb** by these CDK-Cyc complexes. In the
phosphorylated form, Rb dissociates from the E2F transcription factor complex, which
activates transcription of DNA-synthesising enzymes and allows cells to pass into S phase.
With CDK2/Cyc inhibited, Rb cannot be phosphorylated, and therefore remains bound
to E2F preventing progression into S phase.
RPPA was used to study the cellular levels of twenty proteins involved in DDR and
cell cycle arrest, in Os-3- and Ir-10-exposed cells across a 72 h time series. A2780 cells
were exposed to Os-3 at 0.15 (GI50) and 0.45 µM (3 x GI50) and to Ir-10 at 0.15 (⇡13
x GI50) and 0.45 (⇡ GI50), and the protein levels measured after 4, 24, 48 and 72 h.
Figure 5.5 shows the relative fluorescence intensity (RFI) values for the proteins shown
in Figure 5.4, for RFI < 1 the protein levels were lower in the compound-exposed versus
the control, for RFI = 1, the levels did not change with compound addition, and for RFI
> 1, the protein levels increased in response to compound. The RFI values for p21* and
ATM* at 72 h are not presented as they did not pass QC check.
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Figure 5.5: Heat map showing the relative fluorescence intensity (RFI) values for a selec-
tion of DNA damage response (DDR) proteins in cells exposed to Os-3 and Ir-10 across a
72 h time series. RFI values < 1 indicate a drug-induced decrease in protein levels, RFI = 1
indicates no-drug effect and RFI > 1 indicates drug-induced increases in protein levels. The
responses to Os-3 and Ir-10 differ at the protein level. This is most clear with b tubulin (B-Tub)
which is down-regulated in response to Os-3, but up-regulated in waves in response to Ir-10. This
could suggest that Os-3 holds cells in earlier phases of the cell cycle, therefore not needing mitotic
proteins like B-Tub to be expressed.
The levels of BRCA1, ATM and CHK2 are good indicators of DNA damage detection
in A2780 cells. BRCA1 does not show increased levels in response to Os-3 at either
concentration. Dephosphorylated ATM is found in low levels throughout the time series
in response to Os-3, however, active (phosphorylated) ATM* is found in higher levels,
particularly with higher doses of Os-3. Activated CHK2* can also activate p53 to p53*
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during DDR. p53* can activate the expression of multiple downstream genes, including
p21. CHK2* is found in high levels in cells exposed to the higher dose of Os-3, less so
at the lower concentration.
Moving further down the DDR branches, Figure 5.5 shows that CDC25A, required
for G1/S transition is in high levels after 24 h exposure to Os-3, which could permit the
progression of cells through to S phase. However, CDK2, also required for G1/S transition
is down-regulated, which could prevent entry into S phase.
Active p21* is found in differentially higher levels after 48 h exposure to Os-3 at
the lower dose and maximum after just 4 h, during exposure to the higher dose. The
collectively higher levels of activated ATM, CHK2, p53 and p21 highlights the activation
of DDR after cells are exposed toOs-3. Low levels of Rb* and Rb**, due to p21 inhibition
of CDK2 complexes, suggest that cells are not preparing for entry into S phase. With
low levels of CDK1 and b -tubulin suggesting cells are also not at the G2 or M phase.
This likely suggests that cells are being held in G1 phase by Os-3, throughout the time
series.
Flow cytometry experiments were performed in cells exposed to Os-3, to detect which
stage of the cell cycle was most populated. This experiment works by measuring the
red fluorescence of propidium iodide (PI), which intercalates with the DNA inside cells.
Given the DNA content is duplicated during S phase, following the fluorescence levels
of PI can identify which phases of the cycle are most populated. In other words the PI
fluorescence will gradually increase through S phase, before stabilising at double the
original fluorescence reading, going into G2.
Figure 5.6 summarises the flow cytometry results for cells exposed to Os-3 for 24 h,
where control values are shown in blue and osmium-treated cells in orange.
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Figure 5.6: Graph showing flow cytometry data for cells exposed to Os-3. Each pair of values
corresponds to a particular phase of the cell cycle, described on the x axis, with cell populations for
control samples shown in blue, and those forOs-3-exposed samples in orange. * indicates p< 0.10
and ** indicates p < 0.05 after a Welch two sample t-test between control- and compound-exposed
samples in each stage of the cell cycle. The most significant drug effects were shown in G1 and
S phase of the cell cycle. Where Os-3 increased the population of cells found in G1 phase and
reduced the population of cells in S phase.
At any one time, in the control sample most cells are found in G1 phase, this is normal
as G1 phase is the longest phase in the cell cycle. A significant increase in cells populating
G1 phase in response to Os-3, with a subsequent reduction in both S and G2/M phase
cells. This supports the RPPA data for Os-3 which showed differentially lower levels of
S, G2 and M phase markers.
In contrast to Os-3, Ir-10 appears to mobilise a BRCA1 DNA damage response after
24 h, at both low and high concentrations. However, similarly to Os-3, there is activation
of downstream DDR components, e.g. CHK2*, p53* and p21*. This suggests that DNA
damage is also detected in response to Ir-10, but that this type of DNA damage caused
may differ, resulting in BRCA1 involvement.
Assessment of cell cycle markers in response to Ir-10, tells a very different story to
that shown for Os-3. After exposure to Ir-10, there are M-phase markers, particularly
after exposure to the lower dose of Ir-10. For example, there is a high level of b -tubulin
in response to 0.15 µM Ir-10 at both 24 and 48 h, with an additional increase in the
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levels of CDK1. This suggests that cells have the proteins available to allow progression
from G2 to M phase of the cell cycle. At the higher dose of Ir-10, both tubulin and
CDK1 levels do not change from the control, suggesting a larger cell cycle affect is
induced. The higher levels of Rb* protein suggest that cells have passed, or are at least
able to pass, the G1/S transition point. This was not shown after exposure to Os-3.
Therefore in response to Ir-10, cells may be in late S phase, or G2 phase of the cell
cycle.
A second flow cytometry experiment was conducted to explore cell cycle populations
in response to Ir-10, with the results shown in Figure 5.7.
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Figure 5.7: Graph showing flow cytometry data for cells exposed to Ir-10. Each pair of
values corresponds to a particular phase of the cell cycle, described on the x axis, with cell
populations for control samples shown in blue, and those for Ir-10-exposed samples in green. *
indicates p < 0.10 and *** indicates p < 0.01 after a Welch two sample t-test between control-
and compound-exposed samples in each stage of the cell cycle. In comparison to Os-3, Ir-10
affects all three stages of the cell cycle, decreasing the population of cells in G1 phase and G2/M
phase, and significantly increasing the number of cells in S phase.
Figure 5.7 shows a highly significant increase in cells populating S phase of the cell
cycle, with a subsequent decrease in those in G1 and G2/M, compared to the control. This,
together with the RPPA, confirms that DNA damage is detected in response to Ir-10 and
that cells are arrested in S phase of the cell cycle after 24 h exposure.
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5.2.1.2 Cytokine response
The results from the RNA sequencing experiments in Chapter 4 suggested that cells
activated an immune response to both Os-3 and Ir-10. Figure 5.8 shows the involvement
of components in the interferon pathway, activating STAT (signal transducer and activator
of transcription) proteins.
IFNγ IFNα/β 
JAK2 JAK1 
STAT1 STAT1 
JAK1 
STAT1 
TYK2 
STAT2 
IFN inducible genes 
SOCS 
STAT1 
STAT1 
STAT1 
STAT1 
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Nucleus$
Figure 5.8: Schematic showing components involved in interferon signalling. Interferon g , a
and b (IFN) bind to interferon receptors activating phosphorylation events between JAK, STAT and
TYK proteins, where pink spots highlight phosphorylated proteins. Downstream phosphorylated
STAT complexes translocate to the nucleus and initiate the expression of interferon, interleukin
and growth factor inducible genes.
Interleukin and growth factor receptors present similar activation to that of the interferon
receptors shown in Figure 5.8, where STAT1 and 2 are used in interferon inducible gene
expression and the other STAT proteins, 3,4,5,6, are used to activate interleukin/growth
factor responses. In each case, cytokine molecules would either be produced by cancer
cells responding to stress and diffuse from the cell to bind to the cell surface receptors.
In an in vivo situation, cytokines are primarily produced by host immune cells, binding to
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cell surface receptors to initiate a cellular response to target the intracellular “infection”.
STAT proteins are phosphorylated by JAK and TYK proteins, before forming STAT*/STAT*
complexes and translocating to the nucleus to induce response genes. The interferon,
interleukin and growth factor inducible genes are involved in controlling a variety of
processes inside cells, with complex crosstalk mechanisms between pathways.
Using RPPA, 15 upstream components were studied, again at two concentrations (0.15
and 0.45 µM) of Os-3 and Ir-10 across a 72 h time course (Figure 5.9).
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Figure 5.9: Heat map showing the relative fluorescence intensity (RFI) values for a selec-
tion of cytokines in cells exposed to Os-3 and Ir-10 across a 72 h time series. RFI values
< 1 indicate a drug-induced decrease in protein levels, RFI = 1 indicates no-drug effect and
RFI > 1 indicates drug-induced increases in protein levels. The heat map shows a differential
response between the two compounds, most notably shown with increased levels of phosphorylated
STAT1 (STAT1*, P Tyr701) in response to Ir-10, but not in response to Os-3. In response to both
compounds, STAT1 and its second phosphorylated form STAT1(*) (P Ser727) were detected in
high-levels, particularly STAT1(*) after 72 h exposure. This suggests that cells are activating the
JAK-STAT pathway in response to both compounds.
Figure 5.9 shows that in response to both Os-3 and Ir-10, most of the STAT proteins
and their phosphorylated STAT* counterparts were down-regulated across the time series.
Components that were particularly down-regulated included STAT5*, TYK2* (tyrosine
kinase 2), FLT3 (fms-like tyrosine kinase 3) and IKK (IkB kinase). STAT3/3* and
STAT5/5* are used in growth factor-activated pathways, with the remaining STAT pro-
teins involved in various interleukin responses, together with IKK. FLT3 is regulated by
different cytokine receptors, namely TNFa and TGFb which inhibit this proteins activity.
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Therefore the down-regulation of FLT3 agrees with the assignment of TNF and TGF as
upstream regulators involved in cellular response to both Os-3 and Ir-10 in Chapter 4.
Assessing the proteins found in differentially higher levels provides more information
about the immune response. There were only a few components shown in Figure 5.9 that
were up-regulated in response to the compounds. For example, STAT1 and STAT1(*)
(phosphorylated at Ser727) were up-regulated in response to Os-3 and Ir-10, and STAT1*
(phosphorylated at Tyr701) in response to just Ir-10.
This suggests specific modulation of the cytokine response pathways, and highlights
differences between the osmium and iridium compounds. JAK1/1*, which phosphorylates
STAT1, showed some up-regulation in response to both compounds, particularly after
72 h, where JAK1* was at a maximum in response to both compounds, together with
phosphorylated STAT1. TKY2*, which phosphorylates STAT2, was consistently down-
regulated throughout the time series which suggests that cytokine activation is primarily
though IFNg , and not IFNa/b .
5.2.1.3 Apoptosis
The RNAseq results in Chapter 4 showed that apoptoitc initators were up-regulated
between 12 and 24 h, but that pro-apoptotic caspases were down-regulated throughout
the 48 h time series. In addition, apoptotic inhibitor proteins (IAPs) were up-regulated.
Figure 4.21 summarised the components involved in extrinsic and intrinsic apoptosis.
RPPA was used to study the differential levels of eighteen apoptotic proteins, five
pro-survival proteins and thirteen pro-apoptotic proteins, in cells responding to Os-3 and
Ir-10 across a 72 h time series. Figure 5.10 summarises the results as RFI values, where
components above the black line are pro-survival, and below are pro-apoptotic.
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Figure 5.10: Heat map showing the relative fluorescence intensity (RFI) values for a se-
lection of apoptotic proteins in cells exposed to Os-3 and Ir-10 across a 72 h time series.
RFI values < 1 indicate a drug-induced decrease in protein levels, RFI = 1 indicates no-drug
effect and RFI > 1 indicates drug-induced increases in protein levels. XIAP, Survivin, BCL-X,
PARP and BIM represent pro-survival proteins, with the remaining, pro-apoptotic proteins. In
response to both compounds, most pro-apoptotic proteins are down-regulated, with the exception
of apoptotic-initiation proteins like BCL-2 and BAK, which were detected in significantly high
levels after 24 h exposure. High levels of pro-survival proteins like XIAP and Survivin suggest
that apoptosis is blocked at the caspase level, as these are inhibitor of apoptosis (IAP) proteins and
target caspase-activation during the effector phase of apoptosis.
As a general observation, proteins were detected in equal levels for both compounds, at
both concentrations. Compounds Os-3 and for Ir-10 induced high levels of IAP proteins,
survivin and XIAP. The RFI values across the time series for these up-regulated pro-
survival proteins were notably higher in Os-3 exposed cells compared to Ir-10. BCL-X,
which is a pro-survival protein located in the mitochondria, was down-regulated suggesting
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specific modulation of the apoptotic pathway.
Of the pro-apoptotic proteins, most were down-regulated, however, BCL-2 and BAK,
which are initiator proteins, were up-regulated between 24 and 48 h. In addition, cleaved
PARP (PARP*), which is cleaved by CASP-3, was present in higher levels during the
middle of the time course. However, likely due to XIAP, the levels of CASP-3 remained
low, suggesting PARP may have been cleaved by another cellular component (e.g. IFN).
BAD(*), which is also an apoptotic initiator, was found at higher levels in cells exposed
to Ir-10, but consistently lower levels in response to Os-3.
Collectively, RPPA provided a similar conclusion to that of the RNAseq results in
Chapter 4, that apoptosis may occur within a 72 h time period, but that only a small
apoptotic response is activated.
Flow cytometry studies were performed to measure the level of apoptotic cells after
exposure to Ir-10. These experiments measure the fluorescence of annexin V and
propidium iodide dyes, where the former identifies early apoptotic cells and the latter
identifies late-apoptotic and/or necrotic cells. During early apoptosis membrane-bound
phosphatidylserine proteins, which ordinarily face into the cytoplasm, translocate to the
outside of the cell membrane and allow annexin V binding. A cell in early apoptosis, will
still maintain its membrane integrity, therefore DNA intercalating dye, propidium iodide,
cannot pass through. Once the cell has lost viability, its membrane becomes permeable
to propidium iodide, which fluoresces upon binding to DNA.
It is noted that without further assays it is difficult to identify whether necrotic cells are
those which have died via the process of necrosis, or whether the cells are in secondary
necrosis and are therefore in the final stages of apoptotic, autophagic or oncotic cell death.
Figure 5.11 shows a flow cytometry trace measuring annexin (green) and propidium
iodide (red) fluorescence split into four quadrants representing alive, early apoptotic, late
apoptotic and necrotic cells.
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Figure 5.11: Graph showing the segregation of an example flow cytometry trace into cell
death quadrants. Measuring the level propidium iodide (PI) and annexin fluorescence in single
cells allows separation of cell populations into different stages of apoptosis. Cells with high
annexin fluorescence are said to be in early apoptosis as annexin binds to phosphatidylserine
proteins, which are extracellular markers of early apoptosis. High PI fluorescence indicates the
loss of membrane integrity, allowing the dye to intercalate with DNA, and is a marker for necrosis
which either signifies cells are in the final stages of apoptosis or that they have used necrosis as
their primary mechanism for cell death. Here, the majority off cells are still alive (92 %), with 7 %
necrotic and the remainder in apoptosis.
A series of experiments was performed to measure the level of apoptosis in A2780
cells exposed to Os-3 and Ir-10 under various different conditions. The first experiment
assessed the level of apoptosis in cells exposed toOs-3 for 24 and 72 h at 13GI50, compared
to a negative control. Figure 5.12 summarises the results as a % of cells in each of the
four quadrants, in each sample.
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Figure 5.12: Graph showing the % of cells populating each stage of apoptosis/cell death
after exposure to Os-3 for 24 and 72 h. Each triplicate set of values corresponds to a particular
phase of cell death (described along the x axis), with cell populations for control samples shown in
purple, those for 24 h Os-3-exposed in blue and those for 72 h Os-3-exposed samples in green. *
indicates p < 0.10, ** indicates p < 0.05 and *** indicates p < 0.01 after a Welch two sample
t-test between control- and compound-exposed samples in each stage. After 24 h exposure, there is
a significant drop in viable cells, and a significant increase in late apoptotic and necrotic cells.
However, after 72 h exposure the cells have started to recover, with an increase in viable cells and
a decrease in apoptotic/necrotic cells.
The control cells appeared to remain viable throughout the time series with >99% of
cells remaining in this quadrant. After 24 h, 76.5 % of cells were viable, 2.5% in early
apoptosis, 12.3% in late apoptosis and 8.8% necrotic. After 72 h exposure, 95.0% were
viable, 2.2% were early, 1.2% were late apoptotic and 1.6% were necrotic. This could
suggest that Os-3 kills off an initial percentage of cells within 24 h, but after this time,
the remaining cells recover and maintain integrity.
The remaining experiments assess apoptosis in Ir-10-exposed cells under different
conditions. The two graphs in Figure 5.13 show the levels of apoptosis after 24 and 48
h exposure to Ir-10 at two doses, 0.13 µM and 0.40 µM.
After 24 h exposure, there was a slight decrease in cell viability, with a more significant
decrease when exposed to a higher dose of Ir-10 (95.1%) compared to the lower dose
(94.2%). There was a higher population of cells in early apoptosis at the higher dose
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compared to the lower (2.0% and 1.3%, respectively), but a lower number of late apoptotic
(1.1% and 1.5%) and necrotic cells (2.2% and 2.3%).
After 48 h there was a more significant drop in cell viability, now down to 58.0% at
0.13 µM and 56.4% at 0.40 µM. The population of cells in early apoptosis was actually
lower in drug exposed cells than control cells. This is likely due to a lack of nutrients
available in freely dividing control cells. There were on average, a larger population of
cells in late apoptosis at the higher dose of iridium compared to the low, 41.2% and 30.2%.
However, there were more necrotic cells present after exposure to the lower dose of Ir-10,
11.8% and 2.5%.
Finally, an experiment was performed to investigate the recovery of cells exposed
to 0.13 µM Ir-10. Here, cells were exposed to Ir-10 for 24 h, before drug-containing
medium was removed and replaced with fresh medium. The cells where then left for a
further 48 h to recover, and the level of apoptosis compared to that for cells which had
been exposed to Ir-10 for a full 72 h period (Figure 5.14).
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Figure 5.13: Graph showing the % of cells populating each stage of apoptosis/cell death
after exposure to Ir-10 for 24 h (top) and 48 h (bottom), at 0.13 µM ( 13GI50) and 0.40 µM
(GI50). Each triplicate set of values corresponds to a particular phase of cell death (described
along the x axis), with cell populations for control samples shown in blue, those for 0.13 µM
Ir-10-exposed in pink and those for 0.40 µM Ir-10-exposed samples in green. * indicates p< 0.10
and ** indicates p < 0.05 after a Welch two sample t-test between control- and compound-exposed
samples in each stage. Significance testing was done between each treatment and the control (for
each quadrant), using a Welch unpaired t test. In contrast to Os-3, Ir-10 doesn’t cause a significant
reduction in viable cells after 24 h, instead the activation of cell death is more pronounced after
longer exposure. Both the low and high concentrations of Ir-10 cause a similar decrease in cell
viability, however at the lower concentration there is more necrosis compared to the higher.
This figure shows a slight increase in cell viability with a 48 h recovery period, with
a 95.9% population of live cells compared to 94.9% without a recovery period. However,
the level of early apoptotic cells, and the level of necrotic cells showed little difference,
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Figure 5.14: Graph showing the % of cells populating each stage of apoptosis/cell death
after exposure to 13GI50 Ir-10 for 72 h, with and without a 48 h recovery period. Each
triplicate set of values corresponds to a particular phase of cell death (described along the x axis),
with cell populations for control samples shown in blue, those for 72 h Ir-10-exposed in pink and
those for exposed to Ir-10 for 24 h, and then left to recover for 48 h, in green. * indicates p < 0.10
after a Welch two sample t-test between control- and compound-exposed samples in each stage.
There is a slight recovery in cell viability when cells are given 48 h recovery in drug-free media
and a decrease in late-apoptotic cells.
in fact comparing Figure 5.13 with Figure 5.14 there is a further recovery in necrotic cells
from 48 h to 72 h. With regards to late apoptosis, there were fewer cells in this stage with
48 h recovery, compared to 72 h exposure (4.7% and 3.7%). Again, this assay highlights
the nutrient restraints for control cells left to grow for 72 h.
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5.3 Discussion
This chapter aimed to explore cellular response at the translational level, and compare find-
ings to those presented in Chapter 4. Chapter 4 proposed the production of reactive oxygen
species (ROS) had involvement in the MOA ofOs-3 and Ir-10, possibly through mitochon-
drial targeting. Chapter 3 further supported this, showing all compounds to be most active
in breast cell line MDA-MB-468 in the NCI-60 screen, which had inherent deficiencies in
oxidative stress response machinery. Both the upstream mechanisms which produce ROS
and the downstream effects of ROS production span a vast array of pathways inside cells.
Specific pathways were selected for RPPA study, namely DNA damage response, cell cycle
arrest, cytokine activation and apoptosis to tie in with those findings by RNA sequencing.
5.3.1 DNA damage response
DNA is an established target for metal-based anticancer agents, namely cisplatin and
its derivatives.8 Cells are equipped with mechanisms to repair such damage, however,
ovarian cancers often lack the proper tools for DNA damage repair (DDR).9, 10 Resistance
to conventional platinum therapy often originates from the ability of cancer cells to repair
DNA lesions caused by cisplatin, even in cell lines with DDR deficiencies.11 DNA damage
caused by cisplatin is often not selective for cancer cells, and can be just as damaging
to normal cells if used in high doses.
In contrast, it is also possible to damage DNA through indirect mechanisms, and DNA
is a well-known target for reactive oxygen species, particularly guanine bases.5 DNA
damage caused indirectly by anticancer compounds, through selective ROS generation,
could provide a more targeted approach to achieving this MOA.
Assessing DNA damage caused by Os-3 and Ir-10 provided different insights into each
compound. In previous studies, Os-3, has been shown to undergo hydrolysis, but not to
bind to DNA nucleobases. The remaining osmium compounds studied in this thesis have
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also been shown not to bind to DNA. However, Chapter 3 showed a large correlation of
the osmium compounds to DNA interacting agents, although largely not to alkylating
agents like cisplatin.
The RPPA work for Os-3 highlighted the detection of DNA damage response (DDR),
particularly with the typical ATM-CHK2-p53-p21 pathway activation which acts to
maintain arrest in G1 to allow DNA repair. Flow cytometry experiments suggested
that DDR activation resulted in an increase in cells populating the G1 phase of the
cell cycle. Interestingly, at higher concentrations, Os-3 begins to induce S phase arrest
in A549 lung cancer cells.12 As shown in Chapter 1 (Figure 5.15) in colorectal cell
line HCT116p53(-/-), Os-3 is ca. x4 less potent compared to the wild-type cell line.
This suggests that Os-3 requires p53 for potent activity (G1/S arrest), however it is
noted that in the HCT116p53(-/-) cell line the GI50 value was still in the submicromolar
range.
In contrast to the osmium compounds, the iridium compounds have been shown to have
direct DNA-binding tendencies. For example Ir-6 has been shown to bind nucleobases in
pSP73KB plasmid DNA, blocking RNA/DNA synthesis.13 However, in this same study,
only a small percentage of iridium accumulated inside cells as DNA-bound, suggesting
interactions with other molecules to be a more primary MOA.14 In Chapter 3, Ir-10
established itself as a novel compound, sharing little similarity to any of the other
organometallic compounds nor to drugs populating the NCI-60 database. However, it
did share the highest level of similarity in selectivity to Os-5, where these were the only
two compounds to correlate to alkylating agents. From the Sanger Institute screening,
the activity of Ir-10 was shown to be linked with C-KIT mutations, which is required for
functioning of DNA repair mechanisms. Lung cancer cells with mutations in this gene were
more sensitive to Ir-10, suggesting DNA-targetting may play a role in the MOA of Ir-10.
Much likeOs-3, there was measurable activation of DDR through the ATM-CHK2-p53-
184
p21 pathway, however there was also activation of the BRCA1 protein, not shown forOs-3.
RPPA suggested either S or G2/M phase arrest was possible in cells exposed to Ir-10,
with measurements of S and G2/M phase markers at 24 and at 72 h. Interestingly, flow
cytometry experiments showed S phase arrest after 24 h exposure. BRCA1 is an important
protein in S phase of the cell cycle during DNA damage and is required for homologous
recombination and DNA damage-induced S and G2/M phase arrest.15 It could therefore
follow that Ir-10 does not require functional p53 for its MOA, as it does not require cells
to be held in G1. This has been previously demonstrated in HCT116p53(-/-) where Ir-10
did not lose activity, in fact it showed a 2-fold increase in potency (Figure 5.15).
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Figure 5.15: Graph showing GI50 values (± standard deviation) for compounds Os-2, Os-3,
Os-4, Ir-9 and Ir-10 in different cell lines. Ovarian cancer cell lines are shown in blue, and
colorectal cell lines shown in purple. Os-2 shows little dependence on cell type, showing equal
activity in all 5 cell types. Os-3 is significantly less active in oxaliplatin and p53(-/-) HCT116 cells,
suggesting this compound may target DNA. In comparison Os-4, Ir-9 and Ir-10 show preferential
activity in p53(-/-) cells. All compounds, except Os-2 show increased potency in ovarian cancer
cell lines compared to colorectal.14, 16
Collectively this could suggest that Ir-10 has a more directed effect on DNA by exerting
its activity either during DNA replication (S phase) or after the DNA content has been
doubled (G2 phase). Unlike Os-3 which appears to be most effective prior to DNA
replication (G1 phase), and therefore may not have a DNA focussed MOA.
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Unfortunately this means that Ir-10may have a more cisplatin-type MOA, and therefore
may suffer from the same resistance mechanisms. Although, Ir-10 did not correlate with
cisplatin, or any of the platinum compounds through COMPARE. In contrast Os-3 may be
providing a newer approach to damaging DNA, through indirect mechanisms. Os-3 is equi-
potent in platinum resistant cancer cell lines (Figure 5.15), suggesting that either the dam-
age to DNA by ROS is not repairable by platinum-induced DDR enhancement, or that DNA
damage is not a primary MOA.17 Conversely, Ir-10 loses activity in platinum-resistant
A2780 cells suggesting that it is affected by cisplatin-induced resistance mechanisms.
5.3.2 Activating an immune response
One of the biggest issues with using high-content assays like RNAseq and MS-proteomics
is that a drug’s MOA can be swamped by larger cellular responses, like cell survival/death
and stress signalling. Identifying these processes does not serve to help identify the under-
lying MOA of compounds, but can help to predict a response for in vivo and phase I studies.
Most of the upstream regulators identified during pathway analysis for the RNA se-
quencing were immune-related, identifying a general stress response to both compounds.
Combining those findings with RPPA, highlighted some specific immune modulation,
particularly regarding interferong (IFNg), tumour necrosis factor (TNF), transforming
growth factor (TGFb ) and interleukin signalling. Collectively these pathways control
a plethora of cellular processes.
Studies have shown that interferong (IFNg) administration in vitro and in vivo has
antiprolfierative properties, even activating apoptosis in ovarian cancers via p53 and
caspase-1.18, 19 However, the release of INFs from cancer cells, and the interplay between
IFNs and other cytokines with normal and with immune cells in the extracellular space
can dictate tumour invasion. For example cancer cells which release anti-inflammatory
cytokines like TGFb are generally associated with resistance to immune attack by sur-
rounding host cells.19
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TNF and INFg have also been linked to the direct production of reactive oxygen species
(ROS) and nitric oxide (NO). It is therefore possible that the ROS generation measured
for Os-3 and proposed for Ir-10 could be linked to this cytokine response, and not just
to mitochondrial targeting.
We can only know the outcome of cytokine involvement in A2780 cells responding
to Os-3 and Ir-10 in a physiologically relevant environment i.e. containing a variety of
cell types. As proposed in Chapter 4, more assays will need to be conducted to determine
the outcome of immune activation, and whether this response demonstrates an increase
in tumour invasion in response to Os-3 and Ir-10.
5.3.3 Cell death mechanisms
There are many different types of cell death and it is generally easiest to distinguish modes
of cell death with whole cell imaging techniques.20 However, there are often specific
protein and gene markers which can also be studied. For example, apoptosis is normally
characterised by caspase production, and by distinct budding of cell membrane structures
into so-called apoptotic bodies. In contrast, oncosis involves swelling and not shrinking of
the cell and is caused by accidental damage to the cell.21 Necrosis is commonly identified
as its own mode of cell death, but in fact necrosis is the last stage in any cell death pathway,
i.e. both oncosis and apoptosis lead to necrosis and cell death.
Most anti-cancer agents aim to activate apoptosis in cancer cells, simply because
this is the most controlled form of cell death, involving phagocytosis in the final stages.
However, cancer cells often develop mechanisms to evade apoptotic cell death which starts
to highlight the merits of alternative mechanisms, like pyroptosis, an immune-induced
mechanism of cell death.22
Chapter 4 suggested poor transcriptional activation of apoptotic caspase markers, but
some transcription of apoptotic initiators. RPPA has further supported this conclusion,
with waves of apoptotic initiation towards the middle of the time course, followed by
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recovery towards the end. By flow cytometry, late apoptosis was measurable in Os-3-
exposed cells at the 24 h time point, and in Ir-10-exposed cells at the 48 h time point.
However, by 72 h, cells had recovered viability to both compounds.
This suggests that there is a wave of cell death occurring, perhaps as the top layer of
cells in the petri dish are exposed to each compound and that the cells below this top layer
remain intact and viable. To determine whether these remaining cells continue to divide
or arrest cell division a more stringent time series experiment would need to be performed,
either by flow cytometry or RPPA.
It is possible that cells either require a second bolus to activate cell death in a larger popu-
lation or that a higher concentration ofOs-3 and Ir-10 is needed. A previous study in A549
lung cancer cells showed that apoptosis could be increased whenOs-3 was administered at
concentrations up to 5 µM (33 x GI50).12 This would be inline with conventional chemo-
therapy regimes which require repeat dosing. Chapter 7 studies apoptosis in A2780 cells ex-
posed to higher doses of both compounds, measuring the outcome with imaging techniques.
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5.4 Summary and Conclusions
The work in this chapter has helped to support the cell-wide findings presented in Chapter
4, and more accurately highlighted the subtle differences in the MOAs of Os-3 and Ir-10.
DNA damage response was activated in response to both compounds, accompanied with
cell cycle arrest and a small level of apoptosis.
The purpose of the investigations into these organometallic compounds was to find a
safer and more effective alternative to cisplatin. In this sense, onlyOs-3 emerged as a good
candidate, able to maintain it’s activity in platinum resistant cancers. In contrast, Ir-10
may activate DNA damage response inline with that of cisplatin as it is exhibits cisplatin
cross-resistance. However, Ir-10 does not require functional p53 to retain its potency,
where as Os-3 does. This is likely linked to the G1 arrest shown in cells responding to
Os-3. This therefore highlights beneficial and detrimental properties for each compound.
The work in both Chapters 4 and 5 has helped to identify areas for future investigation,
and has established methods for both RNA sequencing and protein microarrays to study
cellular response at both the transcriptional and translational level. However, future
experiments should use a larger number of time points between 4 and 48 h. This would
help to better map the process of DNA damage repair, cell cycle progression and cytokine
production. Measuring ROS over a tighter time course could also identify whether cy-
tokines activate ROS production or whether the mitochondria are the main source. This
would also reveal the exact point at which apoptotic initiators were up-regulated, and help
identify whether dead cells passed though early/late apoptosis before becoming necrotic.
Chapter 6 integrates the RNAseq and RPPA for Os-3 and Ir-10, directly comparing
the transcriptomic and translational responses simultaneously.
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Chapter 6. Dataset Integration
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6.1 Introduction
This chapter analyses the transcriptomic (Chapter 4) and proteomic (Chapter 5) data in an
integrative manner, using Bayesian modelling software, MDI (multiple dataset integration).
This software was developed by Dr Paul Kirk and Sam Mason, extending the previous
work of Dr Rich Savage, all based at Warwick Systems Biology Centre.1, 2
The analysis of complex biological data is often performed using clustering method-
ology, identifying co-expression or co-regulation of groups of genes and/or proteins.3–5
Common clustering methods like k-means and hierarchical clustering treat each dataset
independently, neglecting to consider the dependence between datasets.
MDI allows a unique ability to cluster genes/proteins within and between datasets,
modelling each dataset using a Dirichlet-multinomial allocation (DMA) mixture model.6
A mixture model is a probabilistic model used to identify subpopulations within an overall
population i.e. used to identify groups of co-regulated genes/proteins. Bayesian inference
is performed using a Markov chain Monte Carlo (MCMC) numerical method.
During modelling, each dataset is linked to capture the dependencies between data-
sets. MDI looks for items (genes or proteins) which are fused across datasets i.e.
which group similarly across datasets. The main strength of MDI is the ability to
cluster heterogenous datasets, which is particularly useful when studying genes and
proteins, given the link between the two. The use of MDI has been demonstrated
before, integrating three different data types: gene expression, ChIP data and protein-
protein interactions (PPI).1 This study demonstrated MDIs ability to separate fused
components across all three datasets, into three main clusters with items in each cluster
falling into functional categories. MDI has also been optimised for more clinical
studies, identifying cancer subtypes based on genomic, transcriptomic and epigenetic
data.7
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MDI should identify where transcriptional and translational behaviour in cells is con-
sistent, and whether this behaviour is observed under different treatment conditions. In
addition to identifying groups of genes/proteins which cluster together in one or all
datasets, MDI allows the similarity between this grouping in each pair of datasets, to be
numerically quantified with an inferred posterior parameter (f ) (Figure 6.1).
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Figure 6.1: Schematic showing the clustering of three time series datasets (1, 2 and 3), for
genes i to n. The top tables present hypothetical expression profiles across four time points, for
each gene. These three datasets are then either clustered using independent methods (bottom left)
or using MDI, which shares clustering allocations (bottom right). Here, c is the cluster allocation
for each gene, where ci1 is the cluster allocation of gene i with time series expression observation
xi1 in dataset 1. MDI presents an additional parameter, f , which measures the similarity in
clustering across the datasets, where f 12 is a measure of cluster structure between dataset 1 and 2
for gene i.
MDI will be used to model gene expression data from the RNAseq experiments for
Os-3 and Ir-10 with protein data from RPPA experiments for Os-3 and Ir-10. Only those
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datasets generated after exposure to GI50 concentrations will be included, and only those
genes which have associated protein measurements will be included. The table below
lists the genes/proteins who’s expression profiles included in the analysis.
Table 6.1: Table showing the genes/proteins used in the MDI analysis, together with their functional
ontology. MDI will use the gene expressions and protein levels of these items after 4, 24, 48 and
72 h exposure to Os-3 and Ir-10.
Ontology Protein Ontology Protein
Apoptosis BADP112 DDR ATM
BADP136 BRCA1
BAK1 p21
BAX CHK2P
BCL2 p53
BIM p53P
BID Cytokine STAT1P727
Survivin STAT1P701
CASP3 STAT5P
PARP1 Signalling AKT
PARP1-cleaved p38
Cell cycle CycD MTOR
CycDP MAP2K1
CDC25A PLCG1
CDC25CP PTEN
CDK1P PTENP
CDK2 SRC
RB1 MET
RBP1 JAK1
RBP2 JAK1P
TUBB IKK
Cell motility E-cadherin Transcription p70
B-catenin MYC
B-actin Respiration PDK1
LKB1
RAP1A
FAK
Every tenth sample was recorded, with a total of 3,00000 samples collected for a single
MDI run. The analysis was run five times, and the convergence of the MCMC chains was
assessed for each run. The aim of this analysis was to identify where genes and proteins
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were similarly co-regulated in response to treatment by both compounds. It also identified
where genes and proteins are co-regulated differently in each compound.
6.2 Results
MDI estimates the pairwise similarity in clustering across each of the four dataset, with
a mean fˆ parameter, where f1,2 measures the similarity between dataset 1 and 2 for a
single gene and ˆf1,2 measures the overall similarity between datasets 1 and 2.1 Figure
6.2 plots this measure for each of the four datasets as a similarity matrix.
 
 
 
 
 
 
 
 
O
s-
3 
R
N
A 
O
s-
3 
R
P
PA
 
Ir-
10
 R
N
A 
Ir-
10
 R
P
PA
 
Os-3 RNA 
Os-3 RPPA 
Ir-10 RNA 
Ir-10 RPPA 
Φ 
16 
8 
^ 
Figure 6.2: Similarity matrix plotting pairwise fˆ values. fˆ values are a measure of the
pairwise similarity between each of the four datasets: Os-3 RNAseq, Ir-10 RNAseq, Os-3 RPPA
and Ir-10 RPPA. The higher the value the more similar the pattern of clustering across pairs of
datasets. The highest level of clustering similarity is between the gene expression profiles in
response to both compounds.
Figure 6.2 shows that the highest similarity in clustering is between the RNAseq datasets
for Os-3 and Ir-10 (fˆ= 16.2), with the biggest difference between the RPPA data for
Os-3 and the RNAseq data for Ir-10 (fˆ= 8.9). This suggests that the genes used for MDI
analysis had similar expression profiles in response to both compounds, however, the
protein levels were different.
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6.2.1 Clustering
The aim of using MDI is to identify items, in this case genes and proteins, which behave
similarly and cluster together across different types of data i.e. transcriptomics and proteo-
mics. A posterior similarity matrix (PSM) was plotted to visualise both the independent
clustering in each of the four datasets, together with a consensus clustering structure.7 This
plot describes the posterior probabilities that two observations are in the same cluster.8
Figure 6.3: Consensus posterior similarity matrix (PSM) showing the similarity in clus-
tering structure across the Os-3 RNAseq, Os-3 RPPA, Ir-10 RNAseq and Ir-10 RPPA
datasets. Panels on the right present the independent clustering structure in each dataset, with the
central plot showing an overlay of clustering in all four datasets. Darker spots indicate a higher
probability that the given item (gene/protein) is clustered correctly. The two main clusters are
highlighted in yellow.
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Darker spots in the independent clustering patterns (right) indicate a high probability
of a given pair of items belonging to the same cluster, the consensus plot shows the
average probability over all four datasets, therefore darker spots indicate overlap in cluster
assignments between datasets.7 There are two main clusters of genes/proteins which show
similar expression profiles across all four datasets.
The two main clusters in the consensus PSM are highlighted in yellow. The items
(genes/proteins) associated with each cluster are described in Table 6.2 and 6.3.
Table 6.2: Table listing the genes/proteins associated with Cluster 1, sharing similarity in time
series profiles across all four datasets.
Gene/protein Process Function
BID Apoptosis Pro-apoptotic
BAK1 Pro-apoptotic
BAX Pro-apoptotic
p53 Cell cycle Cell cycle arrest
p53P Cell cycle arrest
p21 DNA repair
CDK1P G2/M phase
PDK1 Metabolism Respiratory enzyme
STAT1P701 Cytokine signalling
STAT1P727 Cytokine signalling
SRC Signalling Kinase activity
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Table 6.3: Table listing the genes/proteins associated with Cluster 2, sharing similarity in time
series profiles across all four datasets.
Gene/protein Process Function
ATM Cell cycle DNA repair/cell cycle arrest
CHK2P DNA repair/cell cycle arrest
BRCA1 DNA repair/cell cycle arrest
CDC25A G1/S phase
CDK2 G1/S phase
CYCD G1/S phase
CYCDP G1/S phase
RB1 G1/S phase
RBP1 G1/S phase
RBP2 G1/S phase
CDC25CP G2/M phase
TUBB M phase
CASP3 Apoptosis Pro-apoptotic
BADP Pro-apoptotic
BCL2 Pro-survival
PARP Pro-survival
PTEN Signalling Kinase activity
PTENP Kinase activity
AKT Kinase activity
MAP2K1 Kinase activity
p38 Kinase activity
MTOR Kinase activity
PLCG1 Various signalling
E-cadherin Cell motility Cell adhesion
LKB1 Cell polarity
RAP1A Migration/adhesion
FAK Migration
B-actin Cell motility/structure
B-catenine Cell-cell interactions
p70 Cell maintenance Protein synthesis
All of the genes/proteins in Tables 6.2 and 6.3 had similar time series profiles in all
four datasets i.e. the genes and proteins in these tables behaved the same in response to
both Os-3 and Ir-10 at their GI50 concentrations. These include apoptotic markers like
BID and BAX which were discussed in Chapters 4 and 5, where both compounds showed
initiation of apoptosis with expression of BID and BAX. Both compounds also induced
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DNA damage repair with the measurement of proteins like ATM and CHK2, both found
in Cluster 2 showing that DNA damage repair was registered at the gene and protein level
in response to Os-3 and Ir-10.
The remaining items, not allocated to cluster 1 or 2, did not show a strong consensus
clustering across the four datasets (Table 6.4).
Table 6.4: Table showing items which did not show similar time series profiles across all four
datasets.
Gene/protein Process Function
BIM Apoptosis Pro-survival
Survivin Apoptosis Pro-survival
PARP-cleaved Pro-apoptosis
PKCa Signalling Kinase
JAK1 Interferon g
JAK1P Interferon g
IKK Inflammatory
STAT5P Cytokine
From Chapter 5, the survivin protein was measured in higher levels in response to Os-3
than to Ir-10 and from Chapter 4, the survivin gene (BIRC5) also showed higher levels
of expression in response to Os-3 compared to Ir-10. Thus resulting in non-consensus
clustering across all four datasets.
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6.3 Discussion
This chapter has assessed cellular response at the transcriptional and translational levels, in
cells responding to Os-3 and Ir-10 over a time series. In previous chapters, this informa-
tion was analysed independently. Here, MDI software has been used to analyse the data in a
more integrative manner. Four datasets were analysed, Os-3-RNAseq, Os-3-RPPA, Ir-10-
RNAseq and Ir-10-RPPA, each with three time points and 51 genes/proteins worth of data.
The aim of MDI is primarily to identify where cluster patterns overlap between different
datasets. A consensus posterior similarity (PSM) matrix was constructed, which displayed
this overlap in clustering structure, together with plots showing the independent clustering
patterns (Figure 6.3).7 Similar clustering was shown across all four datasets, splitting most
of the items into two main clusters. The strongest similarity in clustering pattern was shown
between the two RNAseq datasets, suggesting a high level of similarity in transcriptional
response between the two compounds, for the genes/proteins included in the analysis.
All of the items included in Cluster 1 were similarly elevated in response to both Os-3
and Ir-10. For example, BID and BAX were both up-regulated to initiate apoptosis between
12 and 24 h exposure to both compounds. And at the protein level, p53 was elevated in
response to both compounds to activate DNA damage repair (DDR), primarily at 4 and 48
h. Of the STAT proteins, STAT1P was the most significantly up-regulated in response to
both compounds, particularly after 72 h exposure. This was all demonstrated in heat maps
in Chapters 4 and 5, where apoptotic initiation was shown for both compounds at the gene
and protein level, yet late phase apoptosis markers, like CASP3 were not up-regulated.
MDI has clustered these components together, quantifying the similarity in response for
Os-3 and Ir-10 at the apoptotic, and DNA damage levels for specific components.
The items found in Cluster 2 were similarly elevated in response to both compounds.
Tubulin (TUBB), BRCA1, CycD, p21, ATM, CHK2, CDC25CP and CDC25A were all
elevated at 24 h at the protein level. In comparison, the proteins assigned to Cluster 1
202
were primarily elevated at different stages of the time series (4 and 48 h). Therefore MDI
has separated these protein profiles by time series behaviour, as expected. The fact that
p53, which is also a key component of DDR, was not clustered together with it’s upstream
activators suggests that p53 may also be modulated by different processes, and not just
controlled by DDR.
The similar behaviours of these components in Cluster 1 and Cluster 2 across all four
datasets, suggests that there is some underlying similarity in the cellular responses to both
Os-3 and Ir-10. Certainly, the work in Chapter 4 showed that both compounds induced
oxidative stress, but that the compounds different favourability for their oxidative stress
response pathways. Both compounds showed initiation of apoptosis, but no suggestions
for activation of cell death through caspase cascades. And finally, both showed activation
of DDR pathways, although this resulted in differential cell cycle arrest profiles by flow
cytometry: Os-3 arresting cells immediately in G1 phase and Ir-10 showed slowing of
the cell cycle, and some S phase arrest.
The remaining items, not allocated to Clusters 1 or 2, showed lower probabilities for
being clustered similarly across all four datasets. This was supported in Chapter 5 for
cleaved PARP protein, which was found in high levels after 48 h in response to Os-3,
but not elevated in response to Ir-10 until 72 h. This protein is a measure of apoptosis,
as it is cleaved by CASP3. The expression and translation of survivin was also different
across the two compounds, withOs-3 generally inducing a higher level. This suggests that
although the initiation of apoptosis was similar across both compounds, the down-stream
components like caspase and caspase inhibitors are different in their response profiles.
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6.4 Summary and Conclusions
Most of the biological interpretation of the RNAseq and RPPA data was done in previous
chapters, however, MDI has quantified some of those findings. Highlighting the similarity
in the initiation of apoptosis between both compounds, as well as the induction of DNA
damage repair pathways in response to both.
To fully test MDI, there would need to be more components involved in the analysis,
and there needs to be components involved which we know may behave differently to
Os-3 and Ir-10. This analysis could be achieved in the future by increasing the number
of proteins measured by RPPA, and including this with the existing gene expression data
collected by RNAseq. It could also be interesting to re-measure the protein levels used
in this chapter in a different cell line, and compare findings between different compounds
and different biological systems. However, for such an experiment it could be useful to
perform experiments with synchronised cells, which could increase the performance of
MDI by reducing the biological complexity of the data.
The larger the number of items used in this analysis, the more useful clustering analysis
can become, negating the use for manual plotting and interpretation using heat maps and
basic statistics.
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Chapter 7. Imaging
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7.1 Introduction
This chapter focusses on investigating the mechanisms of action (MOA) of compounds
Os-1 (Os(h6-bip)(NMe2-azpy)I]PF6), Os-3 ([Os(h6-p-cym)(NMe2-azpy)I]PF6), Os-
4 ([Os(h6-bip)(F-azpy)I]PF6), Ir-9 (Ir(h5-Cpxbiph)(ppy)Cl]) and Ir-10 (Ir(h5-Cpxph)(NMe2-
azpy)Cl]PF6) by high content screening (HCS) and of Ir-6 by transmission electron micro-
scopy (TEM). Os-3 and Ir-10 were selected as they were the focus of the transcriptomics
and proteomics analysis. Os-4 and Ir-9 were chosen for their novel patterns of selectivity
in the cancer cell screens of Chapter 3. Ir-6 was chosen for it’s mid-level potency so that
cells may not be too destroyed or degraded for visualisation by TEM.
7.1.1 High content screening
High content screening (HCS) has a prominent place in drug discovery and is simply
the acquisition of images on a high-throughput scale, commonly capturing fluorescent
microscopy readings.1, 2 HCS systems operate on a similar principle to flow cytometry,
measuring fluorescent readings on a single cell scale, except HCS captures images and
not just fluorescent readings. Image analysis software, which is provided by the HCS
system manufacturers allows accurate segregation of cells (Figure 7.1).
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Figure 7.1: High-content screening of rhesus monkey cells. Cell nuclei appear blue and the
infective ‘elementary bodies’ of chlamydia, which form blisters, fluoresce green. The red outlines
are those after image analysis and show separation of fluoresence into individual cell structures.
Image provided by Dr S. Hess of the Max Planck Institute for Infection Biology, Berlin, Germany.
In Figure 7.1, nuclear staining (blue) and chlamydia staining (green) are shown,
with red outlining the cells as calculated by the image analysis software. Like flow
cytometry, the HCS system will count the number of cells with a given fluorophore
detected.
The fluorescent images are captured when light incident on a sample excites a fluoro-
phore, which absorbs the light and emits light of a longer wavelength.3 This occurs as
the molecules in a sample absorb a photon of light, increasing their energy and causing
an electron to enter an excited energy state. As the electron returns to a ground state, it
loses energy in the form of light.
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Figure 7.2: Fluorescent confocal microscopy set-up. A fluorescent or fluorescently-tagged
sample is shown at the bottom of the image. A light source is used to excite the sample, using
an excitation filter to all passage of light at specific wavelengths (e.g. blue) and using a dichroic
mirror to focus the light onto the sample. The sample then emits light of a longer wavelength (e.g.
green) which is focussed to the detector using the dichroic mirror and an emission filter. Image
adapted from Semwogerere (2008) Encyclopedia of Biomaterials and Biomedical Engineering.
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In Figure 7.2 a fluorescent marker in the sample is excited with a laser, passed initially
through an excitation filter and dichroic mirror to allow passing of light in the blue region
onto the sample.3 After excitation, green light is emitted from the marker, and directed to-
wards the detector by the dichroic mirror, through an emission filter which allows rejection
of out-of-focus light. Fluorescence microscopy is a widely used tool in cancer research,
applied to study both cellular drug effects and drug transport. A recent study by Guduru
et al used confocal microscopy to study drug delivery of fluorescently-labelled paclitaxel
into ovarian cancer cells when co-delivered with magneto-electric nanoparticles.4
High content fluorescent microscopy has been used in a plethora of biological studies,
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including those on cellular processes via individual protein tracking, as well as adapting
the technology for use with other high-throughput techniques, like siRNA cell arrays.5–7
High content fluorescent screening was performed by Dr Neil Carragher at the Edin-
burgh Cancer Research Centre to make high throughput fluorescent measurements of
A2780 ovarian cancer cells exposed to Os-1, Os-3, Os-4, Ir-9 and Ir-10. After 48 h
exposure, cells were extracted, dual-dyed and imaged. DAPI stain was used for nuclei
measurements, to allow total cell counts to be obtained. DAPI is excited at 350 nm and
emits at 455 nm as blue fluorescence. To measure the activation of apoptosis in compound-
exposed cells, a NucView 488 Caspase-3 substrate was used. NucView was developed by
Biotum, and follows caspase-3 activity inside cells. The substrate consists of a caspase-3
substrate peptide (DEVD) attached to a DNA binding fluorophore, and is excited at 485
nm, and emits at 515 nm. In the cytoplasm, caspase-3 cleaves the peptide, releasing the
DNA binding probe which co-stains the nucleus (green) together with DAPI (blue).
Results from previous chapters showed little or no detection of caspase-3 in compound-
exposed cells, therefore the concentrations were increased to a maximum of 2.5 µM to
see if the extent of apoptosis could be increased.
The instrument used was The Olympus ScanR Screening Station, which allows image
acquisition and analysis of cell samples in 96-well plates. Both green and blue fluorescence
were taken for each sample and the total number of stained cells were counted.
7.1.2 Electron microscopy
Electron microscopy operates on the same principle as light microscopy, except an electron
beam is used instead of light, allowing for greater resolution imaging. The approximate
resolving power of a transmission electron microscope can be as low as 0.1 nm, compared
to a standard light microscope with a resolving power of only 200 nm. Figure 7.3 shows
the basic set up of a TEM instrument.
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Figure 7.3: Basic set up of a transmission electron microscope. Electrons are fired from the
electron gun and are focussed, through an anode and condenser lens, onto the sample. These
electrons interact with the sample, some scattering and some transmitting. The transmitted
electrons are passed through a series of lenses to project an image of the sample. The contrast seen
in TEM imaging is a result of detracted electrons unable to pass through the specimen. The lighter
regions in TEM images are created from transmitted electrons. Image adapted from Joy (2008)
Encyclopedia Britannica
The electron gun produces a source of electrons with energies in the range 100,000
- 400,000 eV by heating a tungsten filament.8 Negatively charged electrons are passed
through a series of electromagnetic lens, where the image magnification is controlled
by the strength of the lenses. The electron beam must pass through a vacuum to prevent
absorption or deflection by particles in the air. Once the electron beam reaches the sample,
it will either be transmitted through the sample or diffracted by it, the later creating
contrast. When using this technique to image cells, the cells are first embedded in a
polymer resin, before being thinly sliced on a diamond microtome, to a thickness of ca.
100 nm. Often, heavy metal dyes like OsO4 are used as cell stains, where electrons from
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the electron beam are absorbed by the metal deposits lining the cellular compartments.
The image formed by the interaction of the electron beam with the specimen is projected
onto a fluorescent screen, which can be photographed.
For its resolving power, TEM is a valuable tool for cellular imaging and has been used
successfully to explore drug effects on cellular morphology.9 For example, a study by
Morse et al studied cell death mechanisms in breast cell lines after exposure to docetaxel,
showing non-apoptotic cell death through mitotic catastrophe.10
Whole-cell TEM images were taken of A2780 cells exposed to Ir-6 at a high and
low-dose, for 24 h. The machine used to capture the images was a JEOL 1200EXII TEM
with a Gatan 1 k X 1 k CCD camera, situated in the University of Warwick Imaging
Suite (School of Life Sciences). The resolving power of this instrument was leq 0.34 nm,
providing high-resolution cell imaging.
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7.2 Results
7.2.1 High content screening
Human ovarian cell lines A2780 and OVCAR-3 were exposed to compounds Os-1
([Os(h6-bip)(NMe2-azpy)I]+), Os-3 ([Os(h6-p-cym)(NMe2-azpy)I]+), Os-4 ([Os(h6-
bip)(F-azpy)I]+), Ir-9 ([Ir(h5-Cpxbiph)(ppy)Cl]) and Ir-10 ([Ir(h5-Cpxph)(NMe2-azpy)Cl]+)
at an initial concentration of 2.5 µM, as well as a DMSO control, for 48 h. After this
period, adherent cells were stained with DAPI, a blue stain to highlight cell nuclei, and
Nucview, a green stain to highlight apoptotic caspase-3 expressing cells. Fluorescent
images were taken in triplicate for each sample type, and the number of blue and green
stained cells were counted. Figures 7.4 and 7.5 show a representative example of the
fluorescent images taken in A2780 (Figure 7.4) and OVCAR-3 (Figure 7.5).
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Figure 7.4: Fluorescence images showing apoptotic A2780 human ovarian cancer cells
after exposure for 48 h to (A) Control; (B) 2.5 µM Os-1; (C) 2.5 µM Os-3; (D) 2.5 µM
Os-4; (E) 2.5 µM Ir-9; (F) 2.5 µM Ir-10. DAPI is used to stain the nuclei of cells (blue),
with the NucView reagent staining apoptotic cells (green). NucView is activated inside cells by
caspase-3 and caspase-7 which are apoptotic effector proteins, therefore fluorescence of this probe
is an indirect measure of apoptosis. Panels (B) Os-2, (C) Os-3 and (F) Ir-10 all show significant
levels of apoptosis, together with a reduction in stained nuclei compared to the control (A). Panel
(E) shows little nuclei reduction and no apoptosis, suggesting Ir-9 is not cytotoxic at 2.5 µM.
Panel (D) shows no apoptosis, but a reduction in the number of nuclei, suggesting that Os-4 may
be cytotoxic, but may not be activating cell death through apoptosis.
Figure 7.4 shows that each of the compounds behave differently in A2780 cells, with
regards to apoptosis. This is interesting, given that anti proliferative activity is very similar
(Table 1.1). Compounds Os-1 and Os-3 both cause significant apoptosis after 48 h expos-
ure of the cells to 2.5 µM. For Os-1 this is 18X the GI50 value, and for Os-3 this is 16X
the GI50 value. Compound Ir-10 also activates apoptosis, at a concentration 6X its GI50.
Os-4 and Ir-9 do not activate a significant level of apoptosis (both at 4X GI50 concentra-
tion), supported also by the large population of viable cells (blue fluorescence) remaining
after exposure. The reduction in viability shown after exposure to Os-1, Os-3 and Ir-10
shows cytotoxic activity, with cell death occurring through apoptosis for Os-1 and Os-3
and partially through apoptosis for Ir-10. This supported findings by flow cytometry and
RPPA, which showed a higher level of apoptosis activated by Os-3 compared to Ir-10.
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Figure 7.5: Fluorescence images showing apoptotic OVCAR-3 human ovarian cancer cells
after exposure for 48 h to (A) Control; (B) 2.5 µM Os-1; (C) 2.5 µM Os-3; (D) 2.5 µM
Os-4; (E) 2.5 µM Ir-9; (F) 2.5 µM Ir-10. DAPI is used to stain the nuclei of cells (blue),
with the NucView reagent staining apoptotic cells (green). NucView is activated inside cells by
caspase-3 and caspase-7 which are apoptotic effector proteins, therefore fluorescence of this probe
is an indirect measure of apoptosis. Panels (B)Os-2 and (F) Ir-10 show small signs of apoptosis in
OVCAR-3, much less than in A2780 cells. However, the number of stained nuclei is still decreased.
Panels (C) Os-3, (D) Os-4 and (E) Ir-9 show no apoptosis, with (D) and (E) showing no reduction
in nuclei count.
Figure 7.5 shows a similar trend in behaviour as that seen in A2780 cells with Os-1
showing the most activation of apoptosis, this time at 23X times the GI50 value. Os-3 and
Ir-10 show low levels of apoptosis in OVCAR-3 at 9X and 11X their GI50, respectively.
The reduction in cell count is notable for Os-1, Ir-10 and to a lesser extent Os-3. Com-
pounds Os-4 (GI50) and Ir-9 (4X times GI50) showed no measurable apoptosis, although
Ir-9 showed stronger antiproliferative activity compared to Os-4.
The viable A2780 cell counts (blue), and A2780 apoptotic cell counts (green) were
obtained after exposure to 2.5 µM of each of the compound, and were compared to
cisplatin (CDDP) and to a DMSO control used against each compound (Table 7.1).
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Table 7.1: Percentage of cells in apoptosis after exposure to compounds Os-1, Os-3, Os-4, Ir-9,
Ir-10 and CDDP at 2.5 µM for 48 h, ± SD. % of cells in apoptosis was calculated by dividing the
number of cells with NucView fluorescence by the total number of cells (with DAPI fluorescence).
This calculation was performed for compound-exposed samples and for control-exposed samples.
The Ratio describes the number of apoptotic cells in compound-exposed samples compared to
control-samples. In response to Os-1 and Ir-10 there is significant activation of apoptosis at 2.5
µM. In comparison, Os-4 and CDDP do not activate apoptosis in A2780 cells.
Complex % Cells in apoptosis % Cells in apoptosis Ratio⇤⇤
(compound-exposed)⇤ (control-exposed)⇤
Os-1 45.15 ± 481.5 0.78 ± 3.7 57.9
Os-3 25.46 ± 93.7 1.22 ± 4.6 20.9
Os-4 0.99 ± 5.9 0.49 ± 2.4 2.0
Ir-9 0.61 ± 5.5 1.07 ± 2.9 0.6
Ir-10 13.86 ± 64.5 0.27 ± 1.6 51.9
CDDP 1.45 ± 8.8 0.96 ± 3.5 1.5
⇤calculated as [ apoptotic cell countviable cell count ]
⇤⇤calculated as [% apoptosis compound exposed% apoptosis control ]
Table 7.1 reflects the observations shown in Figure 7.4, where Os-1 and Ir-10 showed
the highest level of apoptosis measured in viable cells, followed closely by Os-3. Com-
pounds Os-4, Ir-9 and CDDP all showed minimal apoptosis, due mainly to the large cell
count remaining after exposure. This highlights them as primarily cytostatic agents, with
Os-1, Os-3 and Ir-10 showing measurable cytotoxic behaviour in A2780.
The level of apoptosis was also measured at concentrations more relevant to the GI50
values of each compound in A2780 cells (Table 7.2).
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Table 7.2: Percentage of cells in apoptosis after exposure to compounds Os-1, Os-3, Os-4, Ir-9,
Ir-10 and CDDP at ca. GI50 µM for 48 h, ± SD. % of cells in apoptosis was calculated by
dividing the number of cells with NucView fluorescence by the total number of cells (with DAPI
fluorescence). This calculation was performed for compound-exposed samples and for control-
exposed samples. The Ratio describes the number of apoptotic cells in compound-exposed samples
compared to control-samples. When A2780 cells are exposed to Os-1, Os-3 and Ir-10, at its GI50
concentration there is poor activation of apoptosis compared to exposure at 2.5 µM, suggesting that
these compounds have concentration-dependent mechanisms of action. In comparison, exposure
to Os-4, Ir-9 and CDDP at GI50 concentrations showed little difference in apoptosis activation
compared to exposure at higher doses. This suggests that apoptosis is not concentration-dependent
for these compound.
Complex Conc. % Cells in apoptosis % Cells in apoptosis Ratio⇤⇤
µM (compound)⇤ (control)⇤
Os-1 0.16 1.48 ± 6.7 0.78 ± 3.7 1.9
Os-3 0.32 2.93 ± 19.3 1.22 ± 4.6 2.4
Os-4 0.63 0.80 ± 2.5 0.49 ± 2.4 1.6
Ir-9 0.63 0.73 ± 4.7 0.77 ± 2.9 1.0
Ir-10 0.32 0.60 ± 2.6 0.27 ± 1.6 2.2
CDDP 1 1.58 ± 12.2 0.96 ± 3.5 1.7
⇤calculated as [ apoptotic cell countviable cell count ]
⇤⇤calculated as [% apoptosis compound exposed% apoptosis control ]
After testing at approximately the GI50 concentrations for each compound, Table 7.2
shows a low level of apoptosis after exposure to all compounds, although Os-1, Os-3 and
Ir-10 still show the highest levels.
7.2.2 Transmission electron microscopy for compound Ir-6
Bright field TEM was used to study the morphological changes associated with exposure
of A2780 cells to Ir-6 ([Ir(h5-Cpxbiph)(phen)Cl]+) at 1 µM (approx GI50) and 5 µM (6.9
times GI50) for 24 h. Cells were fixed, and stained with uranyl acetate and lead citrate
before embedding, sectioning and imaging. A total of 48 control images were taken, with
those presented in Figure 7.6 as representative subsets. Figure 7.6 shows TEM images
of the negative control samples.
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Figure 7.6: A2780 control TEM images. Images show typical heterochromatin (H) and euchro-
matin (E) distributions in panel D, mitochondria (M, yellow) in panels A and E, nuclear pores (NP,
purple) in panel A, cell membrane (CM, green) in panel B and rough endoplasmic reticulum (ER,
red) in panel C.
Figure 7.6 highlights the nucleus (Nu), abundant mitochondria (yellow, M) granular en-
doplasmic reticulum (red, ER), nuclear membrane with nuclear pores (purple, NP) and the
cell membrane (green, CM). Also shown, is the heterochromatin (H) and euchromatin (E)
of the nucleolus. Figure 7.7 shows TEM images of samples exposed to 1 µM Ir-6. A total
of twenty-three images were taken, where images in Figure 7.7 are a representative subset.
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Figure 7.7: TEM images of A2780 cells after exposure to 1 µM Ir-6 for 24 h. Images show
the nucleus (Nu), damaged mitochondria (yellow) in panels A, C and E and cell membrane
blebbing (green) in panels B, D and E. Panel A also shows small nuclear vacuoles (blue). These
structural changes are indicative of mitochondria damage and cell death.
Figure 7.7 highlights several changes associated with exposure to Ir-6. Highlighted in
green is the cell membrane, which is shown to bleb and break apart into possible apoptotic
bodies (7.7B and D). However, the cells appear to swell in comparison to those shown
in the control, where apoptosis is associated with cell shrinkage. Instead this could be
a sign of oncosis/necrosis, with the merging of apoptotic bodies as the cell swells.
Also shown, in yellow, are deformed mitochondria which no longer maintain their char-
acteristic structure shown in Figure 7.6 (7.7A, C and E). Instead the mitochondria appear
as vacuoles in the cytoplasm, although their double-layer membrane can still be identified.
Figure 7.8 shows TEM images of samples exposed to 5 µM Ir-6. A total of fifty-one
images were taken, where the images in Figure 7.8 are a representative subset.
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Figure 7.8: TEM images of A2780 cells after exposure to 5 µM Ir-6 for 24 h. Images
show abnormal chromatin distributions (blue) and further mitochondria damage (yellow). These
structural changes show that breakdown of the mitochondria is more significant at higher compound
concentrations, and that higher doses of Ir-6 also induce small vacuole formation around the
nuclear membrane.
Figure 7.8 shows some signs of apoptosis with fragmentation of DNA in the nucleolus,
however, there also appears to be a loss in membrane integrity, particularly in Figure 7.8B
which could be indicative of late necrosis.
Importantly, Figure 7.8 also highlights abnormal mitochondria (Figure 7.8B), although
after exposure to a higher dose of Ir-6, the double membrane is no longer identifiable,
instead the mitochondria are completely devoid of inner structure. Shown in blue are
bubble-like structures both surrounding the nucleolus and localised to the nuclear mem-
brane. The structure of the nucleolus has also changed, becoming condensed, delineated
masses localised on the nuclear membrane.
Figure 7.9 shows zoomed images of the mitochondria in samples exposed to 1 µM Ir-6.
The cristae of the mitochondria are visibly detached (yellow circle), leading to complete
mitochondrial breakdown.
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Figure 7.9: TEM images of A2780 mitochondria after exposure to 1 µM Ir-6 for 24 h.
Circled area highlights a mitochondrion where the cristae are still partially structured. The
remaining mitochondria are significantly damage by the mechanisms of Ir-6, losing both inner and
outer membrane integrity.
To further investigate the effects of Ir-6 on the mitochondria, the polarisation of the
mitochondrial membrane was measured using flow cytometry. Here the fluorescence
on a cationic and lipophillic dye, JC-10 is measured. Ordinarily the JC-10 protein will
aggregate inside the mitochondria and emits red fluorescence. Upon mitochondrial
membrane polarisation, this aggregation is reduced, together with the red light emission.
The fluorescence of JC-10 was measured after 4 and 24 h exposure to Ir-6 at 1 and 0.24 (1/3
GI50) µM, against a positive control, carbonyl cyanide m-chlorophenylhydrazone (5 µM).
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Anaerobic glycolysis plays a signiﬁcant role in the metabolism
of cancer cells; this adaptation allows them to survive under
hypoxic conditions.45 The membrane potential of the
mitochondria in cancer cells is higher (more negative), which
can allow accumulation of cationic lipophilic compounds down
an electrochemical gradient.45,51 Complex 1, which appeared to
have an eﬀect on mitochondria by TEM, has a Log P value of
1.11 ± 0.17, making it hydrophobic, and therefore could be
readily taken up by mitochondria, an example of passive drug
delivery.12
We investigated the integrity of the mitochondrial membrane
by measuring the membrane potential by observing the
ﬂuorescence of JC-10, a cationic and lipophilic dye, using
ﬂow cytometry. In normal mitochondria, JC-10 aggregates and
emits red ﬂuorescence; however, upon mitochondrial mem-
brane polarization, aggregation of JC-10 reduces, together with
red emission. The level of membrane polarization after cells
were exposed to complex 1 for 4 and 24 h (Figure 5) is
approximately midway between the negative and positive
controls. The p-values of each treatment relative to the control
are all signiﬁcant at 5% after a Welch t test.
The proposed eﬀect on the mitochondria could in turn cause
ATP depletion and increased permeability of the outer
membrane, allowing transfer of pro-apoptotic proteins and
the activation of intrinsic apoptosis cascades. This release of
proteins is sometimes accompanied by membrane rupturing, as
shown in Figure 4E (labeled V).50
Inducing Apoptosis. Apoptosis is the process by which
cells die in a programmed fashion, as a result of particular
stimuli. The initiation of apoptosis by pro-apoptotic stimuli is
followed by an eﬀector phase where the machinery required for
cell death is activated.52 After this, the cell enters into the
degradation phase, at which point apoptosis becomes visible.53
There are a plethora of routes by which anticancer agents or
radiotherapy can activate apoptosis, normally characterized by
activation of intrinsic or extrinsic pathways. Caspase enzymes
(cysteine proteases) are eﬀector molecules activated during
either extrinsic (receptor) or intrinsic (mitochondrial) path-
ways.54 Caspases further activate each other through cleavage
next to aspartate residues, amplifying caspase activity down a
Figure 4. Detection of apoptosis in A2780 ovarian cancer cells after treatment with 1. (A−D) Control cells showing typical heterochromatin (H)
and euchromatin (E) distributions, mitochondria (M), nuclear pores (NP), and rough endoplasmic reticulum (ER). (E−H) Cells exposed to 1 μM 1
for 24 h, showing swollen mitochondria (V), nuclear vacuoles (NV), and membrane blebbing (B). (I−L) Cells exposed to 5 μM 1 for 24 h, showing
abnormal chromatin distributions and further vacuole formations.
Figure 5. Bar graph showing the mitochondrial membrane polar-
ization, determined by a reduction in red (FL2) ﬂuorescence, by
complexes 1−4 against that of a negative and positive control (5 μM
carbonyl cyanide m-chlorophenylhydrazone). p-values were calculated
after a Welch t test with the negative control data. Each value is the
mean taken from 3 replicates, with error bars for the standard
deviation.
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Figure 7.10: Bar graph showing mitochondrial membrane polarisation after cells were
exposed to Ir-6 at 0.24 µM ( 13GI50) and 1 µM (ca. GI50), for 4 and 24 h. This assay uses a
positively charged fluorescent probe (JC-10), which aggregates in the mitochondria and fluoresces
red. Upon mitochondrial membrane polarisation, the aggregation of the probe decreases, and
the red fluorescence drops. Therefore ol risat on is determined by a re uction in red (FL2)
fluorescence. p values were calculated after a Welch t-test against the negative control. Results
show that mitochondrial membrane polarisation is activated after just 4 h exposure, at either
concentration of Ir-6.
Figure 7.10 shows that the mitochondria of A2780 cells are polarised by Ir-6 after just
4 h, eve with a lower dose (p = 0.006, Welch paired t-test), compared to the negative
control. After 24 h, there was a slight increase in membrane polarisation after 0.24 µM
exposure (p = 0.03). This result further confirms the effects of Ir-6 on the mitochondria,
whether directly or indirectly.
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7.3 Discussion
7.3.1 Cell death mechanisms
Apoptosis is the most common type of chemotherapy-induced cancer cell death, and
can be determined using a range of techniques.11, 12 The later phases of apoptosis are
morphologically identifiable by microscopy.13
Using high-content screening (HCS) to detect levels of caspase-3, Chapter 7 explored
the effector-phase of apoptosis. The morphological aspects of apoptosis were also studied,
in cells exposed to Ir-6, using transmission electron microscopy (TEM). Previous chapters
suggested little or no apoptosis was activated by these compounds at low doses, with
NCI-60 screening results showing a primarily cytostatic behaviour, therefore imaging
assays were performed at higher doses to see if cell death was concentration-dependent.
High-content screening proved to be a poor method for accurately quantifying apoptosis,
with non-reproducible triplicate results. However, it was possible to extract compound-
based trends and make predictions about the level of apoptosis at higher concentrations,
where there was a significant increase in apoptotic cells at higher concentrations. For
Os-3, this has been shown in a previous study in A549 lung cancer cells.14
The onset of apoptosis is often characterised by condensation of nuclear chromatin,
into delineated masses that localise on the nuclear membrane.11, 15 This behaviour was
shown in cells exposed to Ir-6 at both doses, although more evident at the higher dose.
Such nuclear destabilisation is a result of enzymes called caspase-activated DNase (CAD)
enzymes, which cleave DNA.16 Also shown after exposure to Ir-6 were small nuclear
vacuoles, sometimes localised to the nuclear membrane. These could be an artefact of
abnormal chromatic packaging as a result of CAD activity.16
The membrane of cells exposed to Ir-6 also showed signs that cells were undergoing
apoptosis, forming extensions termed ‘budding’, which would ultimately form ‘apoptotic
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bodies’.11, 15 However, the cells appeared to grow in size, and the apoptotic bodies were
quite large in some of the images. This could point towards a more necrotic form of cell
death. In addition, organelles inside the cell would remain intact until apoptotic bodies
were phagocytosed or degraded by secondary necrosis; however, TEM showed that the
mitochondria were not staying intact.17 It is possible that mitochondrial damage occurred,
which prevented the maintenance of this organelle.
TEM images show signs of apoptosis after exposure to Ir-6, however, this was not
supported by flow cytometry. There are alternative routes to cell death, namely oncosis,
pyropotosis and autophagy. In fact oncosis can be characterised by vacuolisation of the
cytoplasm; it is possible that at higher concentrations of Ir-6, the large vacuoles assumed
to be mitochondria, were in fact signs of oncosis. Both these routes to cell death are
linked to the release of cytokines from the cell, something not demonstrated for Ir-6, but
proposed for both Os-3 and Ir-10.
The TEM images therefore suggest a mix of cell death mechanisms for Ir-6, with
some pictures highlighting apoptotic cell death and some highlighting oncotic cell death.
Similarly, at lower concentrations, there were only a small number of cells in the effector-
phase of apoptosis, yet there had been a drastic decrease in cell count for Os-1, Os-3
and Ir-10, suggesting cells had died via different mechanisms. Assuming a link between
Ir-6, Os-3 and Ir-10 this could explain why a low level of apoptosis was measured by
flow cytometry, yet necrotic cells were counted. Collectively these compounds could be
inducing apoptosis and necrotic-type cell death. As suggested in Chapter 5, performing
these experiments more frequently between 4 and 48 h could help answer these questions,
as could performing TEM analysis on cells exposed to Os-3 and Ir-10.
7.3.2 Mitochondrial targeting by Ir-6
Swelling of the mitochondria, which could distort the visualisation of organelle structure
by TEM, is associated with calcium imbalance inside cells, caused by drug-induced
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oxidative stress.18–20 A prominent consequence of exposure to Ir-6 was swelling of, and
damage to, the mitochondria, evident by both TEM and flow cytometry. Assuming similar-
ity between Ir-6 andOs-3, which was demonstrated in the NCI-60 screen, transcriptomics
of cells exposed to Os-3 also showed a significant effect relating to the mitochondria. The
mitochondrial membrane becomes polarised during apoptosis; however, given the low
detection of apoptosis, it is likely that the significant membrane polarisation shown for
Ir-6 and for Os-3 is due to mitochondrial targeting.14
As discussed in Chapter 4, there is significant interest in mitochondrial-targetting of
anticancer agents which are able to exploit the differences in metabolism between normal
and cancerous cells. In addition, A2780 human ovarian cancer cells are inherently mutated
cancer cells, making them significantly more susceptible to attack and to damage by
ROS production. A recent study by Maillet et al provided evidence for an osmium-based
anticancer agent able to trigger the production of ROS through mitochondrial targeting.21
This was a detailed comprehensive study, however the osmium compound used had a
GI50 value between 50 and 75 µM. Os-3 appears to achieve a similar MOA with a
submicromolar GI50 value.
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7.4 Summary and Conclusions
Imaging has proven a useful tool to visualise those findings proposed by the other methods
used in previous chapters. Future work will collect TEM data for cells exposed to bothOs-
3 and Ir-10. Cell death appears to increase with increasing concentration of compounds,
however, the number of apoptotic cells identified with green fluorescence did not correlate
with the reduction in total cell count. This suggests that apoptosis may account for some
cell death, but it is possible that another mechanism of cell death is responsible for the
remaining cell count reduction. This was demonstrated here for compound Ir-6. Modes
like oncosis and pyroptosis are associated with cytokine release and immune response
activation, so it is possible that these also play a role in compound response. The best
way to investigate this would be to do an extensive TEM imaging study, backed up my
flow cytometry/RPPA, across multiple time points between 4 and 48 h exposure.
A previous study has shown that cells can activate apoptosis, but switch to necrotic-type
cell death if caspase-inhibitors are unregulated.22 RNAseq and RPPA showed the initiation
of apoptosis with components like BCL-2 and BAD, but showed inhibitor of apoptosis
(IAP) proteins were highly up-regulated thus preventing caspase cascade activation. The
study by Vercammen et al showed that when apoptosis was blocked, cells entered into a
necrotic-type cell death involving ROS production. The activation of an immune response
shown toOs-3 and Ir-10 supports a necrotic-type cell death, which activates the production
of cytokines. The ROS production has also been heavily supported for Os-3, with flow
cytometry experiments and RNAseq pathway analysis, and has been proposed for Ir-10.
This is a novel mode of activity for an anticancer compound, and would make for an
exciting treatment program for cancers with inherently resistant apoptotic components,
with ROS production causing irreversible damage to the cell.
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Chapter 8. Concluding Remarks
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The aim of this thesis has been to gain insights into the anticancer activity of organo-
metallic compounds developed at The University of Warwick . Previous reports highlighted
the promising characteristics of these compounds in trying to tackle the limitations with
current metal-based anticancer agents used in the clinic. Namely, drug resistance and
toxicity. Two important areas were explored in this thesis, firstly using cancer cell screens
to identify whether there was a particular cancer subtype to which these compounds were
most potent. The second, was to explore the mechanisms of activity of lead compounds.
8.1 Summary of results
The screening results presented a good level of selectivity, highlighting a selection of cell
lines to which these compounds were particularly potent. Although these in vitro screens
are far from conclusive with regards to patient selection, they have highlighted areas of
importance going forward for in vitro work.
The mechanistic insights were gained by combining results from multiple techniques,
aiming to study the cellular response of ovarian cancer cells to lead compounds Os-3
([Os(h6-p-cym)(NMe2-azpy)I]+] and Ir-10 ([Ir(h5-Cpxph)(NMe2-azpy)Cl]+). Figure 8.1
summarises some of the proposed mechanisms of anticancer activity based on these results.
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Figure 8.1: Schematic summarising the proposed mechanisms of action of compounds
studied in this work. DNA image was adapted from psdgraphics.com.
Previous work has confirmed the presence of excessive ROS in response to Os-3, and
although this is yet to be confirmed for Ir-10, a previous report has highlighted ROS
production in cells responding to Ir-9 ([Ir(h5-Cpxbiph)(ppy)Cl]). The mechanism for
inducing oxidative stress is yet to be determined, and has been suggested to occur through
mitochondrial targeting and/or through stress response pathways.
If ROS production is mediated by the mitochondria then the proposed mechanism
of action could provide a highly selective anticancer agent, exerting less of an effect in
normal cells with functional mitochondria. This has been demonstrated previously for
Os-3, which is much more potent in normal fast dividing fibroblasts. However, as more
conclusive measure of toxicity this assay also needs to be repeated in normal cells that
are not undergoing fast division.
The immune response activation may also contribute to mitochondrial ROS production,
however, the dangers of activating this cellular mechanism needs to be established.1 This
can be strongly linked to increased tumorigenesis, and metastasis, which is one of the
biggest clinical problems with chemotherapy treatment. Therefore future work should
assess the metastatic behaviour of cells exposed to Os-3 and Ir-10 and conclude whether
co-administration with an immune inhibitor is required.
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The production of ROS can be highly damaging to cells, here, DNA damage in partic-
ular has been proposed, however proteins are also a viable target. At low concentrations,
the oxidative stress and DNA damage caused by these compounds results in cell cycle
arrest, but does not lead to cell death. Interestingly, increasing the concentration of these
compounds may increase their cytotoxic activity. This was particularly evident in response
to Ir-6 ([Ir(h5-Cpxbiph)(phen)Cl]+), showing signs of apoptosis and necrosis. Therefore,
these compounds could make viable cytostatic agents, particularly in cases of platinum
resistance, to aid in tumour size control and management. At higher concentrations these
agents could then provide more of a cytotoxic activity, arresting cell growth and destroying
tumour cells. This could have applications both pre- and post-surgery.
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8.2 Significance
8.2.1 Methods
Cancer cell screening can provide a wealth of information for cancer researchers, both
on selectivity and mechanisms of action. However, there are several pitfalls which should
be considered, and database screening should always be experimentally validated. One
of the biggest problems, particularly in combining information from multiple screens,
is the different methodology used by different institutes. For example the NCI and the
Sanger Institute use different exposure period, and use different methods to measure
antiprofilerative activity. Therefore, insights gained in using these screens should always
be followed with in-house assays using uniform experimental conditions. Here, screening
is used to select out two lead compounds and to make generalised selectivity predictions.
Database correlations for the selected leads were then explored experimentally.
Methods like RNA sequencing are rarely used in drug development to study a new
mechanism of action, instead sequencing is used together with prior knowledge i.e. to study
a specific pathway or process of interest. Care was taken when sequencing ovarian cancer
cells, to account for any copy number variations, which could swamp sequence reads.
This thesis used RNA sequencing with little prior knowledge of what could be found and
was therefore performed with sufficiently high-coverage, with paired-end reads, in efforts
to capture as much information as possible. By using sequencing in place of microarrays,
alternative splicing could be investigated in future work, using the existing sequencing files.
Using systems biology methodology, and combining sequencing with other state-of-the-
art techniques has allowed detailed insights to be obtained. Zeptosens protein microarrays
are the gold standard in this field, and offer unparalleled sensitivity. This has been par-
ticularly useful here, by detecting small changes in protein levels. RPPA, like sequencing,
is an expensive method and using both techniques in this thesis has not created a sustain-
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able workflow. However, studying the gene expression has provided useful information,
therefore methods like DNA microarrays may make better alternatives for future work.
Modelling both the sequencing and proteomics data provided quantitative insights
at both the transcriptional and translational response levels. To optimise the use of the
MDI modelling software, the number of proteins included in the analysis needs to be
increased to allow a better assessment of functional ontology in clusters. However, this
study highlighted the potential of this software, identifying extensive co-regulation of
proteins involved in DNA damage and cell cycle arrest. As biological methods seek to
collect more and more data, software like MDI will be invaluable for informative data
analysis, and has already shown promising clinical applications.2
Of the imaging techniques, the transmission electron microscopy results were highly
fruitful. This is a relatively inexpensive method, and provided great detail highlighting
mitochondrial damage and cell death. This should therefore remain a prominent part of
future work with these organometallic compounds. Additions to this technique, perhaps
using dark field electron microscopy, may also provide interesting results about metal
distribution. As could the imaging mass spectrometry (IMS) technique nanoSIMS. Al-
though for both these techniques, the level of osmium/iridium would have to be greatly
increased to allow detection of metal accumulation.
Collectively, this thesis has demonstrated the merits of measuring gene expression, pro-
tein abundance and cell structure in investigating the mechanisms of action of anticancer
agents. Identifying up- and down-stream drug effects and creating a timeline of activity.
The information generated in this work can be used for more detailed in vitro mechanistic
work, focussing on specific areas of the cell.
8.2.2 Results
The aim of this work was not to identify a biological target, but instead to assess cellular
response. This captures not only mechanistic insights, but also toxicity and selectivity-
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focussed results. Simultaneously looking at all of these factors should better predict in
vivo behaviour. The work presented here is of great interest to the metallo-chemistry com-
munity, showing that complex biological techniques have use in early drug development,
and can help shape synthesis early on. The work published on NCI-screening demonstrated
how useful this resource can be in drug development, and how much much more inform-
ation can be gained, outside of selectivity. Measuring gene and protein profiles is not a
new concept in cancer research, however, it is rarely used so early in drug development,
and like screening data, can be used in future to help inform chemical synthesis.
Clinically, the significance of these findings are hard to predict. Certainly the most
important aspect of cancer treatment is patient selection, identifying treatments to exploit
cancer cell characteristics. This can be achieved without knowing the biological target.
For example, from the results presented here, it is possible to postulate that patients with
cancers lacking NRF-2 , or ROS-scavenger machinery, may be well selected for these
organometallic compounds. Although not conclusive, this trait was demonstrated in vitro
in MDA-MB-468, which has GSH deficiencies and was the most sensitive cell line in
the NCI-60 screen. Given the detected DNA damage, patients with DNA damage repair
deficiencies may also be well suited for this treatment. These insights could also help
select drug cocktails. For example co-administering the organometallic compounds with
L-BSO, which depletes cellular levels of the ROS-scavenger GSH, greatly increases the
effect on cancer cells. Future work may explore other combination treatments linked to
oxidative damage and DNA damage mechanisms.
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9.1 Supporting information for Chapter 3
Table 9.1: Table showing the genes contained within amplified regions R184 and R198
R184 R198
CHMP4C ADCY8
FABP4, FABP5, FABP9, FABP12 ASAP1
HEY1 FAM498
IL7 GSDMC
IMPA1
MRPS28
PAG1
PKIA
PMP2
SLC10A5
SNX16
STMN2
TPD52
ZBTB10
ZC2HC1A
ZFAND1
ZNF104
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9.2 Supporting information for Chapter 4
9.2.1 Experiment I sample quality checks
Table 9.2: Summary statistics for each sample. Showing total reads, mapping and quality scores
Sample Sample A260/230 A260/280 RIN
number name
1 0 h control 2.28 1.95 10
2 0 h control 2.01 1.96 10
3 0 h control 2.25 1.94 10
4 0 h control 1.62 2.00 10
5 0 h control 2.22 1.94 10
6 0 h control 1.88 2.00 10
7 4 h control 2.22 1.93 10
8 4 h control 2.27 1.91 10
9 4 h control 2.30 1.92 10
10 4 h 3 2.29 1.94 10
11 4 h 3 2.24 1.94 10
12 4 h 3 2.29 1.93 10
13 12 h control 2.24 1.94 10
14 12 h control 2.20 1.93 10
15 12 h control 2.28 2.00 10
16 12 h 3 2.17 1.92 10
17 12 h 3 2.13 1.94 10
18 12 h 3 2.09 1.95 10
19 24 h control 2.22 2.02 10
20 24 h control 2.25 2.01 10
21 24 h control 2.21 2.01 10
22 24 h 3 1.97 2.00 10
23 24 h 3 1.96 2.00 10
24 24 h 3 2.08 1.99 10
25 48 h control 2.19 1.95 10
26 48 h control 2.20 1.96 10
27 48 h control 2.19 1.95 10
28 48 h 3 2.18 1.95 10
29 48 h 3 2.25 1.96 10
30 48 h 3 2.03 1.99 10
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9.2.2 Experiment II
9.2.2.1 Sequence summary stats
Table 9.3: Summary statistics for each lane. Showing yields, mapping and quality scores
Lane⇤ Yield (Mb Q20) % Mapped Mean quality
reads score
1 20,999 98.1 34.4
2 18,291 97.9 35.6
3 19,081 98.5 35.3
4 16,367 98.3 36.5
5 16,860 98.3 36.4
⇤6 samples per lane
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9.2.2.2 Sample quality checks
Table 9.4: Summary statistics for each sample. Showing total reads, mapping and quality scores
Sample Sample A260/230 A260/280 RIN
number name
1 0 h control 2.28 1.95 10
2 0 h control 2.01 1.96 10
3 0 h control 2.25 1.94 10
4 0 h control 1.62 2.00 10
5 0 h control 2.22 1.94 10
6 0 h control 1.88 2.00 10
7 4 h control 2.22 1.93 10
8 4 h control 2.27 1.91 10
9 4 h control 2.30 1.92 10
10 4 h 3 2.29 1.94 10
11 4 h 3 2.24 1.94 10
12 4 h 3 2.29 1.93 10
13 12 h control 2.24 1.94 10
14 12 h control 2.20 1.93 10
15 12 h control 2.28 2.00 10
16 12 h 3 2.17 1.92 10
17 12 h 3 2.13 1.94 10
18 12 h 3 2.09 1.95 10
19 24 h control 2.22 2.02 10
20 24 h control 2.25 2.01 10
21 24 h control 2.21 2.01 10
22 24 h 3 1.97 2.00 10
23 24 h 3 1.96 2.00 10
24 24 h 3 2.08 1.99 10
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9.2.2.3 Summary stats
Table 9.5: Summary statistics for each sample. Showing total reads, mapping and quality scores
Sample Sample Total reads %Mapped Mean quality
number name reads score
1 0 h control 58,453,334 98.53 36.5
2 0 h control 52,958,428 98.32 36.4
3 0 h control 52,411,032 98.11 36.5
4 0 h control 57,489,392 98.72 36.5
5 0 h control 53,112,138 97.75 36.5
6 0 h control 54,962,488 98.12 36.4
7 4 h control 82,071,522 98.19 34.4
8 4 h control 84,555,686 98.11 34.4
9 4 h control 73,333,434 97.93 34.4
10 4 h 3 69,130,568 97.87 34.4
11 4 h 3 59,742,704 97.99 34.5
12 4 h 3 72,018,526 98.38 34.4
13 12 h control 50,690,134 97.87 36.4
14 12 h control 55,041,730 99.25 36.4
15 12 h control 60,723,390 97.88 36.4
16 12 h 3 58,813,794 98.12 36.4
17 12 h 3 57,945,078 98.82 36.4
18 12 h 3 56,092,354 97.97 36.4
19 24 h control 60,331,926 98.14 35.6
20 24 h control 67,939,036 98.93 35.0
21 24 h control 59,240,982 98.09 35.6
22 24 h 3 64,300,818 95.65 35.5
23 24 h 3 61,522,272 98.48 35.6
24 24 h 3 61,343,334 98.18 35.5
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Table 9.6: Summary statistics for each sample. Showing total reads, mapping and quality scores
Time point Sample Total reads %Mapped Mean quality
(h) name reads score
1 0 h control 58,453,334 98.53 36.5
2 0 h control 52,958,428 98.32 36.4
3 0 h control 52,411,032 98.11 36.5
4 0 h control 57,489,392 98.72 36.5
5 0 h control 53,112,138 97.75 36.5
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9.3 Supporting information for Chapter 5
Table 9.7: RPPA protein details
Protein Protein Gene
label
AKT AKT AKT1
ATM ATM ATM
ATM* ATM/ATR Substrate P Ser/Thr ATM
Aur*** Aurora A/B/C P Thr288/Thr232/Thr198 AURK
b-actin beta-actin ACTB
b-catenin beta-catenin CTNNB1
B-Tub beta-tubulin TUBB
BAD* Bad P Ser112 BAD
BAD(*) Bad P Ser136 BAD
BAK BAK BAK1
BAX BAX BAX
BCL-2 BCL-2 BCL2
BCL-2* BCL-2 P Ser 70 BCL2
BCL-X BCL-X BCL2L1
BID BID BID
BIM BIM BCL2L11
BRCA1 BRCA1 BRCA1
CASP3 Caspase 3 CASP3
CASP3* Caspase 3 cleaved CASP3
CDC25A CDC25A CDC25A
CDC25C* CDC25C P Ser216 CDC25C
CDK1 CDC2 CDK1
CDK1* CDK1(p34cdc2) P Tyr15 CDK1
CDK2 CDK2 CDK2
CHK2* CHK2 P Thr68 CHEK2
Cyc D1 CycD CCND1
Cyc D1* Cyc D CCND1
E-cadherin E-cadherin CDH1
FLT3* FLT3 P Tyr591 P Tyr591 FLT3
IKK* IKK alpha P Ser32 IKK
JAK1 JAK1 JAK1
JAK1* JAK1 P Tyr1022, Thr1023 JAK1
MEK1/2 MEK1/2 MAP2K1
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Table 9.8: RPPA protein details
Protein Protein Gene
label
MET MET MET
MTOR MTOR MTOR
MYC C-MYC MYC
p21 p21 CIP/WAF1 CDKN1A
p21* CIP/WAF1 p Thr145 CDKN1A
p53 p53 TP53
p53* p53 P Ser15 TP53
PARP PARP PARP1
PARP* PARP cleaved PARP1
PDK1 PDK1 PDK1
PLC-gamma1 PLC-gamma1 PLCG1
PKC-alpha PKC-alpha PRKCA
PTEN PTEN PTEN
PTEN* PTEN P Ser380, Thr382, Thr383 PTEN
FAK1 FAK1 PTK2
PUMA PUMA PUMA
RAP1 RAP1 RAP1A
RB RB RB
RB* RB P Ser780 RB
RB** RB P Ser807, Ser811 RB
p70 * p70 S6 kinase RPS6KB1
SRC SRC SRC
STAT1 STAT1 STAT1
STAT1* STAT1 P Tyr701 STAT1
STAT1(*) STAT1 P Ser727 STAT1
STAT3 STAT3 STAT3
STAT3* STAT3 P Tyr705 STAT3
STAT5 STAT5 STAT5
STAT5* STAT5 P Tyr694 STAT5
STAT6 STAT6 STAT6
STAT6* STAT6 P Tyr641 STAT6
LKB1 LKB1 STK11
Survivin Survivin BIRC5
TYK2* TYK2 P Tyr1054, Tyr1055 TYK2
XIAP XIAP XIAP
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List of Figures
1.1 Clinically used platinum(II) metallodrugs cisplatin, carboplatin and ox-
aliplatin. Cisplatin and Carboplatin are commonly used to treat ovarian
cancer, with oxaliplatin used to treat colorectal.15 . . . . . . . . . . . 5
1.2 Ruthenium anticancer drug NAMI-A currently in phase II clinical trials
to treat metastatic cancers.13 . . . . . . . . . . . . . . . . . . . . . . 6
1.3 Lead Osmium (Os) and Iridium (Ir) compounds synthesised in the Sadler
group by Dr Fu Ying and Dr Zhe Liu, respectively. Highlight in blue are
the various arena ligands chelated to Os compounds Os-1 - Os-5. All
Os compounds are chelated to N-N azopyridine (X=N) or iminopyrid-
ine (X=C) ligands, with varying R groups (R1 and R2) described in
the left-hand table. All Os compounds have a +1 charge. Highlighted
in orange are the various arena ligands chelated to Ir compounds Ir-6
- Ir-11. Highlighted in green are the varying N-N and C-N chelating
ligands (XY) for each Ir compound, as described in the right-hand table.
All Ir compounds have a +1 charge, except for Ir-9 which is neutral.20, 24–27 7
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1.4 Graph showing GI50 values (± standard deviation) for compounds Os-2,
Os-3 and Os-4 in different cell lines. Activity values were calculated
from triplicate measurements in colorectal cell lines (purple) and ovarian
cell lines (blue) and show that Os-2 and Os-3 hold their activity in
cisplatin-resistant A2780 cells (A2780cis), but only Os-2 maintains activ-
ity in oxaliplatin-resistant HCT116 (HCT116Ox). Os-4 is more active in
cisplatin-resistant A2780 and approximatively equipotent in oxaliplatin-
resistant HCT116. Interestingly,Os-4 is highly active in p53(-/-) HCT116
cells compared to wild-type HCT116.29, 31 . . . . . . . . . . . . . . . 10
3.1 Dose response curve. Green data points represent the effect of the drug
at varying concentrations. A sigmoid curve is fitted to these measure-
ments and predicts drug-responses outside of the tested range. The slope
parameter (b ) measures the steepness of the drug-response, where a
higher gradient represents a drug with a smaller therapeutic window, rep-
resenting the concentration of a drug required to elicit a desired response
against the concentration of drug required to elicit an adverse response.
A larger therapeutic window (small b ) is more clinically beneficial in
reducing side-effects. . . . . . . . . . . . . . . . . . . . . . . . . . . 48
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3.2 Tukey box-and-whisker plots showing the distribution of GI50 val-
ues for Os compounds Os-1 - Os-5 and Ir compounds Ir-6 - Ir-11,
cisplatin (CD) and oxaliplatin (OX) in the NCI-60 screen. Boxes
show the median and the first and third quarters. The whiskers represent
the highest/lowest values within 1.5 times the interquartile range (IQR),
calculated as the differences between the upper/lower quartiles. Open
circles represent outliers in the data, which fall outside 1.5x IQR. The
large number of outliers for Os-2 result from a majority of the data points
lying within a small range, and a smaller selection of cell lines showing
significantly higher/lower sensitivity. . . . . . . . . . . . . . . . . . . 53
3.3 Heat map of NCI-60 data for Os compounds Os-1 - Os-5 and Ir
compounds Ir-6 - Ir-11, cisplatin (CDDP) and oxaliplatin (OXA).
Dendrograms show clustering of data by compound (top) and cell lines
(side). CDDP and OXA data were taken from the most recent round
of NCI testing in March 2012, found in the DTP/NCI database. Figure
3.4 highlights the trends shown in this heat map, with separation of
compounds into a subsets of similarity {Os-1, Os-3, Os-2, Ir-6 - Ir-8
and Ir-11}. In addition, renal cell lines show significantly poor sensitivity
to all compounds, and MDA-MB-468 (breast) and COLO205 (colon) cell
lines showed significantly high sensitivity. . . . . . . . . . . . . . . . 55
3.4 Heat maps highlighting trends in NCI-60 data shown in Figure 3.3
for Os compounds Os-1 - Os-5 and Ir compounds Ir-6 - Ir-11, cis-
platin (CDDP) and oxaliplatin (OXA). (A) Compounds with similar
patterns of selectivity, (B) Compounds with novel selectivity patterns, (C)
Cell lines with higher sensitivity (MDA-MB-468 and COLO205) and (D)
Cell lines with low sensitivity (renal cell lines). . . . . . . . . . . . . 56
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3.5 Bi-plot of GI50 values for Os compounds 1 - 5 and Ir compounds
6 - 11. Data were plotted using principle component analysis (PCA),
which separates variables by euclidean distance, based on similarity. Cell
lines were plotted in black, with those closer together having similar
sensitivities to compounds. The resistant cell lines in the NCI-60 screen
are circled in blue, with the renal cell lines in one cluster and ovarian
cell line NCI-ADR-RES in the other. The remaining more sensitive cell
lines are clustered together. The compounds were plotted in red, with
their similarity in NCI-60 selectivity proportional to the vector angles
between pairs of compounds. . . . . . . . . . . . . . . . . . . . . . . 57
3.6 Similarity matrix showing the Pearson’s correlation coefficients (r)
between the compounds. Correlation coefficients were calculated from
the NCI-60 data, ranging from 0.4 to 0.9. The higher r values between
Os-1, Os-2, Os-3, Ir-6, Ir-7, Ir-8 and Ir-11 represent the subset of
compounds identified in Figures 3.3 and 3.4. The lower r values forOs-4,
Os-5, Ir-9 and Ir-10 highlight their more novel patterns of selectivity. 58
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3.7 COMPARE results for Os compounds Os-1 - Os-5 and Ir com-
pounds Ir-6 - Ir-11 showing NCI-60 patterns of similarity against other
compounds in the NCI/DTP compound database. Coloured bars shows
a summary of the top 100 positive correlations to each compound, in-
cluding only those with known mechanisms of action (MOA) and r >
0.5. Correlations were split into seven classes: oxidative stress inducers,
mitosis inhibitors, protein synthesis inhibitors, topoisomerase inhibitors.
DNA alkylating agents, DNA antimetabolites, DNA interacting agents.
Compounds Os-1, Os-2, Os-3, Ir-6, Ir-7, Ir-8 and Ir-11 all correlated
to the same classes of compound, primarily DNA interacting agents
and protein synthesis inhibitors. Os-5 correlates to different classes of
compounds, namely DNA alkylating agents and Os-4, Ir-9 and Ir-10
correlated to few compounds, highlighting their novelty. . . . . . . . 59
3.8 Heat maps representing Pearson’s correlation coefficients (r) for
comparisons of similarity between the GI50 values for compounds
Os-1 - Ir-11 and the expression of genes, in the NCI-60 cell lines (a)
Heat map showing genes which correlated to n> 2 compounds and (b)
Individual analysis showing the lack of correlation in the top 10 genes
returned for Os-4 and a higher level of correlation between GI50 and
expression of the top 10 genes returned for Ir-9. Microarray data were
taken from the DTP/NCI database. . . . . . . . . . . . . . . . . . . . 60
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3.9 Heat map showing the expression levels of genesMDH2, HNRPLL
and NUP188 in a selection of cell lines in the NCI-60 screen. Gene
expression values for each cell line were calculated by subtracting the
mean expression across the NCI-60 screen from the individual cell line
expression values. Positive values indicate high expression in a given cell
line with respect to the mean, negative values indicate low expression
compared to the mean expression in the screen. The cell lines will high
expression levels were cell lines with high sensitivity to the organometal-
lic compounds, cell lines with low expression levels were those which
showed poor sensitivity to the organometallic compounds. This suggests
a possible pharmacogenomic relationship for the mechanisms of action. 62
3.10 Tukey box-and-whisker plots showing the distribution of GI50 val-
ues of each compound in the Sanger screen, together with cisplatin
(CDDP). Boxes show the median and the first and third quarters. The
whiskers represent the highest/lowest values within 1.5x the interquart-
ile range (IQR), calculated as the differences between the upper/lower
quartiles. Open circles represent outliers in the data, which fall outside
1.5x IQR. The large number of outliers for Os-1 and Os-3 result from
a majority of the data points lying within a small range, and a smaller
selection of cell lines showing significantly higher/lower sensitivity. The
weighted outliers for Ir-10 suggest a small selection of cell lines show
significantly higher sensitivity. . . . . . . . . . . . . . . . . . . . . . 64
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3.11 Heat map of GI50 values for compounds Os compounds Os-1 and
Os-3 and Ir compounds Ir-9 and Ir-10 in 974 cell lines of the Sanger
screen. Visible clustering of low sensitivity are highlighted with grey
boxes showing resistance of gastrointestinal (GI) cancers to Ir-10 and
leukaemia and central nervous system (CNS) cancers to Os-1 and Os-3.
The dendrogram clusters the compounds by similarity and shows that Os-
1 andOs-3 share high similarity in the screen and thatOs-4 and Ir-9 share
similarity to each other, but significant differences to Os-1, Os-3 and Ir-10. 65
3.12 GI50 values in cancer subtype for compounds Os-3 (a) and Ir-10
(b) in the Sanger Institute screen. The mean values for each popu-
lation are shown with coloured lines, boxed sections highlight the key
differences in activity between the two compounds. These differences
are highlighted in the blood cancers, pancreatic, neuroblastoma, lung and
gastrointestinal. For example, neuroblastoma cell lines are significantly
more susceptible to Ir-10 than to Os-3 and blood cancers like leukemia
and lymphomas are more susceptible to Os-3. . . . . . . . . . . . . . 66
3.13 Plot showing the effect of genetic mutation on compound activity
for Os-3 and Ir-10. All grey dots represent wild-type cancer cells lines
not carrying mutations/amplifications of R184, HGF and KIT. Blue dots
represent cell lines carrying amplified R184 (a), green dots are HGF
mutated (mt) cell lines and pink dots are KIT mutated cell lines. Blocked
central lines are the mean values, with the upper and lower bars showing
the standard deviation. The plot shows that R184 amplifications (effect
size 0.93) and HGF mutations (effect size 1.70) both cause cell lines
to show resistance to Os-3, where as KIT mutated cell lines (effect size
0.83) are more sensitive to Ir-10. . . . . . . . . . . . . . . . . . . . . 69
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3.14 Plot showing the breakdown of pharmacogenomic responses into
cancer cell subtypes for R184 (a), HGF (b) and KIT (c). (a) show
the cell line sensitivities to Os-3, with the wild-type cell lines in grey
and the R184 amplified breast and lung cancer cell lines in blue, showing
that in both cancer subtypes this amplififed region increases resistance to
Os-3. (b) shows the sensitivity of HGF mutated lung and large intestine
cancers (green) and wild-type cancers (grey) to Os-3, again showing that
mutated cell lines showed lower susceptibility to Os-3. (c) shows the
sensitivity of KIT mutated lung cancers (pink) and wild-type cancers
(grey) to Ir-10, this time showing that mutated cell lines are ore sensitive
to the drug compound. . . . . . . . . . . . . . . . . . . . . . . . . . 70
4.1 Gel showing the RNA integrity for 0 h control samples 1 - 6. The
bands for each sample correspond to subunits of rRNA present in each
sample, and is a measure of RNA degradation as a result of the extraction
process. A high quality sample will have two main bands, one for 18S
and one for the 28S subunit, and sometimes for the 5.8S subunit. The
intensity of these peaks, and any other bands around these, are used to
calculate the RNA integrity number (RIN). For the 6 samples in this
Figure, all samples had RIN of 10/10. . . . . . . . . . . . . . . . . . 101
4.2 RNAseq experimental workflow showing RNA extraction, purific-
ation, library preparation and sequencing. Boxed area highlights the
work performed by Oxford Genomics Centre, with everything outside
of this box performed at the University of Warwick. . . . . . . . . . . 103
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4.3 cDNA fragment A, together with its complementary strand are lig-
ated with Y-shaped adapter sequences 1 (Ad 1) and 2 (Ad 2) at the
3’ and 5’ ends. Ad 1 and Ad 2 allow sequencing to be performed along
the forward and reverse strands, which is the fundamental benefit of using
paired-end sequencing, maintaining strand polarity. Figure 4.4 details
the use of these adapters. Image adapted from Parkhomchuk (2009) Nuc.
Acid Res. 37(18):e1235 . . . . . . . . . . . . . . . . . . . . . . . . . 104
4.4 Process of nucleotide reading during strand sequencing. Shown in
grey on the far left is a cDNA sequence (grey); attached either side are the
forward and reverse primers (beige and blue), adapters 1 and 2 (pink and
red) and sample-specific barcode (green). Figure 9.2.2.3 will detail se-
quencing of the reverse strand, utilising the barcode, reverse primer and ad-
apter 2. The first step exposes the strand to a pool of labelled nucleotides,
which complementarily bind using the read 1 sequence primer (Rd1SP),
and are read using lasers to excite fluorescent tags attached to each nucle-
otide. Once the signal is read, and the nucleotide identified, the tags and
blocker groups are removed, and the process repeated until 50 base pairs
have been read. Image adapted from an Illumina multiplexing worksheet6105
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4.5 Process of paired-end sequencing. Step 1 shows the forward strand
being sequenced, as shown in Figure 4.4, with step 2 showing the sequen-
cing of the barcode index (green) required for multiplexed samples. This
barcode is read using the index primer (IndSP), and assigns a particularly
set of sequencing reads to a specific sample. Between steps 2 and 3, a
complementary reverse strand is constructed so that in step 3 the reverse
strand is sequenced, now using the reverse strand read 2 primer (Rd2 SP).
Once 50 nucleotides have been read from both the forward and reverse
strands, the information is combined using sequencing analysis software.
Image adapted from an Illumina multiplexing worksheet6 . . . . . . . 106
4.6 Data analysis work flow chosen to analyse Experiments I and II.
Tophat and Bowtie were used for filtering out poor quality sequence
reads and for aligning reads to the human genome. HTSeq was used to
count the number of reads associated to each gene in the human genome.
And edgeR was used to explore differential gene expression between
drug-exposed and control samples. . . . . . . . . . . . . . . . . . . . 108
4.7 edgeR data analysis work flow. HTseq was used to count the number
of reads per gene, with edgeR filtering out those genes with low counts
or which did not provide ¿10 counts in all three triplicate samples. edgeR
then normalised the data using trimmed mean of M-values (TMM) which
scales each dataset so that genes with large read counts do not swamp
those with low. Finally edgeR allows exploration of differential gene
expression between treatment and control groups. . . . . . . . . . . . 110
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4.8 Ingenuity Pathway Analysis (IPA) data analysis work flow. IPA was
used to allocate highly- and lowly-differentially expressed genes into
biological pathways to allow interpretation of results. Networks of expres-
sion are gradually built up by IPA, by first forming nodes for key genes
and then gradually growing networks outwards from these genes. Each
pathway formed is associated with a hypergeometric probability for over-
representation and identifies the significance of a particular pathways in-
volvement in drug-response with respect to all other pathways in the dataset.112
4.9 Mapping of reads to individual chromosomes from Experiment I.
Heat map showing chromosomal mapping of sequence reads to the human
genome after normalisation to chromosome length and sample library size
(FPKM). Chromosomes are described in the centre of the heat map, from
1 - 22, X and M. The key on the left describes the sample order, starting
from the inner most circle (0 h control) to the outer most circle (48 h
compound-exposed), where each ring is a mean value from each triplicate
sample. Darker boxes indicate a large number of reads per length of
each chromosome. For all samples, control- and compound-exposed,
the mitochondrial chromosome (M) has the largest log10FPKM values,
suggesting a significant expression of mitochondrial genes both before
and after compound-exposure. . . . . . . . . . . . . . . . . . . . . . 117
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4.10 Graph showing total number of reads mapped to the ChrM.Graphs
show normalised reads for control- and compound-exposed samples
across each time series for Os-3 (left) and Ir-10 (right). The reads are
normalised to sample library size, with the grey line as the mean across
the triplicate values. * indicates p < 0.10 and ** indicates p < 0.05
after a Welch two sample t-test. In response to Os-3 there is a significant
increase in mitochondrial gene expression after 12 and 24 h. In contrast,
the response to Ir-10 is only significant after 12 h exposure. . . . . . . 118
4.11 Schematic of the components in the electron transport chain (ETC).
The grey coloured region is the inner mitochondrial membrane, with
the blue and purple structures as enzyme complex I (NADH dehydro-
genase), II (succinate dehydrogenase), III (coenzyme Q reductase), IV
(cytochrome C reductase) and V (ATPase) of the ETC. During oxidat-
ive phosphorylation, the last step in aerobic respiration, electrons are
transferred from complex I to complex IV utilising NADH, FADH2,
co-enzyme Q (Q) and cytochrome C (Cyt C) electron carriers. As these
electrons are transferred, protons are pumped across the inner membrane
to the outer membrane space by complexes I, III and IV. This creates
a proton-motive gradient which is used by complex IV to catalyse the
production of ATP from ADP and organic phosphate. A byproduct of
this process is water, through reaction of protons with molecular oxygen.119
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4.12 Amino acid sequence of protein MT-ND5. The MT-ND5 subunit sits
in the inner mitochondrial membrane and is responsible for pumping
protons across the membrane. Residues highlighted in blue are part of
transmembrane helices, with those in black found outside of the mem-
brane. The mutations identified in A2780 cells were highlighted in red:
p.I257V (isoleucine to valine substitution at the 257th residue), p.N447S
(asparagine to serine substitution) and p.L517P (leucine to proline sub-
stitution). The p.N447S and p.L517P substitutions would have the most
significant structural implications. . . . . . . . . . . . . . . . . . . . 121
4.13 Multidimensional scaling (MDS) plot for Experiment I. MDS al-
lows the similarity between variables to be assessed by plotting each
dataset in space, by euclidean distance. In these plots, samples which
are plotted close together share higher similarity. Both plots display the
same data, grouping samples 1-24 by similarity where samples 1-3 are
4 h controls, 4-6 are 4 h Os-3-exposed, 7-9 12 h control, 10-12 12 h
Os-3-exposed, 13-15 are 24 h controls, 16-18 are 24 h Os-3-exposed,
19-21 are 48 h controls and 22-24 are 48 h Os-3-exposed. The plot on the
left highlights grouping of samples into control (blue) and Os-3-exposed
(orange) demonstrating a drug-induced differential response at the gene
level. The right-hand plot shows grouping of samples across the time
series, with 4 h control and Os-3-exposed samples in blue, 12 h in green,
24 h in orange and 48 h in red. This second plot highlights how different
the 48 h datasets are, compared to earlier time points. . . . . . . . . . 122
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4.14 Multidimensional scaling (MDS) plot for Experiment I. MDS al-
lows the similarity between variables to be assessed by plotting each
dataset in space, by euclidean distance. In these plots, samples which
are plotted close together share higher similarity. Both plots display the
same data, grouping samples 7-30 by similarity where samples 7-9 are
4 h controls, 10-12 are 4 h Ir-10-exposed, 12-15 12 h control, 16-18 12
h Ir-10-exposed, 19-21 are 24 h controls, 22-24 are 24 h Ir-10-exposed,
25-27 are 48 h controls and 28-30 are 48 h Ir-10-exposed. The plot on the
left highlights grouping of samples into control (blue) and Ir-10-exposed
(orange) demonstrating a drug-induced differential response at the gene
level. The right-hand plot shows grouping of samples across the time
series, with 4 h control and Ir-10-exposed samples in blue, 12 h in green,
24 h in orange and 48 h in red. This second plot highlights how different
the 48 h datasets are, compared to earlier time points. . . . . . . . . . 123
4.15 Venn diagrams showing the number of differentially-expressed genes
at 4, 24 and 48 h after exposure to Os-3 (left) and Ir-10 (right). Only
those genes with -1.0 < LogFC > 1.0 and FDR < 0.05 were included.
The Venn diagrams show that cells exposed to Os-3 have the largest
gene response after 48 h, compared to those exposed to Ir-10 where
the largest response is after only 24 h. Overall there were 668 genes
differentially-expressed at these time points in response to Os-3 and 746
in response to Ir-10. . . . . . . . . . . . . . . . . . . . . . . . . . . . 124
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4.16 Venn diagrams showing the overlap in differential-expression between
Os-3 and Ir-10 at 4, 24 and 48 h. Only those genes with -1.0< LogFC
> 1.0 and FDR < 0.05 were included. After 4 and 24 h there were more
genes differentially expressed in response to Ir-10 (blue) compared to
Os-3 (green), with ⇡ 100 genes differentially expressed to both, and the
remainder showing compound-specific expression. At 48 h, there were
more genes differentially expressed toOs-3, with almost 200 genes differ-
entially expressed to both compounds, and the remainder compound-specific.125
4.17 Graphs showing the number of up- (red) and down-regulated (green)
genes at each time point. The results for Os-3 are shown in the left
graph, and for Ir-10 on the right. Only those genes with -1.0 < LogFC
> 1.0 and FDR < 0.05 were included. The graph on the left shows that
at 4 and 48 h there are more genes down-regulated (green) then up (red),
in contrast to 12 h, where there are more genes up-regulated in response
to Os-3. In response to Ir-10 there are significantly more down-regulated
genes after 12 h exposure, compared to 4, 24 and 48 h where the number
of genes up- and down-regulated was almost equal. . . . . . . . . . . 125
4.18 Diagram showing the main components in the NRF-2 and AP-1
transcription factor pathways during oxidative stress response. Upon
detection of oxidative stress, NRF2 dissociates its KEAP1/actin complex
and translocates from the cytosol to the nucleus. Using co-factors like
MAF, NRF2 binds to the human antioxidant regulatory element (hARE)
and transactivates the expression of various antioxidant genes. In addition
to this, two AP-1 transcription factor complexes (C-FOS/C-JUN and
FRA-1/C-JUN) also bind to the hARE cis-regulatory element and activate
different antioxidant genes. All three transcription factors bind compet-
itively to hARE depending on the type of antioxidant response activated.131
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4.19 Heat map of DEG in the oxidative stress response pathway across
the time series after exposure to Os-3 (left) and Ir-10 (right). Only
DEG with FDR < 0.10 are included, blank values lie outside of this signi-
ficance threshold. In response to Os-3, cells activate the NRF2 (NFE2L2)
and FRA-1(FOSL1)/C-JUN (JUN) complexes, with up-regulation of these
genes after just 4 hours, and maximum expression after 48 h. In contrast,
in response to Ir-10, cells activate the FOS (FOS)/C-JUN (JUN) and
FRA-1/C-JUN complex, with a particularly high up-regulation of FOS
after just 4 h exposure. Although NFE2L2 is up-regulated in response to
Ir-10, it’s co-factor MAF is significantly down-regulated, suggesting less
involvement of NRF2 compared to the AP-1 transcription factor complexes.132
4.20 Heat map showing the differential gene expression of elements in-
volved in mitochondrial function after exposure to Os-3. Only DEG
with FDR< 0.10 are included, blank values lie outside of this significance
threshold. In response to Os-3 there is a significantly higher level of
differential expression after 48 h, compared to earlier time points, so
nuclear-genes encoding mitochondrial proteins. There is a mixture of up-
and down-regulation, however, there is significant down-regulation of
genes coding for Complex I components, suggesting an impact in the elec-
tron transport chain (ETC). Up-regulation of genes like UCP2 and MAOA
occur when reactive oxygen species (ROS) are detected at the mitochon-
drial inner membrane, suggesting mitochodrially-driven oxidative stress.134
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4.21 Diagram showing the main components in the extrinsic and in-
trinsic apoptosis pathways. Intrinsic pathway activation is normally
associated with chemotherapy and UV damage, first triggering BAX
and BID, before activating cytochrome C release from the mitochondrial
and subsequent capsize activation. The extrinsic pathway is activated by
death ligands, which trigger caspase-8 activity through FADD. Inhibitor
of apoptosis (IAP) proteins can control the process of apoptosis at the
capsize level, for example XIAP inhibiting the caspase-3 and -9 activity.
Image taken from Legewie S, et al (2006) PLoS Comput. 2(9): e120 . 137
4.22 Heat map of DEG in the apoptosis pathway across the time series
after exposure to Os-3. Only DEG with FDR < 0.10 are included,
blank values lie outside of this significance threshold. Shown with high
levels of differential expression are non-apoptotic capsizes like CASP1
and CASP12, mostly associated with inflammatory responses. There
is some up-regulation of intrinsic apoptotic genes BID and BAX after
12 h exposure to Os-3, suggesting some apoptotic invitation. However,
down-regulation of apoptotic capsases like CASP3 and CASP9 suggest
apoptosis may only be initiated and not put into effect. Cell survival gene
BIRC3 which codes for survivin, an inhibitor of apoptosis (IAP) protein
shows significant up-regulation after just 4 h exposure, suggesting further
that caspase activity is not activated within 48 h exposure. . . . . . . . 138
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4.23 Heat map of DEG in the apoptosis pathways across the time series
after exposure to Ir-10. Only DEG with FDR < 0.10 are included,
blank values lie outside of this significance threshold. There are notice-
ably fewer genes with significant differential expression after cells were
exposed to Ir-10 compared toOs-3. However, there are similarities in the
up-regulation of apoptotic inhibitor BIRC3, and inflammatory caspases
like CASP5 and CASP1. The expression of apoptotic initiator genes like
BAX and BID were hardly affected by Ir-10, suggesting there may be
less initiation of apoptosis compared to that shown after Os-3-exposure. 139
4.24 Heatmap of DEG in the autophagy pathways across the time series
after exposure to Ir-10. Only DEG with FDR < 0.10 are included,
blank values lie outside of this significance threshold. Autophagy is an
important mechanism of cell death, often linked to inflammation. The heat
map shows minimal up-regulation of autophagy markers, the most com-
mon of which are BECN1 (beclin) and MAP1LC3B/A (LC3), in response
to both Os-3 and Ir-10 across the time series. This suggests that this
mechanism of cell death does not play an important role in drug-response.140
5.1 Figure summarising the experimental workflow for reverse phase
protein microarrays (RPPA). Once seeded cells were exposed to either
control- or drug-containing solutions across a 72 h time series. Cells were
then collected, and the soluble protein extracted. Protein lysates were
then immobilised onto microarray slides, and using antibody staining,
the levels of individual proteins were determined. All experimental work
was performed at the Edinburgh Cancer Research Centre, with the data
analysis performed by the author at University of Warwick. . . . . . . 160
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5.2 Schematic of the layout of a ZeptoCHIP. The top diagram shows 6
microarrays per ZeptoCHIP, with the experimental layout of each array
(middle) described. The 2 columns for each compound (Os-3 and Ir-10)
represent duplicate measurements, with the respective time series points
down the rows: 4, 24, 48 h and 72 h. The 0.1% DMSO control sample
(C) is run on the same array as each sample. Each protein lysate extracted
from each sample is serial diluted across 4 concentrations: 0.2, 0.15, 0.1
and 0.05 mg/mL. This allows a concentration gradient to be plotted for
fluorescence measurements of each protein. Either side of these dilutions
are reference controls, shown in red. These are used to correct for slide
variation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 162
5.3 Schematic showing the difference in excitation between standard
confocal excitation compared to that for RPPA. Each schematic
shows bound antibodies to a surface, with unbound fluorescently-labelled
antibodies floating above the surface. The top figure shows standard
confocal excitation, with a 2µm distance exciting both the bound and
unbound antibodies. The figure below shows the excitation achieved
using an evanescent technique with RPPA, where the excitation distance
from the surface is much smaller at 0.1 µm, thus exciting only bound
antibodies. Fluorescence measurements using evanescent instead of con-
focal excitation reduce background noise and allow the high-sensitivity
achieved using RPPA. . . . . . . . . . . . . . . . . . . . . . . . . . . 164
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5.4 Diagram showing some of the components in the DNA damage re-
sponse (DDR) pathways. Boxed components indicate areas where cell
cycle arrest may occur. Circled-P symbols designate phosphorylation/de-
phosphorylation processes and * counterparts as the phosphorylated form
of the protein. When DNA damage is detected, ATM is phosphorylated
to ATM* which in turn phosphorylates CHK2 and BRCA1. There are
two main branches of activation after this point, the right branch acting
as a faster response and the left as a delayed response. Both branches
primarily control the progression of cells from G1 into S phase, thus
preventing damaged DNA being replicated during S phase. . . . . . . 166
5.5 Heat map showing the relative fluorescence intensity (RFI) values
for a selection of DNA damage response (DDR) proteins in cells
exposed to Os-3 and Ir-10 across a 72 h time series. RFI values <
1 indicate a drug-induced decrease in protein levels, RFI = 1 indicates
no-drug effect and RFI > 1 indicates drug-induced increases in protein
levels. The responses to Os-3 and Ir-10 differ at the protein level. This is
most clear with b tubulin (B-Tub) which is down-regulated in response to
Os-3, but up-regulated in waves in response to Ir-10. This could suggest
that Os-3 holds cells in earlier phases of the cell cycle, therefore not
needing mitotic proteins like B-Tub to be expressed. . . . . . . . . . . 168
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5.6 Graph showing flow cytometry data for cells exposed to Os-3. Each
pair of values corresponds to a particular phase of the cell cycle, described
on the x axis, with cell populations for control samples shown in blue,
and those for Os-3-exposed samples in orange. * indicates p < 0.10 and
** indicates p < 0.05 after a Welch two sample t-test between control-
and compound-exposed samples in each stage of the cell cycle. The most
significant drug effects were shown in G1 and S phase of the cell cycle.
Where Os-3 increased the population of cells found in G1 phase and
reduced the population of cells in S phase. . . . . . . . . . . . . . . . 170
5.7 Graph showing flow cytometry data for cells exposed to Ir-10. Each
pair of values corresponds to a particular phase of the cell cycle, described
on the x axis, with cell populations for control samples shown in blue,
and those for Ir-10-exposed samples in green. * indicates p < 0.10
and *** indicates p < 0.01 after a Welch two sample t-test between
control- and compound-exposed samples in each stage of the cell cycle.
In comparison to Os-3, Ir-10 affects all three stages of the cell cycle,
decreasing the population of cells in G1 phase and G2/M phase, and
significantly increasing the number of cells in S phase. . . . . . . . . 171
5.8 Schematic showing components involved in interferon signalling.
Interferon g , a and b (IFN) bind to interferon receptors activating phos-
phorylation events between JAK, STAT and TYK proteins, where pink
spots highlight phosphorylated proteins. Downstream phosphorylated
STAT complexes translocate to the nucleus and initiate the expression
of interferon, interleukin and growth factor inducible genes. . . . . . . 172
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5.9 Heat map showing the relative fluorescence intensity (RFI) values
for a selection of cytokines in cells exposed to Os-3 and Ir-10 across
a 72 h time series. RFI values < 1 indicate a drug-induced decrease in
protein levels, RFI = 1 indicates no-drug effect and RFI> 1 indicates drug-
induced increases in protein levels. The heat map shows a differential
response between the two compounds, most notably shown with increased
levels of phosphorylated STAT1 (STAT1*, P Tyr701) in response to Ir-10,
but not in response to Os-3. In response to both compounds, STAT1 and
its second phosphorylated form STAT1(*) (P Ser727) were detected in
high-levels, particularly STAT1(*) after 72 h exposure. This suggests that
cells are activating the JAK-STAT pathway in response to both compounds.174
5.10 Heat map showing the relative fluorescence intensity (RFI) values
for a selection of apoptotic proteins in cells exposed to Os-3 and
Ir-10 across a 72 h time series. RFI values< 1 indicate a drug-induced
decrease in protein levels, RFI = 1 indicates no-drug effect and RFI> 1 in-
dicates drug-induced increases in protein levels. XIAP, Survivin, BCL-X,
PARP and BIM represent pro-survival proteins, with the remaining, pro-
apoptotic proteins. In response to both compounds, most pro-apoptotic
proteins are down-regulated, with the exception of apoptotic-initiation
proteins like BCL-2 and BAK, which were detected in significantly high
levels after 24 h exposure. High levels of pro-survival proteins like XIAP
and Survivin suggest that apoptosis is blocked at the caspase level, as these
are inhibitor of apoptosis (IAP) proteins and target caspase-activation
during the effector phase of apoptosis. . . . . . . . . . . . . . . . . . 176
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5.11 Graph showing the segregation of an example flow cytometry trace
into cell death quadrants. Measuring the level propidium iodide (PI)
and annexin fluorescence in single cells allows separation of cell pop-
ulations into different stages of apoptosis. Cells with high annexin
fluorescence are said to be in early apoptosis as annexin binds to phos-
phatidylserine proteins, which are extracellular markers of early apoptosis.
High PI fluorescence indicates the loss of membrane integrity, allowing
the dye to intercalate with DNA, and is a marker for necrosis which either
signifies cells are in the final stages of apoptosis or that they have used
necrosis as their primary mechanism for cell death. Here, the majority off
cells are still alive (92 %), with 7 % necrotic and the remainder in apoptosis.178
5.12 Graph showing the % of cells populating each stage of apoptosis/-
cell death after exposure to Os-3 for 24 and 72 h. Each triplicate set
of values corresponds to a particular phase of cell death (described along
the x axis), with cell populations for control samples shown in purple,
those for 24 h Os-3-exposed in blue and those for 72 h Os-3-exposed
samples in green. * indicates p < 0.10, ** indicates p < 0.05 and ***
indicates p < 0.01 after a Welch two sample t-test between control- and
compound-exposed samples in each stage. After 24 h exposure, there
is a significant drop in viable cells, and a significant increase in late
apoptotic and necrotic cells. However, after 72 h exposure the cells
have started to recover, with an increase in viable cells and a decrease
in apoptotic/necrotic cells. . . . . . . . . . . . . . . . . . . . . . . . 179
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5.13 Graph showing the % of cells populating each stage of apoptosis/-
cell death after exposure to Ir-10 for 24 h (top) and 48 h (bottom),
at 0.13 µM (13GI50) and 0.40 µM (GI50). Each triplicate set of values
corresponds to a particular phase of cell death (described along the x axis),
with cell populations for control samples shown in blue, those for 0.13
µM Ir-10-exposed in pink and those for 0.40 µM Ir-10-exposed samples
in green. * indicates p < 0.10 and ** indicates p < 0.05 after a Welch
two sample t-test between control- and compound-exposed samples in
each stage. Significance testing was done between each treatment and
the control (for each quadrant), using a Welch unpaired t test. In contrast
to Os-3, Ir-10 doesn’t cause a significant reduction in viable cells after
24 h, instead the activation of cell death is more pronounced after longer
exposure. Both the low and high concentrations of Ir-10 cause a similar
decrease in cell viability, however at the lower concentration there is
more necrosis compared to the higher. . . . . . . . . . . . . . . . . . 181
5.14 Graph showing the % of cells populating each stage of apoptosis/-
cell death after exposure to 13GI50 Ir-10 for 72 h, with and without
a 48 h recovery period. Each triplicate set of values corresponds to a
particular phase of cell death (described along the x axis), with cell pop-
ulations for control samples shown in blue, those for 72 h Ir-10-exposed
in pink and those for exposed to Ir-10 for 24 h, and then left to recover
for 48 h, in green. * indicates p < 0.10 after a Welch two sample t-test
between control- and compound-exposed samples in each stage. There
is a slight recovery in cell viability when cells are given 48 h recovery
in drug-free media and a decrease in late-apoptotic cells. . . . . . . . 182
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5.15 Graph showing GI50 values (± standard deviation) for compounds
Os-2, Os-3, Os-4, Ir-9 and Ir-10 in different cell lines. Ovarian can-
cer cell lines are shown in blue, and colorectal cell lines shown in purple.
Os-2 shows little dependence on cell type, showing equal activity in all
5 cell types. Os-3 is significantly less active in oxaliplatin and p53(-/-)
HCT116 cells, suggesting this compound may target DNA. In comparison
Os-4, Ir-9 and Ir-10 show preferential activity in p53(-/-) cells. All
compounds, except Os-2 show increased potency in ovarian cancer cell
lines compared to colorectal.14, 16 . . . . . . . . . . . . . . . . . . . 185
6.1 Schematic showing the clustering of three time series datasets (1, 2
and 3), for genes i to n. The top tables present hypothetical expression
profiles across four time points, for each gene. These three datasets are
then either clustered using independent methods (bottom left) or using
MDI, which shares clustering allocations (bottom right). Here, c is the
cluster allocation for each gene, where ci1 is the cluster allocation of gene
i with time series expression observation xi1 in dataset 1. MDI presents
an additional parameter, f , which measures the similarity in clustering
across the datasets, where f12 is a measure of cluster structure between
dataset 1 and 2 for gene i. . . . . . . . . . . . . . . . . . . . . . . . . 195
6.2 Similarity matrix plotting pairwise fˆ values. fˆ values are a meas-
ure of the pairwise similarity between each of the four datasets: Os-3
RNAseq, Ir-10 RNAseq, Os-3 RPPA and Ir-10 RPPA. The higher the
value the more similar the pattern of clustering across pairs of datasets.
The highest level of clustering similarity is between the gene expression
profiles in response to both compounds. . . . . . . . . . . . . . . . . 197
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6.3 Consensus posterior similarity matrix (PSM) showing the similar-
ity in clustering structure across the Os-3 RNAseq, Os-3 RPPA,
Ir-10 RNAseq and Ir-10 RPPA datasets. Panels on the right present
the independent clustering structure in each dataset, with the central
plot showing an overlay of clustering in all four datasets. Darker spots
indicate a higher probability that the given item (gene/protein) is clustered
correctly. The two main clusters are highlighted in yellow. . . . . . . 198
7.1 High-content screening of rhesus monkey cells. Cell nuclei appear
blue and the infective ‘elementary bodies’ of chlamydia, which form
blisters, fluoresce green. The red outlines are those after image analysis
and show separation of fluoresence into individual cell structures. Image
provided by Dr S. Hess of the Max Planck Institute for Infection Biology,
Berlin, Germany. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 208
7.2 Fluorescent confocal microscopy set-up. A fluorescent or fluorescently-
tagged sample is shown at the bottom of the image. A light source is used
to excite the sample, using an excitation filter to all passage of light at
specific wavelengths (e.g. blue) and using a dichroic mirror to focus the
light onto the sample. The sample then emits light of a longer wavelength
(e.g. green) which is focussed to the detector using the dichroic mirror and
an emission filter. Image adapted from Semwogerere (2008) Encyclopedia
of Biomaterials and Biomedical Engineering. 705-714 . . . . . . . . 209
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7.3 Basic set up of a transmission electron microscope. Electrons are
fired from the electron gun and are focussed, through an anode and con-
denser lens, onto the sample. These electrons interact with the sample,
some scattering and some transmitting. The transmitted electrons are
passed through a series of lenses to project an image of the sample. The
contrast seen in TEM imaging is a result of detracted electrons unable to
pass through the specimen. The lighter regions in TEM images are created
from transmitted electrons. Image adapted from Joy (2008) Encyclopedia
Britannica . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 211
7.4 Fluorescence images showing apoptotic A2780 human ovarian can-
cer cells after exposure for 48 h to (A) Control; (B) 2.5 µM Os-1;
(C) 2.5 µM Os-3; (D) 2.5 µM Os-4; (E) 2.5 µM Ir-9; (F) 2.5 µM
Ir-10. DAPI is used to stain the nuclei of cells (blue), with the NucView
reagent staining apoptotic cells (green). NucView is activated inside
cells by caspase-3 and caspase-7 which are apoptotic effector proteins,
therefore fluorescence of this probe is an indirect measure of apoptosis.
Panels (B) Os-2, (C) Os-3 and (F) Ir-10 all show significant levels of
apoptosis, together with a reduction in stained nuclei compared to the
control (A). Panel (E) shows little nuclei reduction and no apoptosis,
suggesting Ir-9 is not cytotoxic at 2.5 µM. Panel (D) shows no apoptosis,
but a reduction in the number of nuclei, suggesting that Os-4 may be
cytotoxic, but may not be activating cell death through apoptosis. . . . 214
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7.5 Fluorescence images showing apoptotic OVCAR-3 human ovarian
cancer cells after exposure for 48 h to (A) Control; (B) 2.5 µMOs-
1; (C) 2.5 µMOs-3; (D) 2.5 µMOs-4; (E) 2.5 µM Ir-9; (F) 2.5 µM
Ir-10. DAPI is used to stain the nuclei of cells (blue), with the NucView
reagent staining apoptotic cells (green). NucView is activated inside cells
by caspase-3 and caspase-7 which are apoptotic effector proteins, there-
fore fluorescence of this probe is an indirect measure of apoptosis. Panels
(B)Os-2 and (F) Ir-10 show small signs of apoptosis in OVCAR-3, much
less than in A2780 cells. However, the number of stained nuclei is still
decreased. Panels (C) Os-3, (D) Os-4 and (E) Ir-9 show no apoptosis,
with (D) and (E) showing no reduction in nuclei count. . . . . . . . . 215
7.6 A2780 control TEM images. Images show typical heterochromatin (H)
and euchromatin (E) distributions in panel D, mitochondria (M, yellow)
in panels A and E, nuclear pores (NP, purple) in panel A, cell membrane
(CM, green) in panel B and rough endoplasmic reticulum (ER, red) in
panel C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 218
7.7 TEM images of A2780 cells after exposure to 1 µM Ir-6 for 24 h.
Images show the nucleus (Nu), damaged mitochondria (yellow) in panels
A, C and E and cell membrane blebbing (green) in panels B, D and
E. Panel A also shows small nuclear vacuoles (blue). These structural
changes are indicative of mitochondria damage and cell death. . . . . 219
7.8 TEM images of A2780 cells after exposure to 5 µM Ir-6 for 24 h.
Images show abnormal chromatin distributions (blue) and further mito-
chondria damage (yellow). These structural changes show that breakdown
of the mitochondria is more significant at higher compound concentra-
tions, and that higher doses of Ir-6 also induce small vacuole formation
around the nuclear membrane. . . . . . . . . . . . . . . . . . . . . . 220
274
7.9 TEM images of A2780 mitochondria after exposure to 1 µM Ir-6
for 24 h. Circled area highlights a mitochondrion where the cristae are
still partially structured. The remaining mitochondria are significantly
damage by the mechanisms of Ir-6, losing both inner and outer membrane
integrity. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 221
7.10 Bar graph showing mitochondrial membrane polarisation after
cells were exposed to Ir-6 at 0.24 µM (13GI50) and 1 µM (ca. GI50),
for 4 and 24 h. This assay uses a positively charged fluorescent probe
(JC-10), which aggregates in the mitochondria and fluoresces red. Upon
mitochondrial membrane polarisation, the aggregation of the probe de-
creases, and the red fluorescence drops. Therefore polarisation is determ-
ined by a reduction in red (FL2) fluorescence. p values were calculated
after a Welch t-test against the negative control. Results show that mi-
tochondrial membrane polarisation is activated after just 4 h exposure,
at either concentration of Ir-6. . . . . . . . . . . . . . . . . . . . . . 222
8.1 Schematic summarising the proposedmechanisms of action of com-
pounds studied in this work. DNA image was adapted from psdgraph-
ics.com. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 232
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